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Introduction 
In the 20th century, the incidence and mortality of lung cancer has increased so 
dramatically that it can be considered one of the major epidemics of the former century1. 
Lung cancer continues to be the leading cause of death from cancer throughout the 
world, with a median survival rate of only 8 months and 13% of patients still alive five 
years after the diagnosis2-4. Highest cure rates result from surgical resection, especially 
for stage I and II non-small cell lung cancer (NSCLC) patients, with 5-year survival rates 
of 40-50%. However, a potentially curative resection is only possible in about 25% of 
new cases. Whether or not patients are eligible for surgery, depends on the tumors’ 
resectability (stage of the disease) and the patients’ operability (physical condition).  
 
Resectability and NSCLC staging 
TNM-stages for NSCLC are classified as I-IV, with decreasing survival rates (Tables 1 and 
2). Generally, patients with stages I and II (T1 and T2 tumors without mediastinal lymph 
node involvement, N0-1 disease) are considered to be eligible for potentially curative 
surgical resection. The presence of mediastinal lymph node metastases (N2-3 disease, 
stages IIIA and IIIB) and locally advanced tumor growth are ominous prognostic signs 
and considered contraindications for primary surgical resection. Stages III and IV (distant 
metastases) are generally considered incurable and are predominantly treated with 
chemo- and/or radiotherapy in clinical or experimental settings, or not treated at all. 
Because of these different survival rates and the impact on choice of therapy, proper 
staging is of utmost importance. Staging of NSCLC is done by imaging modalities 
(computed tomography (CT) scanning, F-18-deoxyglucose positron emission tomography 
(18FDG-PET) scanning, magnetic resonance (MR) imaging) and by (minimally) invasive 
tools like bronchoscopy, transbronchial needle aspiration (TBNA), mediastinoscopy and, 
more recently, transoesophageal ultrasound-guided fine needle aspiration (EUS-FNA) and 
endobronchial ultrasound (EBUS). 
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Table 1 TNM Descriptors 
 
Primary tumor (T) 
Tx 
 
 
T0 
Tis 
T1 
 
 
T2 
 
 
 
 
 
T3 
 
 
 
 
T4 
Primary tumor cannot be assessed, or tumor proven by the presence of malignant 
     cells in sputum or bronchial washings but not visualized by imaging or 
     bronchoscopy 
No evidence of primary tumor 
Carcinoma in situ 
Tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without 
     bronchoscopic evidence of invasion more proximal than the lobar bronchus * (ie, 
     not in the main bronchus) 
Tumor with any of the following features of size or extent: 
     > 3 cm in greatest dimension 
     Involves main bronchus, ≥ 2 cm distal to the carina 
     Invades the visceral pleura 
     Associated with atelectasis or obstructive pneumonitis that extends to the hilar 
        region but does not involve the entire lung 
Tumor of any size that directly invades any of the following: chest wall (including 
     superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or 
     tumor in the main bronchus < 2 cm distal to the carina, but without involvement 
     of the carina; or associated atelectasis or obstructive pneumonitis of the entire 
     lung 
Tumor of any size that invades any of the following: mediastinum, heart, great 
     vessels, trachea, esophagus, vertebral body, carina; or tumor with a malignant 
     pleural or pericardial effusion ‡, or with satellite tumor nodule(s) within the 
     ipsilateral primary tumor-lobe of the lung 
Regional lymph nodes (N) 
Nx 
N0 
N1 
 
N2 
N3 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and 
     intrapulmonary nodes involved by direct extension of the primary tumor 
Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s) 
Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral 
     scalene, or supraclavicular lymph node(s) 
Distant metastases (M) 
Mx 
M0 
M1 
Presence of distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis present § 
* The uncommon superficial tumor of any size with its invasive component limited to the bronchial 
wall, which may extend proximal to the main bronchus, is also classified T1. 
‡ Most pleural effusions associated with lung cancer are due to tumor. However, there are few 
patients in whom multiple cytopathologic examinations of pleural fluid show no tumor. In these 
cases, the fluid is nonbloody and is not an exudate. When these elements and clinical judgment 
dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging 
element and the patient’s disease should be staged T1, T2 or T3. Pericardial effusion is classified 
according to the same rules. 
§ Separate metastatic tumor nodule(s) in the ipsilateral nonprimary-tumor lobe(s) of the lung also 
are classified M1. 
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Table 2 Stage groupings - TNM subsets * 
 
Stage TNM subset 
0 Carcinoma in situ 
 
IA 
 
IB 
T1N0M0 
 
T2N0M0 
 
IIA 
 
IIB 
T1N1M0 
 
T2N1M0 
T3N0M0 
 
IIIA 
 
 
 
 
IIIB 
T3N1M0 
T1N2M0 
T2N2M0 
T3N2M0 
 
T4N0M0 
T4N1M0 
T4N2M0 
T1N3M0 
T2N3M0 
T3N3M0 
T4N3M0 
 
IV Any T any N M 1 
* Staging is not relevant for occult carcinoma, designated TxN0M0 
 
 
A whole body 18FDG-PET to evaluate the mediastinum is recommended for NSCLC 
patients who are candidates for surgery5. Controversy exists among the use of PET 
imaging in patients with peripheral cT1N0 tumors because evidence indicates that the 
incidence of finding either unsuspected distant or mediastinal metastases on PET in these 
patients is quite low. In patients with mediastinal lymph node enlargement on CT, 
mediastinoscopy (or other invasive biopsy) is likely to be indicated regardless of the PET 
findings in the mediastinum6. Especially in certain subgroups of patients (those with 
tumors adjacent to the mediastinum, adenocarcinomas, or N1 nodal involvement), 
physicians seem to argue whether or not mediastinoscopy is needed in case of a negative 
PET result. 
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Cervical mediastinoscopy, considered as ‘the gold standard’ for detecting N2-3 disease, is 
recommended to confirm metastatic disease in patients with a PET scan that is positive 
(15-20% false positive6) in the mediastinum and in patients with a PET scan negative in 
the mediastinum in whom confirmation of the absence of mediastinal lymph node 
metastases is deemed desirable5-7. Ideally, cervical mediastinoscopy at least requires 
sampling of lymph nodes from stations 4 (left and right lower paratracheal) and 7 
(subcarinal) routinely, along with the nodes from station 2 (left and right upper 
paratracheal), if accessible, as described in the American Thoracic Staging system8 
(Figure 1). In case of a primary pulmonary tumor without evidence for distant or 
mediastinal metastases, patients are considered eligible for resection. Patients will only 
benefit from a complete resection, which means complete removal (macro- and 
microscopically) of all malignant tissue (pulmonary and lymph nodes). 
 
Operability and physical condition 
Whether or not to perform a resection depends, besides the stage of the disease, on the 
patients’ physical condition, comorbidity and cardiopulmonary function (operability). The 
pulmonary physician preoperatively tries to predict which patients will survive a 
pulmonary resection and not be left a respiratory cripple, experiencing incapacitating 
dyspnoea and being unable to carry out activities of daily living, with obviously very poor 
quality of life. On the other hand, what is an unacceptable morbidity and surgical 
mortality in a disease with a 100% mortality unless treated surgically9? In the past, 
numerous studies have addressed this issue and have tried to identify the pulmonary 
function limits below which patients are defined inoperable10-14. This has led to widely 
accepted algorithms for the assessment of the cardiorespiratory reserves of lung 
resection candidates, like the one introduced by Bolliger et. al. in 199815.  
Since lung cancer patients are often old and almost always smokers, presence of 
comorbidity (presence of other diseases besides lung cancer) in these patients is 
frequent. Just like decreased (cardio)pulmonary function, presence of comorbidity may 
lead to complications during or after treatment (surgically or systemic). Because of this, 
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Figure 1 
Regional lymph node stations for lung cancer staging. Adapted from Mountain CF, Dresler CM, 
Chest 1997; 111: 1718 
 
 
elderly patients and patients with comorbidity are often treated less aggressively 
compared to younger patients or patients without comorbidity16;17. 
 
Postoperative aspects 
Depending on the size and localisation of the tumor, more or less pulmonary tissue will 
have to be removed, in order to obtain a complete resection. Major lung resection, 
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especially pneumonectomy, causes a significant decrease in cardiopulmonary function 
and still has a high mortality rate of approximately 10-12% for right-sided procedures 
and 0-3,5% for left-sided procedures18. Right-sided pneumonectomy is more likely 
associated with the development of complications, like bronchopleural fistula, empyema 
and postpneumonectomy pulmonary edema, and therefore has higher mortality rates.  
Normally, after pneumonectomy, forced vital capacity (FVC) and forced expiratory 
volume in 1 second (FEV1) decrease by 30-40% while maximum oxygen uptake during 
exercise (VO2max) decreases by approximately 20%18.  
Furthermore, immediately after pneumonectomy, right ventricular (RV) dysfunction 
occurs19-23. Several studies have shown RV enlargement and a decreased RV ejection 
fraction the first few days after surgery21-23. Increasing RV afterload, due to rising 
pulmonary artery pressure and pulmonary vascular resistance, is supposed to be the 
main cause of this RV dysfunction. Successful adaptation of the RV to increased 
pulmonary blood flow depends upon the ability of the pulmonary vascular bed to expand. 
Failure of this mechanism results in increased intravascular pressure which can lead to 
the development of pulmonary hypertension and eventually RV failure24. Nowadays, 
cardiovascular magnetic resonance (CMR) imaging offers a unique possibility to study the 
cardiac function in an altered geometric position of the heart. CMR not only is accurate 
and reproducible in normal as well as abnormal ventricles25, but also free of ionising 
radiation and independent of the geometric assumptions and acoustic windows that limit 
echocardiography26. 
 
In summary, several different aspects (like the TNM stage, the patients’ cardiopulmonary 
condition and the presence of comorbidity) influence treatment choice in patients with 
NSCLC. Highest cure rates result from surgical resection, however major lung resection, 
especially pneumonectomy, extensively influences cardiac and pulmonary function and 
still has one of the highest mortality rates that may be encountered by patients 
submitted to non-emergent surgery. 
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Outline of the Thesis 
This thesis contains studies on two different aspects in lung cancer patients, described in 
two parts. In the first part, aspects influencing the preoperative selection of patients that 
are eligible for resection are studied. The second part consists of studies regarding 
postoperative cardiopulmonary function in surgically treated patients.  
 
Part I consists of studies on aspects influencing treatment choice, like the TNM stage 
and comorbidity. With the rising mean age more patients will be diagnosed with one or 
more other serious diseases at the time of lung cancer diagnosis (comorbidity). Little is 
known about either the best way to treat elderly patients with comorbidity or the 
outcome of treatment. The effect of comorbidity on treatment choice and prognosis of 
elderly patients with NSCLC is studied in Chapter 1. 
Even after the introduction of 18FDG-PET, mediastinoscopy remains the gold standard for 
detecting N2-3 disease. However, with an accuracy of 92% or better, mediastinoscopy is 
not always perfect and its result may be surgeon dependent. Also, results from large 
studies in academic centers are probably not totally concordant with all-day clinical 
practice. In Chapter 2, we investigated the accuracy of mediastinal staging procedures 
in daily practice. For this, we studied the degree of adherence of treating physicians to 
the accepted staging procedures in their hospitals. And, in case mediastinoscopy was 
performed, how often this was performed according to gold standards.  
In the past years, 18FDG-PET is increasingly used to stage NSCLC patients. Addition of 
FDG-PET to conventional workup of NSCLC patients who are possible candidates for 
surgical resection can be very useful in guiding mediastinal biopsy during 
mediastinoscopy and reduces the number of futile thoracotomies27. Because 18FDG-PET 
became available in our hospital in 2002, we also studied (Chapter 3) whether the 
implementation of PET in daily practice has resulted in improved performance and 
adherence to preoperative surgical mediastinal staging procedures, compared to the 
results from Chapter 2. Results from PET studies pertaining to its accuracy in 
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mediastinal staging are robust, but as the technique is disseminating and becoming more 
available in even the smaller hospitals, observer variation and learning curves need to be 
documented (Chapter 4).  
 
Part II consists of studies regarding cardiac and pulmonary function after 
pneumonectomy for lung cancer. Several formulas are in use aiming to predict 
postoperative lung function after resection. These formulas were validated relatively soon 
after the operation and in a small number of patients after pneumonectomy, 
nevertheless, they are worldwide accepted in guidelines. Since recruitment occurs after 
lung resection, especially after pneumonectomy, it is still unclear what the validity of 
these formulas might be for predicting lung function at a much later stage. In Chapter 5 
we investigated the validity of these formulas in pneumonectomy patients surviving for 
more than two years after the operation.  
In contrast to postoperative pulmonary function studies, relatively few studies have 
investigated postoperative cardiac function in patients after pneumonectomy. 
Immediately after pneumonectomy, right ventricular (RV) enlargement occurs due to 
increased RV afterload. We wondered whether and to what extent the RV function 
recovers and how long it takes before this recovery is complete. Also, does cardiac 
function differ between patients after left- or right-sided pneumonectomy? The literature 
agrees to the fact that pulmonary artery pressure and pulmonary vascular resistance are 
normal or slightly increased at rest, but increase on exertion. However, whether or not 
this chronically increased state of stress also causes RV hypertrophy, is unclear. 
Therefore, to answer all these questions, we studied cardiac function in patients 
immediately after and three months after pneumonectomy (Chapter 6) and also, more 
than 5 years after pneumonectomy (Chapter 7). Next to this, we investigated whether 
the extreme anatomical changes that sometimes occur after pneumonectomy have 
influence on cardiac function and whether these changes differ between patients after 
right- or left-sided pneumonectomy (Chapter 7). At the end of this thesis, in Chapters 
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8.1, 8.2 and 8.3, several patients with unusual features after pneumonectomy are 
presented and discussed. 
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Abstract 
Background:  With the rising mean age more patients will be diagnosed with one or more 
other serious diseases at the time of lung cancer diagnosis. Little is known about the best 
way to treat elderly patients with comorbidity or the outcome of treatment. This study was 
undertaken to evaluate the independent effects of age and comorbidity on treatment and 
prognosis in patients with non-small cell lung cancer (NSCLC). 
 
Methods: All patients with NSCLC diagnosed between 1995 and 1999 in the southern part of 
the Netherlands (N=4072) were included. 
 
Results: The proportion of patients with localised NSCLC who underwent surgery was 92% in 
patients younger than 60 years and 9% in those aged 80 years or older. In patients aged 
60-79 years this proportion also decreased with comorbidity. In patients with non-localised 
NSCLC the proportion receiving chemotherapy was considerably higher for those aged less 
than 60 years (24%) than in those aged 80 years or older (2%). The number of comorbid 
conditions had no significant influence on the treatment chosen for patients with non-
localised disease. Multivariable survival analyses showed that age, tumor size and treatment 
were independent prognostic factors for patients with localised disease, and stage of disease 
and treatment for those with non-localised disease. Comorbidity had no independent 
prognostic effect.  
 
Conclusions: It is questionable whether the less aggressive treatment of elderly patients 
with NSCLC is justified. 
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Introduction 
Lung cancer occurs mainly in the elderly. Because of a demographic shift towards an older 
population and improved survival of patients with cardiovascular diseases, more elderly 
people are at risk of developing lung cancer. The proportion of patients aged 70 years or 
older has increased from 26% in 1970 to 43% in 20001. With the rising mean age, more 
patients will be diagnosed with one or more other serious diseases at the time of lung cancer 
diagnosis (comorbidity)2. Comorbidity may lead to complications during or after surgical 
and/or systemic treatment3-6. The clinical management of lung cancer is therefore becoming 
increasingly complex. Furthermore, these patients are often excluded from clinical trials. 
This means that little is known about the best way to treat elderly patients with comorbidity 
and about the outcome of treatment such as complications and survival. 
Population based cancer registries are able to facilitate studies of these patients if they 
collect data directly from medical records. The Eindhoven Cancer Registry, at the request of 
clinicians, has been collecting data on clinically relevant concomitant diseases for all cancer 
patients diagnosed since 1993 in the southern part of the Netherlands. We report here on 
the influence of age, stage of disease and comorbidity on the choice of treatment and 
survival of patients with non-small cell lung cancer (NSCLC). 
 
Patients and Methods 
The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in 
the southern part of the Netherlands, an area with about two million inhabitants. Since 1993 
serious comorbidity with an impact on prognosis has also been recorded for all patients 
according to a slightly adapted version of the index developed by Charlson et al. (Table 1)7. 
The data were extracted from previous admissions, letters from and to other specialists, 
medical history and preoperative screening. Comorbidity was defined as diseases that were 
present at the time of cancer diagnosis.  
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Table 1 Classification of comorbidity, according to an adapted version of the 
list of Charlson et al. (1987) 
 
Chronic Obstructive Pulmonary Diseases (COPD) 
Cardiovascular diseases 
- myocardial infarction, cardiac decompensation, angina pectoris 
- peripheral arterial disease, intermittent claudication, abdominal aneurysm 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia) 
Other malignancies (except basal cell skin carcinoma) 
Hypertension (medically treated) 
Diabetes mellitus 
Other: 
-  soft tissue diseases (Besnier Boeck disease, Wegener's disease, SLE (systemic lupus erythematosis)) 
- rheumatoid arthritis (only severe) 
- kidney diseases (chronic glomerulonephritis, chronic pyelonephritis) 
- bowel diseases (Crohn's disease, ulcerative colitis) 
- liver diseases (cirrhosis, hepatitis) 
- dementia 
- chronic infections 
 
 
Patients with NSCLC diagnosed between 1995 and 1999 (N=4076) were included. Those 
with cancer diagnosed at post mortem examination (N=138) were excluded. 
Clinical tumor staging was performed according to the Tumor-Node-Metastasis (TNM) 
system of the Union Internationale Contre le Cancer, version 48. Tumors were classified as 
localised (stages I and II) and non-localised (stages III and IV). 
Non-small cell lung tumors were classified as squamous cell carcinoma, adenocarcinoma and 
large cell undifferentiated carcinoma, according to the WHO classification9. 
Treatment for localised disease was classified as surgery (with or without adjuvant 
radiotherapy), radiotherapy alone and ‘other or none’. Treatment was only classified as 
surgery when the tumor was resected during surgical intervention; diagnostic surgery was 
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not included. For patients with non-localised disease treatment was classified as surgery 
(with or without radiotherapy), radiotherapy alone, chemotherapy (with or without 
radiotherapy) and ‘other or none’. 
Data on vital status were available up to 1 April 2002. In addition to passive follow up via 
the hospitals, information was also obtained from the municipal registries in the area of the 
Eindhoven Cancer Registry and the Central Bureau for Genealogy, an institution that collects 
data on all deceased Dutch citizens via the civil municipal registries. In this way, information 
on patients who moved outside the registry area was also obtained. Patients who died 
outside the Netherlands were lost to follow up. The estimated proportion of these patients 
was 0.2%. Of 4076 patients with NSCLC 637 (16%) were still alive and 3439 (84%) were 
dead at the end of the study. 
 
Analysis of data 
Overall survival rates were computed (3 year for patients with localised disease and 1 year 
for patients with non-localised disease). Survival time was defined as the time from 
diagnosis to death or the end of the study (if the patient was still alive on 1 April 2002). The 
log rank test was performed to evaluate significant differences between survival curves in 
univariate analyses. For evaluation of the independent effects of the prognostic factors, a 
multivariable Cox regression model was built. The models were stratified according to stage. 
This was done because both the guidelines for treatment of localised NSCLC and the survival 
rates are clearly different from those for non-localised NSCLC. Since interaction terms with 
age were not statistically significant, multivariable analyses were not stratified according to 
age. The independent prognostic effects of age, sex, stage of disease and comorbidity were 
first estimated using a model without treatment. Treatment was then included in the model 
to investigate whether the prognostic effects of age and comorbidity could be fully explained 
by less aggressive treatment. With respect to comorbidity, the prognostic effects of both the  
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Table 2 General characteristics of the patients 
 
  Age <60 Age 60-69 Age 70-79 Age 80+ 
  N (%) N (%) N (%) N (%) 
Gender Male 732 (68) 1230 (84) 1095 (86) 230 (85) 
 Female 344 (32) 233 (16) 172 (14) 40 (15) 
Histology Squamous cell 389 (36) 725 (50) 657 (52) 158 (58) 
 Adenocarcinom 388 (36) 376 (26) 287 (23) 40 (15) 
 Large cell 
undiff. 
299 (28) 362 (25) 323 (25) 72 (27) 
Stage Localised 1 251 (23) 403 (28) 366 (29) 82 (30) 
 Non-localised 710 (66) 848 (58) 694 (55) 128 (48) 
 Unknown 115 (11) 212 (14) 207 (16) 60 (22) 
Comorbidity  0 555 (52) 462 (32) 303 (24) 66 (24) 
(N) 1 302 (28) 506 (35) 449 (35) 88 (33) 
 2+ 134 (12) 397 (27) 463 (37) 95 (35) 
 Unknown 85 (8) 98 (7) 52 (4) 21 (8) 
Comorbidity  COPD 159 (15) 362 (25) 349 (28) 72 (27) 
(type) 2 Cardiovascular 122 (11) 338 (23) 382 (30) 80 (30) 
 Previous cancer 88 (8) 191 (13) 230 (18) 50 (19) 
 Hypertension 84 (8) 209 (14) 191 (15) 29 (11) 
 Diabetes 47 (4) 110 (8) 130 (10) 31 (11) 
 Other 93 (9) 188 (13) 231 (18) 44 (16) 
1 Stage I or II 
2 More diseases per patient possible 
 
number of comorbid conditions and the specific diseases/combinations of diseases were 
evaluated. Survival generally decreases with age and the prevalence of comorbidity 
increases with age. We therefore also calculated relative survival rates for each age group 
according to stage. Relative survival is an estimation of disease specific survival. It reflects 
survival of cancer patients, adjusted for survival in the general population with the same age 
structure. Relative survival is calculated as the ratio of the observed to the expected rates10. 
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Expected survival rates were calculated from life tables for regional male and female 
populations with the same 5 year age distribution. 
 
Results 
The general characteristics of the patients are shown in Table 2. The male:female ratio 
increased dramatically from 2.1 for patients younger than 60 years to 6.4 for patients aged 
70-79 years and then decreased to 5.8 for patients aged 80 years or older. The proportion 
with squamous cell carcinoma was clearly higher among the elderly. The prevalence of 
concomitant diseases for NSCLC patients clearly increased with age; in patients aged 70 
years or older the prevalence of comorbidity was 73% for men and 61% for women. The 
most frequent comorbid conditions in men aged 70 or older were cardiovascular diseases 
(31%) and COPD (29%); in older women the most common conditions were cardiovascular 
diseases (22%), hypertension (22%) and COPD (20%). 
The proportion of patients with localised NSCLC who underwent surgery with or without 
radiotherapy was only 9% of those aged 80 or older versus 92%, 79% and 61% of the age 
groups <60, 60-69 and 70-79, respectively. In patients aged 60-69 and 70-79 the 
proportion who underwent surgery also decreased with comorbidity (Figure 1a). In patients 
aged 60-69 the proportion who underwent surgery was especially low in the presence of 
COPD alone (67%), COPD and cardiovascular disease (58%) or COPD and previous cancer 
(33%), compared to 88% in patients without comorbidity. For patients aged 70-79 the 
proportion who underwent surgery was 78% of those without comorbidity but only 59% in 
patients with cardiovascular disease, 55% of those with previous cancer, 53% of those with 
previous cancer in combination with COPD and 40% of those with COPD. Most patients with 
non-localised NSCLC received radiotherapy alone (Figure 1b). The proportion receiving 
chemotherapy (with or without radiotherapy) was considerably higher in patients younger 
than 60 years (24%) than in those aged 80 or older (2%). More elderly patients did not 
receive any treatment. The number of comorbid conditions had no significant influence on 
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Figure 1A  
Treatment of localised NSCLC, according to age, comorbidity and stage 
 
 
 
 
 
Figure 1B  
Treatment of non-localised NSCLC, according to age, comorbidity and stage 
 
 
<60 years 60-69 years 70-79 years 80+ years 
<60 years 60-69 years 70-79 years 80+ years 
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the treatment chosen for patients with non-localised disease. However, for patients with 
stage IIIa aged 70-79 the presence of COPD lowered the proportion who underwent surgery 
(10% versus 19% of patients without comorbidity, results not shown). 
Table 3 shows univariate and multivariable analyses of survival for patients with localised 
NSCLC. Three year survival decreased significantly with age (p<0.0001) with relative 3 year 
survival of 62% for patients younger than 60 and 13% for those aged 80 or older. The 3 
year overall survival decreased from 61% to 8%. Among patients aged 70-79 the prognosis 
for those with adenocarcinoma was better than for those with squamous cell carcinoma or 
large cell undifferentiated carcinoma. Survival was better for T1 tumors and was also better 
after surgery. The number of comorbid conditions seemed to have no significant influence on 
survival, but the 3 year survival for patients aged 70-79 was especially low for those with 
COPD in combination with previous cancer (11% compared with 38% for patients without 
comorbidity). In multivariable analyses age, subtype, tumor size and the presence of two or 
more comorbid conditions were independent prognostic factors. The effects of age and 
tumor size remained significant after treatment was included, but the prognostic effects of 
subtype and comorbidity disappeared (Table 3). In the model with the specific diseases and 
combinations of diseases only the combination of a previous tumor and COPD had a negative 
influence on survival. However, this prognostic effect disappeared when treatment was 
included in the model. This means that the effect of the combination of a previous tumor 
and COPD might be ascribed to the less aggressive treatment of these patients. 
Table 4 shows univariate and multivariable analyses of survival for patients with non-
localised NSCLC. One year survival decreased significantly with age (p<0.0001) with 1 year 
relative survival of 31% for patients younger than 60 and 13% for those aged 80 or older. 
One year overall survival decreased from 31% to 11%. Furthermore, histological subtype 
(only for age group 70-79), stage and treatment were prognostic factors in univariate 
analyses. Comorbidity had no influence on survival nor did the specific diseases or 
combinations of diseases. 
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Table 3 Univariate and multivariable analysis of overall survival for patients with 
localised* NSCLC, according to age, sex, histology, tumor size, 
comorbidity and treatment 
 
 Age <60 Age 60-69 Age 70-79 Age 80+ All ages
Total (N) 251 403 366 82 1102 
Alive at 3 yrs (N) 154 198 117 7 476 
Relative 3-yr 
survival (%) 
62 52 38 13 47 
 Overall 3-year survival (%) and univariate p-values Multivariable
 % P % P % P % P HR2 P
Age      
<60 61    0.84 0.1
60-691   49  1 
70-79    32  1.28 .007
80+    8  1.31 0.07
Gender      
Female1 69  51 43 18  1 
Male 57 0.1 48 0.8 30 0.1 6 0.7 0.86 0.2
Histology      
Squamous cell1 66  49 30 -  1 
Adenocarcinoma 60  53 44 -  1.10 0.4
Large cell undiff. 37 0.1 38 0.5 24 0.03 -  1.08 0.4
Tumor size      
T11 78  69 42 -  1 
T2 51 <.001 39 <.001 27 .007 -  1.62 <.001
Comorbidity      
01 53  53 38 10  1 
1 66  48 33 4  0.94 0.5
2+ 59 0.2 43 0.2 30 0.2 - 0.5 1.13 0.2
Treatment      
Radiotherapy1 -  21 10 -  1 
Surgery (+/-) RT 63  57 47 -  0.49 <.001
Other/none -  - <.001 2 <.001 -  1.35 0.02
* Stage I or II       
1 Reference category 
2 Hazard Ratio for death 
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Table 4 Univariate and multivariable analysis of overall survival for patients with 
non-localised* NSCLC, according to age, sex, histology, stage, 
comorbidity and treatment 
 
 Age <60 Age 60-69 Age 70-79 Age 80+ All ages
Total (N) 710 848 694 128 2380 
Alive at 1 yrs (N) 219 219 146 14 598 
Relative 1-yr 
survival (%) 
31 26 22 13 26 
 Overall 1-year survival (%) and univariate p-values Multivariable
 % P % P % P % P HR2 P
Age     
<60 31   0.93 0.2
60-691   26 1 
70-79    21 1.05 0.3
80+    11 1.14 0.2
Gender     
Female1 32  20 11 14 1 
Male 30 0.6 27 0.08 23 0.06 10 0.9 1.04 0.5
Histology     
Squamous cell1 35  29 28 12 1 
Adenocarcinoma 28  28 18 13 1.07 0.2
Large cell undiff. 29 0.3 20 0.08 14 0.01 8 0.6 1.03 0.6
Stage     
III2 41  35 28 13 1 
IV 19 <.001 13 <.001 10 <.001 9 0.7 1.14 0.01
Comorbidity     
01 31  25 23 - 1 
1 31  29 22 - 1.01 0.8
2+ 25 0.4 25 0.6 19 0.5 - 1.05 0.4
Treatment     
Radiotherapy1 28  29 28 - 1 
Surgery (+/- RT) 55  49 37 - 0.69 <.001
Chemo (+/- RT) 39  35 38 - 0.90 0.2
Other/none 9 <.001 8 <.001 8 <.001 - 1.13 0.03
* Stage III or IV 
1 Reference category 
2 Hazard Ratio for death 
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In a multivariable analysis age and stage were independent prognostic factors. After 
inclusion of treatment the prognostic effect of age disappeared and that of stage became 
weaker but remained significant. In a model with the specific diseases and combinations of 
diseases, none of the concomitant diseases had an independent effect on survival.  
 
Discussion 
In this population based study we found that the prevalence of serious comorbidity in 
patients with NSCLC was high, especially in elderly patients and in men. Furthermore, 
elderly patients were treated less aggressively than younger patients. In patients with 
localised disease a lower proportion of patients with comorbidity underwent surgery. The 
survival of patients with localised disease was lower for older patients but the effect of 
comorbidity on the prognosis was small. 
In 2003 the completeness and accuracy of the data on comorbidity were validated in a series 
of 500 consecutive patients with lung cancer aged 40 and older and diagnosed between 
1995 and 1999. Comorbidity scored by the registry team was compared with that scored by 
a team consisting of a surgeon and an epidemiologist. Recording of comorbidity was correct 
for about 70% of patients. There was some underregistration, especially of cardiovascular 
diseases (internal report). This means that the effects of comorbidity on treatment and 
survival, as described here, are probably weaker than the real effects. 
 
Prevalence 
The higher prevalence of comorbidity in older patients was expected because the prevalence of 
diseases generally increases with age. The prevalence of comorbidity in older patients may 
even be underestimated due to ascertainment bias. Younger patients underwent surgery more 
often, which means that the prevalence of comorbidity reported by the chest physician may be 
higher in patients with resectable disease because of the required preoperative examination. 
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The high risk of cardiovascular diseases and COPD for patients with lung cancer can be 
explained by the high proportion of smokers among these patients, especially men. 
 
Treatment 
Patients with localised disease underwent surgery less often when they were older and when 
comorbidity was present. The resection rate was very low for those with COPD, probably 
because of the expected higher incidence of postoperative complications and mortality11. 
However, in everyday practice the resectability is not determined primarily by comorbid 
conditions but by the effects of comorbidity, such as pulmonary and cardiac function. 
Age seemed to have more influence on the choice of treatment than comorbidity, especially 
for patients with localised disease. Apparently, comorbidity alone does not entirely explain 
why elderly patients with localised disease undergo surgery less often and why those with 
non-localised disease receive systemic chemotherapy less often. The lower proportion of 
elderly patients who undergo surgery or chemotherapy was also reported in another area of 
the Netherlands12. The lower proportion of surgery in elderly patients may be explained by 
an increased risk of surgical mortality13-15. In previous studies less aggressive treatment of 
patients with comorbidity was also shown for breast cancer, prostate cancer and 
lymphoma16-19. In contrast, age and comorbidity had a negligible influence on the resection 
rate in patients with colorectal cancer20. It seems that when surgery is inevitable, as in 
patients with colorectal cancer, or when no alternative treatment is available, age and 
comorbidity have a negligible influence on the resection rate. In our study elderly patients 
received chemotherapy less often than younger patients. In previous studies, however, 
treatment with vinorelbine was shown to be well tolerated by elderly patients with non-
localised NSCLC21,22. The effects of age and comorbidity on the application of chemotherapy 
for NSCLC in our study may be underestimated because we did not have any information on 
dose reduction or delay of chemotherapy. 
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Survival 
Age, stage of disease and treatment were prognostic factors for patients with NSCLC, 
independent of sex, histology and comorbidity. Since age and treatment were both 
independent prognostic factors for patients with localised disease, the effect of age on the 
prognosis cannot be completely explained by less aggressive treatment of the elderly. 
Overall survival of older patients with lung cancer is worse because of the lower expected 
survival rate for the elderly in the general population. However, the effect of age remained 
significant when relative survival rates (adjusted for survival in the general population with 
the same age structure) were calculated. Since we also adjusted for comorbidity, the lower 
survival rate for the elderly should be explained by prognostic factors other than 
comorbidity, such as performance status, decreased organ reserves, worse pulmonary 
function, or psychic and social factors23-27, which were not available for analysis in the 
Eindhoven Cancer Registry. 
Comorbidity seemed to have a negligible influence on survival of patients with lung cancer, 
despite less aggressive treatment in case of comorbidity. This contradicts the findings in 
some other studies where comorbidity was found to be an independent prognostic factor for 
surgically resected stage I NSCLC, stage III NSCLC and all lung cancer patients, 
respectively26-29. However, these studies were not population based and they used other 
scales for measuring comorbidity (the Kaplan-Feinstein Index30 and the Cumulative Illness 
Rating Scale-Geriatric (CIRS-G)31). In one of the studies, comorbidity influenced overall 
survival in surgically resected patients with stage I NSCLC in whom comorbidity was rated 
according to CIRS-G but not according to the Charlson scale26. In another American study 
comorbidity count and the Charlson index were significant predictors for lung cancer 
survival, but explained only 2.5% and 2.0%, respectively, of the variation in survival32. The 
influence of comorbidity on survival is probably of less importance in lethal diseases such as 
lung cancer. Most of these patients die of lung cancer before they have a chance to die of 
the comorbid condition. 
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A possible shortcoming of all the studies is the classification of total severity in cases of 
two or more comorbid conditions. More conditions may have a multiplicative effect rather 
than an additive effect. Classifying comorbidity as the number of diseases present, or as 
the sum of scores, or as the most severe condition present may miss the burden of 
multiple diseases on prognosis. In our data set we also analyzed the prognostic effect of 
the individual diseases and their combinations. However, none of the (combinations of) 
diseases had an independent effect on prognosis. A negative effect of comorbidity on 
prognosis may also be cancelled out by earlier detection, with lung cancer possibly being 
detected at an earlier stage during routine examination for the comorbid condition. 
Treatment was a strong prognostic factor, even after adjustment for age. The question 
therefore arises whether the less aggressive treatment of elderly patients is justified. For 
careful preoperative selection, studies of the complications during and after treatment 
should be performed, including data on performance status and pulmonary function. 
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Abstract  
Background: An adequately staged mediastinum remains obligatory in patients with 
NSCLC prior to surgery. In this study, we investigated the accuracy of preoperative 
surgical mediastinal staging procedures in 4 hospitals.  
 
Setting: Non-university teaching hospital and three surrounding community hospitals in 
Eindhoven, The Netherlands. 
 
Methods and results: Patients with NSCLC who underwent mediastinoscopy and/or 
thoracotomy, between 1993 and 1999. Adherence to guidelines for indicating and 
performing mediastinoscopy were investigated and compared in four hospitals. 
Guidelines for indicating mediastinoscopy were adequately followed in two-thirds of 
cases. Mediastinoscopy was performed according to gold standards in 40% of cases. The 
hospital with the smallest number of evaluated patients scored the worst. 
Postoperatively, 17% of patients appeared to have unforeseen N2-3 disease. In 
approximately 18% of these “upstaged” patients, thoracotomy could have been 
prevented, if guidelines had been followed adequately. 
 
Conclusions: In clinical practice the adherence to staging guidelines with respect to 
mediastinoscopy is insufficient in 1/3 of patients. Furthermore, mediastinoscopy was 
performed according to gold standards in 40% of patients.   
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Introduction 
Lung cancer continues to be the leading cause of death from cancer throughout the 
world. It is the second most common type of cancer in both men and women1-3. Surgical 
resection results in 5-year survival in 40-50% of patients with early stage non-small cell 
lung cancer (NSCLC). After radical radiotherapy only a small number is alive after 5 
years. However, a potentially curative resection is only possible in about 25% of new 
cases. Involvement of mediastinal lymph nodes (MLN) is a negative prognostic factor for 
both resectability and survival rate.   
Surgical biopsy of MLN by mediastinoscopy has to be considered as the gold standard for 
thorough preoperative, minimally invasive mediastinal staging4. Based on historical data, 
mediastinoscopy can only be omitted in patients with small (< 3 cm) peripheral 
squamous cell tumours without MLN enlargement on CT scan5-7. This was considered 
common daily practice in most hospitals in the Netherlands in that period, as described in 
these manuscripts5-7. 
Ideally, cervical mediastinoscopy at least requires sampling of nodes from stations 4 
(left- and right lower paratracheal) and 7 (subcarinal) routinely along with the nodes 
from station 2 (left- and right higher paratracheal), if accessible, as described in the 
American Thoracic Society staging system8. However, with an accuracy of 92% or better, 
mediastinoscopy is not always perfect and its result may be surgeon dependent9;10. Also, 
results from large studies in academic centres are probably not totally concordant with 
all-day clinical practice. Surgeons may refrain from biopsy of nodal stations because MLN 
cannot be visualized, due to lack of experience11, or due to risk of bleeding from adjacent 
large vessels. In cases where positive MLN were not biopsied by mediastinoscopy, wrong 
therapeutic decisions might be made. 
In view of the increasing demand for adequate preoperative mediastinal staging of highly 
suspected or proven lung cancer, we analyzed the results of mediastinoscopy and 
thoracotomy of three general hospitals and one teaching hospital in the Netherlands. Our 
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main study objective was to investigate the accuracy of preoperative surgical mediastinal 
staging procedures, which we divided and formulated as follows:  
1) To investigate the degree of adherence of treating physicians to the accepted staging 
procedures in their hospitals.  
2) To study, in case mediastinoscopy was performed, how often this was performed 
according to gold standards in normal clinical practice settings.  
For all objectives the results from the different hospitals were compared.  
Next to this main research question we investigated whether non-adherence to guidelines 
and not performing mediastinoscopies according to gold standard procedures might have 
had clinical implications. For this, in all patients postoperatively diagnosed having N2/N3-
disease localized at Naruke stations12 accessible for mediastinoscopy, we checked 
whether preoperative mediastinal surgical staging was adequately done. By doing so, we 
tried to obtain an indication about how many thoracotomies might have been prevented 
if protocols were followed adequately. 
 
Patients and Methods 
In a retrospective study data were evaluated of all patients who had mediastinoscopy 
and/or thoracotomy for lesions proven or highly suspicious for malignancy. From a non-
university, teaching hospital and three surrounding community (non-teaching) hospitals, 
data of patients treated between 1993 and 1999, were included. At that time, fluoro-2-
deoxy-D-glucose (FDG) positron emission tomography (PET) was not yet available in 
these hospitals. Of all participating hospitals data were collected by the regional cancer 
registry of the IKZ. Of this registry, several studies have been published in the area of 
lung cancer13;14. Surgery for proven N2 or N3 disease was not considered beneficial and 
therefore not performed in these patients during this study. The described staging 
procedures were not changed during the investigated period.  
From the patient records we gathered: demographic data, preoperative diagnosis (known 
or unknown), results of preoperative CT-scan, results of mediastinoscopy and 
thoracotomy, tumour histology, final staging data (cTNM data, in case of thoracotomy 
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pTNM data) and follow up data. Preoperative CT-scans were reviewed in case the 
radiologists’ report was unclear regarding the presence of enlarged MLN. Only patients 
diagnosed with NSCLC were included for analysis. When lymph node metastases were 
present, attention was given to whether metastases were limited to lymph nodes only, or 
also capsular involvement was present. Microscopic examination of MLN by the 
pathologist was standardized and slices were taken every 5 mm.  
 
Accuracy of preoperative surgical mediastinal staging procedures 
1) Adherence to staging management guidelines for indicating mediastinoscopy. 
Three of the four hospitals used the following guideline for indicating a mediastinoscopy: 
mediastinoscopy should be performed in all patients with NSCLC, except in case of a 
peripheral clinically staged (c)T1N0 squamous cell carcinoma. In the other non-teaching 
hospital, mediastinoscopy should be performed in all patients with NSCLC, except in case 
of a peripheral cT1N0 NSCLC in the right upper lobe. According to these guidelines, in 
case of the presence of a coin lesion suspicious for malignancy without histological proof, 
mediastinoscopy should be done, especially when enlarged MLN were present at 
preoperative CT-scan. We analyzed results of all investigated hospitals. For each patient, 
we compared clinical practice to the corresponding guidelines. These guidelines were 
agreed upon and accepted for use in clinical practice during a weekly conference between 
surgeons, radiologists and pulmonologists. Treatment plans were made according to 
these guidelines as described.  
 
2) Performance of mediastinoscopy according to gold standards in each hospital. 
From the files of the surgeon and the pathologist all information concerning site of 
biopsies and specification of tissue present in biopsies with the results of pathologic 
examination were registered. Locations of MLN were classified as 2 right/left, 4 right/left, 
7 and ‘other’, according to Naruke12. In case of doubt concerning localizations from which 
biopsies were taken, surgeons were additionally consulted. We considered 
mediastinoscopy to be performed according to gold standards if lymph node stations 4 
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(right and left) and 7 were biopsied with lymph node tissue present in all three biopsies. 
All other results were not considered to be performed according to gold standards. We 
did not include lymph nodes 2 right and 2 left (often difficult to reach), because it was 
felt that adherence to this method would be unfeasible in all-day clinical practice. On the 
other hand, we believe it is obligatory for adequate preoperative mediastinal staging to 
sample at least one contralateral lymph node.  
Again, results from individual hospitals were compared. 
 
Postoperative upstaging and adequacy of preoperative staging 
Thoracotomies done more than 28 days after mediastinoscopy were not included for 
analysis of final staging. In the hospitals no specific guidelines existed concerning MLN 
sampling during thoracotomy. In general, only MLN that were found to be enlarged were 
removed. In case of upstaging post-thoracotomy, we investigated which MLN were found 
to be positive during thoracotomy. Next, we investigated whether mediastinoscopy was 
performed according to gold standards in these cases and whether positive MLN found 
during thoracotomy would have been accessible for mediastinoscopy in these particular 
patients.  
 
Statistical analysis 
We used SPSS 11.0 for statistical analysis. To determine accuracy of preoperative 
surgical mediastinal staging procedures, adequacy of mediastinal lymph node sampling 
during thoracotomy and to compare results from different hospitals, we performed chi-
square test. Statistical significance was defined at p < 0.05. 
 
Results  
In total, 2177 patients were diagnosed having lung cancer (1562 NSCLC, 397 small-cell 
and 218 ‘other’) in our study cohort. From 1993 to 1999, 671 patients suspected of 
having malignant pulmonary lesions in these four hospitals were evaluated by either 
mediastinoscopy or thoracotomy, or both. The diagnosis of lung malignancy was 
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histologically proven in 635 patients (90%), of which 569 were NSCLC. These 569 
patients were included for analysis. Mean age was 64.0 years (ranging from 37-81 years) 
and 460 (81%) were men. Out of 569 NSCLC, 308 were squamous cell carcinoma, 128 
adenocarcinoma, 40 bronchoalveolair cell carcinoma, 4 adenosquamous carcinomas, and 
89 large cell undifferentiated carcinomas.  
Mediastinoscopy was performed in 387 patients. In 317 of these the diagnosis of NSCLC 
was known prior to the diagnostic procedure. Out of the 182 (32%) patients without a 
mediastinoscopy, 98 did not have a diagnosis of NSCLC established prior to surgery.  
 
Accuracy of preoperative surgical mediastinal staging procedures 
1) Adherence to staging management guidelines for indicating mediastinoscopy. 
Table 1 presents accuracy data for indicating a mediastinoscopy in the different hospitals, 
tested according to the corresponding guideline for that hospital. This table shows that in 
373 out of 569 (66.1%) patients, guidelines for indicating mediastinoscopy were followed 
correctly. Comparing the different hospitals, we found that the percentage of correctly 
indicated mediastinoscopies was lowest (26%) in the one hospital with the smallest 
number of evaluated patients (Table 1). This was significantly different from the other 
hospitals (p < 0.0001). No other significant differences could be detected between the 
hospitals. 
Surprisingly, in almost all (175 of the 182) patients without a mediastinoscopy, a 
mediastinoscopy should have been performed if guidelines were used strictly. Of all 569 
patients whom were evaluated, 387 underwent mediastinoscopy. In 13 out of these 387 
patients, mediastinoscopy could have been omitted according to corresponding 
guidelines. Nonetheless, one of these demonstrated mediastinal metastases of squamous 
cell carcinoma.  
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Table 1 Accuracy data for indicating mediastinoscopy, comparing different 
hospitals 
 
 GFC1 GNFC2 Total patients evaluated % Correct 
1 (Teaching) 190 83 273 69.6 
2 (Non-Teaching 1) 113 45 158 71.5 
3 (Non-Teaching 2) 61 31 92 66.3 
4 (Non-Teaching 3) 12 34 46 26.1 
Total  376 193 569 66.1 
1 GFC = Guidelines Followed Correctly 
2 GNFC = Guidelines Not Followed Correctly 
 
 
Table 3 Results from mediastinal lymph node sampling during thoracotomy 
 
Number of locations from which MLN were sampled  
during thoracotomy 
Hospital None (%) 1 2 3 4 5 6 
Total thoracotomies 
performed 
1 (Teaching) 98 (44 1) 65 37 16 3 2 1 222 
2 (Non-Teaching 1) 2 39 (30 1) 58 26 8 1 - - 132 
3 (Non-Teaching 2) 54 (66 1) 22 5 1 - - - 82 
4 (Non-Teaching 3) 36 (82 1) 7 1 - - - - 44 
Total 227 (47) 152 69 25 4 2 1 480 
1 All significantly different from each other 
2 Significantly best, p = 0.007 compared to the teaching hospital and p = 0.0001 compared to the 
other two non-teaching hospitals 
 
 
2) Performance of mediastinoscopy according to gold standards in each hospital. 
Performance results of all mediastinoscopies, according to hospital are presented in 
Figure 1. Out of all 387 mediastinoscopies, 151 (39.0%) were done according to gold 
standards and 60 (15.5%) were positive for mediastinal metastases. Table 2 presents 
detailed information about localizations from which MLN were biopsied at 
mediastinoscopy, comparing different hospitals. Mean overall amount of biopsied  
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Figure 1 
Results from all mediastinoscopies, comparing different hospitals 
 
 
localizations was 2.63 (±0.9, range 0-5). Figure 1 and Table 2 show that the more 
patients are evaluated, the better MLN are sampled during mediastinoscopy. 
 
Postoperative upstaging and adequacy of preoperative staging 
MLN (Naruke 1-9) were sampled in 253 (53%) out of 480 patients during thoracotomy. 
In Table 3 results from MLN sampling during thoracotomy are shown, comparing the 
different hospitals, which were all significantly different from each other. 
1 ? Teaching hospital            (34/202 (16.8%) with positive result)  
2 ? Non-Teaching hospital 1    (16/115 (13.9%) with positive result) 
3 ? Non-Teaching hospital 2    (9/60 (15%)    with positive result) 
4 ? Non-Teaching hospital 3    (1/10 (10%)    with positive result) 
        1           2 3    4  
Chapter 2 
_______________________________________________________________________________________________________ 
 - 52 -
Table 2 Details on localizations from which MLN were sampled at 
mediastinoscopy, comparing different hospitals 
 
(n)  Hospital 
Localizations of biopsies   1 (Teach) 2 (Non-
Teach 1) 
3 (Non-
Teach 2) 
4 (Non-
Teach 3) 
Amount (Mean (SD)) 1  2.63 (0.9) 2.7 (0.9) 2.58 (0.8) 1.0 
Combinations of MLN sampled at MS 2 
 4R+4L+7 
4R+7 
4L+7 
4R+4L 
4R 
4L 
7 
None 3 
90 
29 
5 
16 
13 
5 
19 
22 
42 
35 
8 
14 
9 
- 
1 
2 
19 
9 
9 
2 
1 
1 
15 
3 
- 
- 
- 
- 
2 
1 
- 
- 
 2R 
2L 
2R+2L 
17 
7 
15 
21 
4 
3 
4 
5 
2 
- 
- 
- 
 ‘Other’ 17 11 24 - 
 Unknown 3 4 1 7 
MS performed 4  202 115 60 10 
1 Mean amount of different localizations that were biopsied at mediastinoscopy. Maximum amount 
= 6 (Naruke stations 2 right/left, 4 right/left, 7 and ‘other’). SD = Standard error of mean.  
2 Biopsies without lymph node tissue present were excluded from this table. Localizations are 
according to Naruke. MS = Mediastinoscopy. 
3 None of the MLN at gold standard locations (4R, 4L or 7) was sampled. 
4 Numbers do not add up because of possible combinations between localizations. 
 
 
Mean amount of localizations from which MLN were sampled was 1.5 (range 1-6). Again, 
in the hospitals where most patients were evaluated and operated on (numbers 1 and 2 
in Table 3), MLN were generally sampled more often and more thorough. Table 4 
presents data on localizations of sampled MLN during thoracotomy, according to Naruke.  
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Table 4 Frequency of MLN sampled at different lymph node stations, 
according to Naruke, of all patients that underwent thoracotomy 
and MLN sampling (n = 253) 
 
Naruke 2R 3 4R 4L 5 6 7 8 9 UK 1 
Frequency 2 1 62 34 98 10 54 38 49 48 
Of which positive result 1 - 9 2 15 1 6 3 5 8 
1 UK = Unknown localization 
 
 
Overall, in 43 out of the 253 (17.0%) patients in whom MLN were sampled during 
thoracotomy, one or more MLN proved to be malignant. Maximum time interval of 28 
days was exceeded in 20 patients, so data of 233 out of 253 patients were available for 
analysis of upstaging. Mean time interval between mediastinoscopy and thoracotomy was 
14 days (range 2 – 28 days). Table 5 presents an overview of the presence of 
“unforeseen N2 disease”, in these 233 patients. 
Mediastinoscopy was performed in 156 of these 233 patients. Postoperatively, 27 
patients had N2- and 1 patient had N3 disease. Out of these 28 upstaged patients, 10 
had MLN positive at thoracotomy that would have been accessible for mediastinoscopy. 
Amongst these 10 patients, mediastinoscopy was not done according to gold standards in 
3 patients. One of these 3 patients was upstaged because of a positive MLN found at 
thoracotomy which was not biopsied during mediastinoscopy. 
Theoretically, this upstaging might have been prevented if this MLN station was 
adequately biopsied during mediastinoscopy. Furthermore, mediastinoscopy was also not 
performed according to gold standards in another 3 out of the 28 upstaged patients, but 
accessibility of MLN in these 3 patients could not be determined due to lack of 
information about localization of excised MLN at thoracotomy in these patients’ records.  
Mediastinoscopy was not performed in 77 patients of these 233 patients. Almost half (37) 
of these 77 patients underwent thoracotomy without a preoperative histological 
diagnosis. 
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Table 5 Presence of “unforeseen N2 disease” in all 233 patients that had 
thoracotomy and sampling of MLN with adequate time interval 
between mediastinoscopy and surgery 
 
(n) 
MS 1 + 
GS 3 +       GS - 
MS – 
+   Indicated  - 
Total 
Amount  66              90   77                 0  233 
Unforeseen N2/3 disease (intranodal) 14 (10)    14 (12) 11 (8)              - 39 (30) 
Positive MLN accessible for MS 
(Y/N/UK) 2 
7/5/2         3/8/3 6/4/1               - 16/17/6
Accessible MLN biopsied at MS   7                2   9 
N of thoracotomy that might have been 
prevented  
  0             1/0/3 6/0/1               - 7 
1 MS = Mediastinoscopy 
2 Y/N/UK = Yes / No / Unknown 
3 GS + = According to gold standards 
 
 
Postoperatively, 10 patients had N2- and 1 patient had N3 disease. Out of these 11 
upstaged patients, 6 had MLN positive at thoracotomy, which would have been accessible 
for mediastinoscopy. In another patient, accessibility could not be determined, due to 
lack of information about localization of excised MLN in patients’ record. All these patients 
should have had mediastinoscopy if guidelines for indicating mediastinoscopy would have 
been followed adequately.  
Table 5 shows that overall, 39 out of 233 (16.7%) patients who had some kind of 
mediastinal staging during thoracotomy appeared to have “unforeseen N2/3-disease” 
postoperatively. Thirty of those 39 were limited to intranodal metastases. Theoretically, 
upstaging and thoracotomy could have been prevented in at least 7 out of these 39 
(17.9%) patients, maybe even in 11 (28.2%) if the patients with positive MLN of 
unknown localization at thoracotomy had positive MLN at localizations accessible for 
mediastinoscopy. 
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Discussion 
This study shows that in all-day clinical practice, guidelines to perform or to skip 
mediastinoscopy in patients suspected for malignant lung lesions were adequately 
followed in approximately two-third of cases in four general hospitals. Physicians were 
especially reluctant to perform mediastinoscopy in patients with peripheral lesions 
without a preoperative histological diagnosis. Within the four hospitals the one with the 
smallest number of evaluated patients scored the worst percentage of correctly indicated 
mediastinoscopies, which was significantly different from the other hospitals. 
This study also shows that of all mediastinoscopies performed, 40% were done according 
to gold standards with regard to sampling of lymph nodes. There was a close relation 
between the number of mediastinoscopies done and the percentage of mediastinoscopies 
performed according to gold standards.  
Finally, sampling of MLN during thoracotomy was done more often and more thorough in 
the hospitals were most patients were evaluated and operated on. We found that MLN 
sampling during thoracotomy was done in approximately 50% of cases, which led to 
upstaging in 17% of patients. In almost one out of every five cases, upstaging and 
surgical intervention could theoretically have been prevented when mediastinoscopy 
would have been indicated and performed according to gold standards. 
 
Even nowadays, an adequately staged mediastinum remains obligatory in patients with 
NSCLC prior to surgery. N2 disease at mediastinoscopy is generally considered as an 
absolute contraindication to primary surgical resection. The few exceptions being 
unexpected N2 disease after adequate negative cervical mediastinoscopy, limited 
intranodal disease in the aortopulmonary nodes for a left upper lobe squamous cell 
carcinoma and in case complete resectability is anticipated by the surgeon15;16.  
Incidence of pN2 disease in cT1N0 squamous cell carcinomas is approximately 4%, 
varying from 0-8% in different studies5;17-20. For other carcinomas, for example 
adenocarcinomas, this percentage in cT1N0 is higher, varying from 10-20%17;21. 
Therefore, physicians in most Dutch hospitals at the time of this study felt that 
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mediastinoscopy can be omitted in patients with a preoperatively identified cT1N0 
squamous cell carcinoma without enlarged MLN on CT5-7;22. Nonetheless, many 
controversies still exist concerning invasive staging procedures for possibly resectable 
NSCLC, as is reflected in the literature19;23-25. Nowadays, after introduction of F-18 
fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, mediastinoscopy 
in most Dutch centres is omitted when MLN on FDG-PET are negative and the primary 
tumour is located peripherally26. On the other hand, mediastinoscopy remains obligatory 
to confirm all FDG-PET positive lymph nodes27.  
 
We found that in approximately one-third of cases, guidelines for indicating 
mediastinoscopy were not adequately followed. This can partly be explained by the 183 
thoracotomies that were performed in patients without prior mediastinoscopic 
examination of the MLN. Almost half of these patients went directly to thoracotomy 
without a preoperative histological diagnosis. When we excluded patients with peripheral 
lesions without a histological diagnosis and without mediastinoscopy (n = 97), the 
percentage of correctly followed guidelines for indicating mediastinoscopy rose from 66% 
to 79.5% (data not shown).  
Comparing the different hospitals, we found that the one hospital with the smallest 
number of evaluated patients scored the worst percentage (28%) of correctly indicated 
cases, which was significantly different from the other hospitals (p < 0.0001). After 
excluding data from this hospital, no significant differences could be detected. This 
finding is consistent with an American study11, in which authors suggested that the 
quality of care relates to the number of procedures performed in an hospital.   
Data from this study, as presented in Figure 1 and Table 1, also show that the more 
mediastinoscopies were performed in a specific center, the better MLN were sampled 
during the procedure. This difference might in part be explained by the fact that in the 
teaching hospital, mediastinoscopies are performed by cardiothoracic surgeons, in 
contrast to general surgeons in the non-teaching hospitals. Cardiothoracic surgeons may 
be more familiar and experienced with thoracic surgery and can therefore be more 
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thorough in performing mediastinoscopies. Results from our study could suggest that it is 
better to centralize mediastinoscopy and thoracotomy for NSCLC to larger hospitals with 
better results. In a recently published study by Birkmeyer28, an inverse association was 
found between surgeon volume and operative mortality for lung cancer resection. They 
therefore suggested that selected operations (including lung resection surgery) should be 
restricted to a smaller number of surgeons. Also, in a review article on this subject, 
Hillner et al29 suggested that, for all forms of cancer, efforts to concentrate its initial care 
would be appropriate. 
Nonetheless, overall, 40% of all mediastinoscopies were done according to gold 
standards. Apparently, in many cases, surgeons refrain from biopsy of one or more 
(Naruke 4R, 4L and 7) ‘gold standard’ mediastinal lymph nodes. Most often because no 
(enlarged) MLN were visible or could be visualized.  
In our study, only 60 out of 387 (16%) mediastinoscopies were positive for mediastinal 
metastases. Other studies present a higher percentage of positive mediastinoscopies, 
varying from 25-30% overall, to 7-10% in stage I NSCLC alone18;19;23;30. This difference 
in results from our study compared to the literature might be caused by our liberal 
guidelines for indicating mediastinoscopy which makes mediastinoscopy necessary in 
almost every patient with (suspected) lung cancer eligible for surgical resection. On the 
other hand, it can also be explained by the fact that in our study the mediastinum was 
not sampled as thorough as might be desirable.  
 
Considering the fact that in general patients with stage IIIA-B NSCLC are not cured by 
thoracotomy, this study provides important information. After thoracotomy and/or 
mediastinoscopy, 39 patients (17%) appeared to have N2 or N3 disease, of which at 
least 16 had MLN accessible for mediastinoscopy. Theoretically, at least 7 out of these 39 
thoracotomies could have been prevented because staging procedures were not 
adequately followed in these cases. We believe however, taking also into account that in 
47% of thoracotomies no MLN were sampled, that the actual number of patients having 
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“unforeseen N2-3 disease”, and thus possible ‘futile thoracotomy’, in our study was in 
fact higher.  
On the other hand, most (30/39) false negative mediastinoscopies in our study proved to 
be minimal N2 disease (Table 5) at thoracotomy. Because several studies show that 
survival is significantly better in unforeseen, intranodal N2 disease when complete 
surgical resection is possible, the clinical relevance of this finding remains unclear7;31. In 
patients with NSCLC, it would be interesting to investigate whether the recent 
introduction of FDG-PET scanning will result in an improved staging process and better 
selection of patients for surgical resection in clinical practice. 
 
Of course, our results might be biased due to the retrospective nature of our study. Our 
results are very much dependent on completeness of data in patient’ and pathologist’ 
records and accuracy of documentation on localizations of MLN by surgeons. 
Nevertheless, we believe that by using the Eindhoven Cancer Registry, which records 
data on all patients newly diagnosed with lung cancer in the southern part of the 
Netherlands with a completeness exceeding 95%, as our primary data source, our data 
were accurate14. Furthermore, we feel the results on upstaging are important because it 
gives us an impression on how often postoperative upstaging might have been prevented 
in our study population. 
 
Conclusion 
This study shows that in clinical practice, accuracy of preoperative surgical mediastinal 
staging procedures and sampling of MLN during thoracotomy is not as adequate as one 
should hope for. Furthermore, non-adherence to protocols for indicating and performing 
mediastinoscopy and surgical sampling was significantly higher in the smallest hospital. 
Because of this finding it might be recommended to perform these procedures only in 
those centres where one has sufficient experience. Local monitoring of these aspects of 
care in each center is of great importance, firstly to see whether problems in these areas 
might be present and secondly to instigate procedures to improve this, if necessary. 
Surgical Mediastinal Staging in Daily Practice 
_______________________________________________________________________________________________________ 
 - 59 -
Whether this will be effective and whether this might also have implications on clinical 
outcome calls for further prospective studies.      
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Abstract 
Background: In this study we investigated the impact of implementation of FDG-PET in 
daily practice on adherence to mediastinal staging protocols and performance of 
mediastinoscopy in NSCLC patients who are possible candidates for surgical resection. 
 
Methods: From a non-university teaching hospital and three surrounding community 
hospitals in Eindhoven, the Netherlands, we studied data of 143 patients with NSCLC who 
underwent mediastinoscopy and/or thoracotomy in three consecutive periods (I: 9 
months, II: 9 months and III: 13 months) after introduction of PET. Adherence to 
surgical mediastinal staging guidelines and performance of PET and mediastinoscopy 
were investigated and compared between the three periods and with our previous study 
before introduction of PET. 
 
Results: Guidelines for indicating mediastinoscopy were adequately followed in 
significantly more (80%) cases after introduction of PET, compared to the period before 
PET (66%). ‘Optimal’ harvest (N7, N4 right and left nodes) of mediastinoscopy (in 27% 
of cases) was not significantly different form the period before PET (39% of cases). 
Compared with the historical data, the percentage of positive mediastinoscopies 
increased from 15.5 to 17.6 (NS). We found no significant differences between the three 
consecutive periods with regard to adequacy of indicating and performance of 
mediastinoscopy. 
 
Conclusions: After introduction of PET, adherence to staging guidelines with respect to 
mediastinoscopy improved. Although fewer mediastinoscopies had an optimal harvest, 
more proved to be positive for metastases. Nevertheless, when mediastinoscopy is 
indicated, surgeons must be encouraged to reach an optimal harvest because PET 
positive nodes might be false negative. 
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Introduction 
In patients presenting with non-small cell lung cancer (NSCLC), one of the earliest and 
most important issues is determining resectability and operability, since complete 
resection offers the best prospects for patients with NSCLC. Resectability depends mainly 
on the presence of mediastinal lymph node metastases, which is an ominous prognostic 
sign and generally a contraindication to primary surgical resection. Even nowadays, after 
introduction of F-18-deoxyglucose positron emission tomography (FDG-PET), 
mediastinoscopy remains the gold standard for detecting N2-3 disease. 
In a former study, we found that adherence to staging guidelines and performance of 
mediastinoscopy in general practice is not as high as one should hope for1. Addition of 
FDG-PET to conventional workup of NSCLC patients who are possible candidates for 
surgical resection can be very useful in guiding mediastinal biopsy during 
mediastinoscopy and reduces the number of futile thoracotomies2. PET scanning is 
becoming more and more available, even in the smaller hospitals. Recently (October 
2002), FDG-PET scanning became available in our hospital. In this present study we 
investigated whether the non-supervised implementation of FDG-PET in daily practice 
resulted in improved performance and adherence to preoperative surgical mediastinal 
staging procedures. Secondly, we compared these results with our previous study before 
introduction of PET1. Thirdly, we studied in patients who were upstaged post-operatively 
whether upstaging might have been prevented in case preoperative staging protocols 
would have been followed correctly  
 
Patients and Methods 
Study design 
Data of all NSCLC patients who had mediastinoscopy and/or thoracotomy were collected. 
From a non-university teaching hospital and three surrounding community (non-
teaching) hospitals, data of NSCLC patients evaluated between October 2002, after the 
introduction of FDG-PET scanning, and April 2005, were included. To find out whether the 
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degree of adherence to staging guidelines or performance of mediastinoscopy improved 
as time after implementation of PET progressed, three arbitrarily chosen consecutive 
periods were analyzed: the first 9 months after FDG-PET became available (October 
2002-June 2003, period I), the second 9 months (July 2003-March 2004, period II) and 
the final 13 months (April 2004-April 2005, period III). Accessibility to PET was made 
known to physicians at its introduction and repeatedly mentioned during the weekly 
treatment planning conference of physicians involved in the treatment of lung cancer 
patients. The described staging procedures were not changed during the investigated 
period.  
Preoperative CT scans in the non-university teaching hospital were prospectively 
reviewed by two independent radiologists (ADG, ADR). Presence of pathologically 
enlarged mediastinal lymph node stations, defined as > 10 mm (or > 15 mm for 
subcarinal nodes) in short axis diameter, was systematically documented for all Naruke 
stations3. Furthermore, all preoperative PET scans were reviewed by two independent 
nuclear medicine physicians (ME, DH), in presence of CT scans. The localization of the 
primary tumor on PET was classified as: ‘peripheral’ or ‘central / adjacent to the 
mediastinum’. Mediastinal lymph nodes were localized according to Naruke. Criteria for 
PET positivity were the presence of focally enhanced uptake versus background. 
Whenever radiologists or nuclear medicine physicians disagreed, scans were reviewed 
again till agreement was obtained, which was possible in all cases. Results regarding 
adherence to mediastinal staging procedures and performance of mediastinoscopy were 
compared between the three consecutive periods and with the results from our previous 
study. 
 
Accuracy of surgical mediastinal staging procedures 
1) Adherence to staging management guidelines 
According to staging protocols in the four hospitals, PET should be performed in all 
patients with (suspicious) malignant lesions that were eligible for surgical resection. In all 
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four hospitals at the time of this study, PET was generally used to evaluate the 
mediastinum and to detect distant metastases. 
All four hospitals used the following guideline to decide whether or not to perform a 
mediastinoscopy: only in case of a peripheral tumor, without evidence of mediastinal 
lymph node metastases on PET and CT, mediastinoscopy could be omitted. In case no 
PET was performed, only in patients with histologically proven clinical(c) T1N0 squamous 
cell carcinomas, mediastinoscopy could also be omitted (like during the period before 
introduction of PET1). For each patient, we compared clinical practice to the 
corresponding guidelines. Surgery for proven N2 or N3 disease was considered non-
beneficial and therefore not performed in these patients during this study. There were no 
specific guidelines existed concerning mediastinal lymph node sampling during 
thoracotomy in the participating hospitals. In general, enlarged nodes were removed. In 
case of upstaging we analyzed whether preoperative mediastinal staging guidelines were 
adequately followed and if not, whether upstaging could have been prevented in case 
guidelines would have been followed correctly. 
 
2) Performance of mediastinoscopy 
Of all mediastinoscopies, information concerning site of biopsies and histopathologic 
diagnosis were registered. Locations of mediastinal lymph nodes were classified 
according to Naruke3. We considered the harvest of mediastinoscopy optimal, in case 
lymph node stations 4 (right and left) and 7 were biopsied with lymph node tissue 
present in all three biopsies. If these 3 sites were not biopsied results were considered to 
be non-optimal. In case PET showed positive mediastinal lymph nodes that were 
accessible for mediastinoscopy, we investigated whether these nodes were actually 
biopsied during mediastinoscopy. 
 
3) Upstaging 
In case of upstaging post-thoracotomy, we investigated whether these positive 
mediastinal lymph nodes found during thoracotomy would have been accessible for 
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mediastinoscopy and if so, whether this “false negative” staging procedure might have 
been caused by non-adherence to staging guidelines. 
 
Statistical analysis 
We used SPSS 13.0 for statistical analysis. To determine accuracy of preoperative 
surgical mediastinal staging procedures and to compare results from this study with the 
ones from our previous study, we performed chi-square test. Statistical significance was 
defined at p < 0.05. 
 
Results 
From October 2002 to April 2005, 143 patients with histologically proven NSCLC 
undergoing either mediastinoscopy, thoracotomy or both, were evaluated. Mean age was 
65 years ± 9 (range 41-84) and 107 (74.8%) were men. Of the 143 NSCLC patients, 46 
had squamous cell carcinoma, 64 adenocarcinoma, 4 bronchiolo-alveolair cell carcinoma 
and 28 large cell undifferentiated carcinoma; 52 (36.4%) were analyzed in period I, 46 
(32.2%) in II and 45 (31.5%) in III. 
 
Accuracy of surgical mediastinal staging procedures 
1) Adherence to staging management guidelines 
Table 1 presents data on adherence to staging guidelines and the number of diagnostic 
procedures that were performed in each period of time. There were no differences 
between these three periods. Overall, guidelines for indicating mediastinoscopy were 
adequately followed in 80% of patients. 
Mediastinal lymph nodes were sampled in 75 out of 122 patients (61.5%) during 
thoracotomy (Table 1). Maximum time interval of 28 days between mediastinoscopy and 
thoracotomy was exceeded in 9 patients, so data from 66 out of 75 patients were 
available for analysis on upstaging. Mean time interval between mediastinoscopy and 
thoracotomy was 17.2 days (range 7 – 26 days). In 8 out of the 66 (12.1%) patients, 
one or more sampled mediastinal lymph nodes proved to be malignant. 
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Table 1 Adherence to staging guidelines and the number of diagnostic  
procedures that were performed in each period of time after 
implementation of PET 
 
Period  PET1 MS (HO)2 GFC/GNFC3 Surgery Sampling4 Upstaged5 
 
 
Y 34 
 
Y 18 (5) 
 
N 16 
16 / 2 
 
14 / 2 
Y 15 
 
Y 16 
Y 12 
 
Y 9 
0 
 
0 
I (n = 52) 
 
N 18 
Y 12 (3) 
 
N 6 
12 / 0 
 
2 / 4 
Y 9 
 
Y 6 
Y 4 
 
Y 3 
2 
 
1 (GNFC)* 
Total % 65.4 % 30 (8)(26.7%) HO 84.6 % 46 60.9 % 11.5 % 
 
Y 33 
 
Y 13 (5) 
 
N 20 
13 / 0 
 
13 / 7 
Y 8 
 
Y 20 
Y 6 
 
Y 15 
1 
 
2 (GFC) II (n = 46) 
 
N 13 
 
Y 7 (2) 
 
N 6 
7 / 0 
 
0 / 6 
Y 2 
 
Y 6 
Y 1 
 
Y 1 
0 
 
0 
Total % 71.7 % 20 (7)(35%) HO 71.7 % 36 63.9 % 14.3 % 
 
Y 31 
 
Y 16 (4) 
 
N 15 
16 / 0 
 
13 / 2 
Y 13 
 
Y 15 
Y 9 
 
Y 8 
1 
 
1 (GFC) III (n = 45) 
 
N 14 
 
Y 8 (1) 
 
N 6 
8 / 0 
 
0 / 6 
Y 6 
 
Y 6 
Y 4 
 
Y 3 
0 
 
0 
Total % 68.9 % 24 (5)(20.8%) HO 82.2 % 40 60 % 10.5 % 
Overall  68.5 % Y 74 (27%) HO 79.7 % Y 122 61.5 % 12.1 % 
1 Y  = procedure performed; N = procedure not performed 
2 Number of mediastinoscopies (MS) performed (between brackets, the number and/or percentage 
of mediastinoscopies with optimal harvest (HO; HNO = harvest not optimal) 
3 Guidelines followed correctly/Guidelines not followed correctly (GFC/GNFC) 
4 Percentage of thoracotomies during which mediastinal lymph nodes were sampled 
5 Percentage of patients diagnosed having N2-3 disease after thoracotomy (between brackets 
whether guidelines were followed correctly) 
* Mediastinal lymph nodes that proved positive for metastases during thoracotomy were not 
accessible for mediastinoscopy 
 
 
In the one patient where mediastinal staging guidelines were not followed correctly 
(GNFC) (Table 1), mediastinal lymph nodes that proved to be involved during 
thoracotomy were not accessible for mediastinoscopy. So upstaging could not have been 
prevented in this patient if guidelines would have been adequately followed. 
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2) Performance of mediastinoscopy 
In Table 2 results of PET and mediastinoscopy are presented. The number of separate 
mediastinal lymph nodes that were positive on PET and accessible for mediastinoscopy 
was respectively 15, 13 and 3 for the three consecutive periods. There were no 
differences between these three periods with regard to upstaging. 
We found that out of all 74 mediastinoscopies, 20 (27%) were done with an optimal 
harvest (Table 1) and 13 (18%) were positive for mediastinal metastases (Table 2). 
Overall, out of 49 separate PET positive nodes that were accessible for mediastinoscopy, 
31 (63%) were actually biopsied (Table 2). During all 74 mediastinoscopies, a total of 
163 separate mediastinal lymph node localizations were biopsied, of which 14 (9%) 
separate nodes proved positive for metastases (data not shown). This was not 
significantly different compared to the results from our previous study1, where a total of 
981 mediastinal lymph node localizations were biopsied during 387 mediastinoscopies, of 
which 97 (10%) proved to be positive for metastases. 
Overall, data from 66 patients could be analyzed for upstaging; PET was performed in 54 
of these patients. PET appeared to be false negative for mediastinal lymph node 
metastases in 3 patients (5.6%) with PET-positive (peripherally located) 
adenocarcinomas (Table 2). 
 
Comparison to period before introduction of PET1 
In Table 3 an overview comparing the results from this study with those from our 
previous study is presented. After the introduction of PET in our study cohort, adherence 
to guidelines on whether or not to perform mediastinoscopy increased significantly (p = 
0.002) from 66% to 80%. The percentage of mediastinoscopies performed with an 
optimal harvest decreased and the number of thoracotomies where mediastinal lymph 
nodes were sampled increased, however, for both this did not reach significance. 
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Table 2 Results of PET and mediastinoscopy in each period of time after 
implementation of PET 
 
Period  PET 1 Separate 
MLN 2 
Accessible MLN 
biopsied 3 
MS Upstaged  
P 16 23 15 (65.2%) 
P 1 
N 14 
ND 1 
- 
0 
0 
N 18 - -  
P 0 
N 3 
ND 15 
- 
0 
0 
I (n = 52) 
ND 18 - - 
P 2 
N 10 
ND 6 
- 
2 
1 
       
P 20 18 13 (72.2 %) 
P 3 
N 10 
ND 7 
- 
1 
0 
N 13 - -  
P 0 
N 0 
ND 13 
- 
1 
1 
II (n = 46) 
ND 13 - - 
P 4 
N 3 
ND 6 
- 
0 
0 
      
P 16 8 3 (37.5 %) 
P 1 
N 13 
ND 2 
- 
1 
0 
N 15  - - 
P 0 
N 2 
ND 13 
- 
0 
1 
III (n = 45) 
ND 14 - - 
P 2 
N 6 
ND 6 
- 
0 
0 
      
Overall Total 98 49 31 (63.3 %) P 13 8 
1 Results from PET pertaining to the mediastinum (P: positive ? either separate mediastinal lymph 
nodes were positive or presence of a tumor adjacent to the mediastinum; N: negative) 
2 Number of separate mediastinal lymph nodes that were positive on PET and accessible for 
mediastinoscopy 
3 Number of separate positive mediastinal lymph nodes on PET that were actually biopsied during 
mediastinoscopy 
Abbreviations: MS mediastinoscopy; MLN mediastinal lymph nodes; P positive result; N negative 
result; ND not done 
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Table 3 Influence of introduction of PET on adherence to mediastinal 
staging protocols and performance of mediastinoscopy, in 
percentages 
 
1 MS = mediastinoscopy 
2 NS = not significant 
3 in case surgery was performed 
* Smulders SA. Lung Cancer 2005; 47(2): 243-2 
 
 
Discussion 
In this study PET scan was pre-operatively performed in 69% of patients undergoing 
mediastinoscopy and/or thoracotomy for NSCLC. We found that in daily practice, 
guidelines on whether or not to perform mediastinoscopy were correctly followed in 4 out 
of every 5 patients. This was significantly better compared to the period before the 
introduction of PET (p = 0.002). In only 27% of mediastinoscopies harvest of mediastinal 
lymph nodes was considered optimal, however 18% of mediastinoscopies proved to be 
positive for metastases. Overall, 63% of separate positive mediastinal lymph nodes on 
PET that were accessible for mediastinoscopy were actually biopsied. Finally, sampling of 
mediastinal lymph nodes during thoracotomy was done in 62% of cases, which led to 
upstaging in 12% of patients. PET proved to be false negative for mediastinal lymph 
node metastases in 6% of cases. 
 
In this study we found that adherence to guidelines on whether or not to perform 
mediastinoscopy was significantly (p = 0.002) increased after the introduction of PET. 
% 
Pre-PET period 
n = 569* 
Post-PET period 
n = 143 p 
% correctly indicated MS 1 66.1 79.7 0.002 
% MS according to gold standards 39.0 27.0 0.083 
% positive MS 15.5 17.6 NS 2 
% thoracotomies with nodes sampled 3 52.7 61.5 0.082 
% patients upstaged after thoracotomy  16.7 12.1 NS 
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Perhaps shortly after the implementation of such a promising new diagnostic imaging tool 
like the PET scan, clinicians are more aware of the current literature and try extra hard to 
adhere to existing guidelines. Furthermore, it is possible that these guidelines after the 
introduction of PET were simply easier to adhere to than before. However, in contrast to 
what we expected, the number of patients that underwent PET, did not increase in time. 
Results from our study might furthermore be influenced because in 1 out of every 3 
patients, PET was not done, possibly due to non acquaintance of some physicians with 
PET in the beginning of this study and because of problems implementing its use in 
practice, like long waiting lists. 
 
Although we hypothesized that performance of mediastinoscopy would improve, because 
of the awareness of our previous study and the introduction of PET, the opposite 
appeared to be true. In fact, the number of mediastinoscopies with an optimal harvest 
decreased, although not significantly, from 39% to 27%. This may be caused by the fact 
that results of PET are considered as a guide to biopsy only one or two PET positive 
nodes, rather than trying to get an optimal harvest during mediastinoscopy. 
Furthermore, we found that not all positive mediastinal lymph nodes on PET were 
actually biopsied during mediastinoscopy. Despite this we found in our present study a 
slightly higher percentage of positive mediastinoscopies (17.6%), compared to our 
former study (15.5%) (NS).  
Herder et al. demonstrated that use of PET for all lung cancer patients is not better than 
the normal staging procedures4. On the other hand it was demonstrated that the use of 
PET in NSCLC patients considered for surgery is cost-effective2. Despite this proven cost-
effective use, introducing a new diagnostic tool, without additional measures for optimal 
implementation, does not automatically result in significant change of attitude of 
physicians and incorporation of new guidelines in daily routine. As such, this is well-
known from other areas of pulmonary medicine, such as introduction of guidelines for 
optimal use of diagnostic techniques for pulmonary embolism5-8. For the introduction of 
expensive new drugs resulting in improvement of medical treatment despite additional 
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costs, regulatory boards like FDA and EMEA have to evaluate this and consider whether 
the benefit is sufficiently large to have significant impact on outcome. For the 
introduction of new diagnostic techniques there is no comparable standard procedure and 
it needs more than simply making the technique available, to come to optimal use. 
Professional organizations should not only develop guidelines but need to evaluate its use 
as well and, if insufficient, stimulate optimal use by supervised introduction within quality 
care projects. Governmental health care and/or insurance companies need to stimulate 
these by supplying financial support for the introduction of cost-effective diagnostic 
algorithms and treatment9,10. Furthermore, clinicians have their own responsibility to be 
aware of the characteristic performance of the new tool used in their institution before 
integrating it into diagnostic algorithms11. 
 
In summary after the introduction of PET we found that: 
1. Staging protocol is followed in 80% of all cases. 
2. One out of three patients did not underwent a PET scan. 
3. Optimal harvest in mediastinoscopy in only 27% of all cases. 
4. Only 62% of positive PET nodes accessible for mediastinoscopy were actually 
biopsied. 
5. Introducing optimal use of a new diagnostic technique fails if not actively 
supported.   
We believe that monitoring these aspects of care is extremely important but sadly in 
most hospitals not performed. 
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Abstract  
Background: 18FDG-PET scans are obtained to stage non-small cell lung cancer (NSCLC). 
Lymph node status at PET is important to guide the further staging procedure, especially 
with the introduction of new less invasive biopsy techniques such as endoscopic 
ultrasound. This study was designed to test the extent of variation among nuclear 
medicine physicians with respect to this aspect of NSCLC staging at PET, and to assess 
how their interpretations differed from that of expert readers. 
 
Methods: Two groups of nuclear medicine physicians with different levels of PET 
experience (‘experienced’ (n=7) and ‘inexperienced’ (n=7)) reviewed thirty PET scans of 
patients with suspected operable NSCLC. They were requested to identify and localise 
suspicious mediastinal lymph nodes (MLN) on each scan and to formulate a clinical 
management advise using standardized algorithms. Results were compared between the 
2 groups, between individuals and with expert reading. 
 
Results: Overall, 80% of the management recommendations and 68% of N-stage 
classifications were correct, with moderate and good interobserver agreement (kappa 
0.59 and 0.65, respectively). Detection rate (72% versus expert reading) and most 
common mislocalisations of separate MLN stations were equally distributed between the 
2 groups. Experience with PET translated into a better ability to localise MLN stations 
(68% versus 51%, respectively), and experienced readers appeared to be more familiar 
with translating PET readings into clinically useful statements. 
 
Conclusions: Although our results suggest that clinical experience with PET increases 
observers’ ability to read and interpret results from PET adequately, there is still room for 
improvement, even among experienced observers. Education with structured databases 
in a skill’s lab setting supported by expert feedback might be an effective instrument of 
knowledge transfer. 
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Introduction 
In non-small cell lung cancer (NSCLC), proven ipsi- (N2) or contralateral (N3) 
mediastinal lymph node involvement precludes cure by surgery. F-18-deoxyglucose 
positron emission tomography (18FDG-PET) is increasingly used to stage NSCLC patients. 
The yield of whole-body PET pertains to typing the primary pulmonary lesion and on the 
preoperative identification of distant and lymph node metastases. Moreover, PET may 
simplify and improve lymph node evaluation by setting the indication for biopsy and 
improving its yield. Mediastinoscopy is the standard technique of invasive lymph node 
staging but the results in daily practice are quite variable1. It has been suggested that 
the proportion of tumor positive procedures increases if guided by PET2;3. So far, 
mediastinoscopy is the most often used invasive method, but more recently endoscopic 
techniques (like EUS-FNA) have been developed. Since the mediastinal areas covered by 
mediastinoscopy and EUS-FNA are largely complementary, proper localisation of possible 
malignant nodes is important to assign patients to the appropriate procedure. 18FDG-PET 
criteria of test positivity for mediastinal lymph node staging are based on recognition of 
focally enhanced uptake (‘hot spots’) versus background, rather than on quantitative 
assessment (like the 1 cm short axis criterion with CT scanning). Results from PET 
studies pertaining to its accuracy in mediastinal staging are robust4, but as the technique 
is disseminating, observer variation and learning curves need to be documented.   
The aim of the present study was to measure the observer agreement and accuracy 
versus expert readings of mediastinal lymph nodes in NSCLC staging with 18FDG-PET, at 
various levels of complexity and as a function of experience. 
 
Materials and Methods 
Study Design 
We used a set of 30 PET scans from the study by Joshi et al.5 of consecutive patients 
referred for staging to the Department of Nuclear Medicine and PET Research of the 
VUmc. To obtain an adequate case mix, we included scans of patients with a range of 
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mediastinal lymph node sizes at CT scanning: 1) ≤ 10 mm short axis diameter (n = 10), 
2) 10.1-15 mm (n = 10) and 3) > 15 mm (n = 10). PET scans had been performed 
according to the standard protocol in our institution using a full ring BGO PET scanner 
(ECAT EXACT HR+, CTI/Siemens, starting 60 min. after 370 MBq 18FDG)5. 
The scans were analysed by 14 nuclear medicine physicians, who had extensive 
experience with SPECT but variable expertise with PET and mediastinal lymph node 
staging in NSCLC: 7 had no personal experience with PET (the ‘inexperienced group’) 
whereas the others had at least one year of experience with PET in NSCLC patients in 
their own clinical practice which comprised access to mobile PET once every one or two 
weeks (the ‘experienced group’). On average, the inexperienced group had reviewed 0-
15 PET scans each compared to a 100-150 (with at least 50% NSCLC) each in the 
experienced group. Prior to this study, the observers had been instructed in workshops 
by two expert PET readers, a pulmonologists and a surgeon about the concepts, 
principles and practice of mediastinal staging in NSCLC by PET and other methods. The 
results of the observers were compared to the combined judgement of the two expert 
nuclear medicine physicians (EFC, OSH), and the latter readings were used as the gold 
standard. The expert readers had been working together in the same university hospital 
for numerous years and had a broad experience with PET6-8. 
 
We developed a software tool running Matlab 5.3, which allowed simultaneous 
visualisation of PET images in the axial, coronal and sagittal planes (at 5 or 10 mm slice 
thickness), with possible cross linking. Each observer was requested to identify and 
interpret any abnormal hot spot representing primary tumor or lymph node, blinded for 
the results of the other readers. This software tool was installed on the personal 
computer of each observer, and the results were electronically stored for analysis. In 
order to be able to accurately relate results of different observers, the coordinates of 
each hot spot identified by an observer were stored and linked to the assigned 
interpretation. Since none of the observers had worked with this software before, we 
provided a test set (derived from the original data set) of three scans to each observer 
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Table 1 Classification system of tumor and lymph nodes 
 
Primary tumor 
- Presence 
* No tumor present 
* Primary tumor 
* Second primary 
 
- Localisation 
* Peripheral 
* Adjacent to mediastinum 
* Adjacent to hilus 
Lymph node localisation a 
* No lymph nodes present      
* N1 L / R                       
* N2 L / R                       
* N3                                     
* N4 L / R     
* N5 / * N6 / * N7 
* N8 L / R 
* N9 L / R 
* N10 L / R 
* Clavicular L / R 
Likelihood of malignancy 
* Definitely benign 
* Probably benign 
* Equivocal 
* Probably malignant 
* Definitely malignant 
Management recommendation  
* Invasive lymph node evaluation 
* Thoracotomy 
* Expectative policy 
a According to Naruke’s map of lymph node definitions (Figure at page 16) 
 
 
prior to the study. These three scans comprised 29 separate abnormal mediastinal lymph 
node localisations and therefore provided an adequate way to practice working with 
Naruke’s map of lymph node localisations (Figure adapted from Mountain, page 16 of this 
thesis)9. Observers had knowledge of the clinical information provided with the original 
PET scan referral, except for the mediastinal stage at CT. 
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Data acquisition 
The observers were asked to interpret abnormal hot spots pertaining to the primary 
tumor and lymph nodes in terms of their localisation and likelihood of malignancy using 
the classification systems shown in Table 1 and the figure at page 16. Criteria for test 
positivity was the presence of focally enhanced uptake vs. background. Furthermore, 
observers were asked to formulate a recommendation with respect to the next 
management step to the referring clinician (Table 1). In this context, we instructed them 
to use the following protocol: 1) recommend biopsy of mediastinal lymph nodes in case 
of suspected (hilar or mediastinal) lymph node involvement, and in case of tumors 
adjacent to the mediastinum or hilus; 2) recommend thoracotomy in case of a peripheral 
primary tumor without suspicious mediastinal lymph nodes at PET; 3) recommend an 
expectative policy in case PET shows no abnormal uptake in either the primary site nor in 
lymph nodes. For the purpose of the present investigation, they were instructed to ignore 
possible suspicious extrathoracic localisations in these management considerations. 
 
Data analysis 
Using the individual scores of the observers, we assigned an ‘N-stage according to PET’ 
for each observer and each patient using the following classification:  
1. N0 (peripheral primary tumor, no mediastinal hot spot)  
2. N1 (peripheral primary tumor and separate hot spot considered to be a hilar 
lymph node) 
3. N0-N1 (primary tumor within hilar area, no separate mediastinal hot spot) 
4. N0-N2 (primary tumor adjacent to mediastinum, no separate mediastinal hot 
spot) 
5. N2 (hot spot compatible with ipsilateral mediastinal lymph node) 
6. N3 (hot spot compatible with contralateral mediastinal or clavicular lymph node) 
We performed a more detailed analysis of the nature of the errors in the ‘management 
recommendation’ classification versus the expert reading, identifying whether these 
errors followed the observers’ own interpretation of suspicious lymph node stations, or 
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resulted from true errors (protocol violation). For example, the former situation occurred 
if, in case of a peripheral primary tumor, an observer considered the ipsilateral right 
lower tracheobronchial station to be positive at PET, whereas the expert only identified 
the primary lesion. The resulting discrepant management recommendations 
(mediastinoscopy versus thoracotomy, respectively) directly flow from these 
classifications. We coined such an incorrect answer as a mistake (M). However, if this 
observer would have advised to proceed directly to thoracotomy, this was considered a 
protocol violation (P). 
 
We also measured the accuracy of defining and localising suspected mediastinal lymph 
node stations at PET. Compatible with known limitations of PET with respect to spatial 
resolution and accounting for different levels of clinical relevance, we accepted the 
following differences of nodal classifications (Figure at page 16): Naruke stations 1 and 2 
(left (L) / right (R) respectively); 4R and 10R; 4L and 10L and 5; 8 and 9 (L / R, 
respectively). Using this simplified system, we analysed whether observers defined and 
localised suspected lymph node metastases versus the expert reading ‘correctly’, 
‘incorrectly’ or ‘not at all’. 
 
Statistical Analysis 
Statistical analysis was done by SPSS 13.0 software. To determine interobserver 
agreement regarding ‘management recommendation’ and ‘N-stage’, and to compare this 
to expert readings, we calculated the Kappa coefficients, using AGREE 7.2. We used 
weighted kappa’s for the N-stage analysis. Furthermore, to detect potential differences 
between the two groups of observers with different PET experience with respect to the 
nature of the management recommendation errors, and the classification of separate 
mediastinal hot spots, we used the Wilcoxon-Mann-Whitney test. Statistical significance 
was set at p < 0.05. 
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Table 2 Inter observer agreement and accuracy as a function of experience 
with respect to the classification of ‘N-stage’ and ‘management 
recommendation’ 
 
 
Inexperienced  
Observers  
(n = 7) 
Experienced  
Observers  
(n = 7) 
 
Overall 
Management  
recommendation a 
- Agreement versus expert 
 
 
0.60 
(0.42 – 0.77) 
 
 
0.58 
(0.37 – 0.79) 
 
 
0.59 
(0.42 – 0.76) 
- Pair wise agreement 0.48 
(0.35 – 0.62) 
0.56 
(0.41 – 0.71) 
0.50 
(0.37 – 0.63) 
N-stage b 
- Agreement versus expert 
 
0.58 
(0.36 – 0.80) 
 
0.72  
(0.55 – 0.88) 
 
0.65 
(0.47 – 0.83) 
- Pair wise agreement 0.56 
(0.44 – 0.68) 
0.61 
(0.49 – 0.74) 
0.58  
(0.46 – 0.69)  
a Kappa (95% confidence interval) 
b Weighted kappa (95% confidence interval) 
 
 
Results 
The 30 PET scans comprised a total of 89 locations of suspected malignancy, according to 
the gold standard (expert reading). Thirty-four represented tumor locations, 55 were 
lymph nodes (10 hilar, 39 mediastinal and 6 supraclavicular). According to expert 
readers, there was a mean of three sites (primary lesion and lymph nodes) per patient 
(range 1-13). The experts classified 82 lesions as ‘definitely malignant’, 5 as ‘probably 
malignant’ and 2 as ‘equivocal’. In the final analysis, these ‘probably’ and ‘definitely’ 
malignant locations were classified as malignant. The expert N-stage classifications 
included 9 ‘N0’, 3 ‘N1’, 1 ‘N0-N1’, 3 ‘N0-N2’, 9 ‘N2’ and 5 ‘N3’, according to the 
definitions mentioned earlier. 
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Table 3 Details on N-stage (using the classification system described in the 
methods section) in 30 scans for each inexperienced observer 
 
Inexperienced observers 
N-stage 
classified correctly  
[% (n)] a 
N-stage  
overestimated 
[% (n)] b 
INEXP 1 70.0 (21) 20.0 (6) 
INEXP 2 56.7 (17) 20.0 (6) 
INEXP 3 70.0 (21) 13.3 (4) 
INEXP 4 63.3 (19) 23.3 (7) 
INEXP 5 66.7 (20) 20.0 (6) 
INEXP 6 66.7 (20) 20.0 (6) 
INEXP 7 66.7 (20) 10.0 (3) 
Total 65.7 (138) 18.1 (38) 
 
Experienced observers   
EXP 1 63.3 (19) 30.0 (9) 
EXP 2 76.7 (23) 6.7 (2) 
EXP 3 73.3 (22) 10.0 (3) 
EXP 4 73.3 (22) 20.0 (6) 
EXP 5 73.3 (22) 13.3 (4) 
EXP 6 73.3 (22) 16.7 (5) 
EXP 7 60.0 (18) 20.0 (6) 
Total 70.5 (148) 16.7 (35) 
a Percentage of N-stages classified correctly versus expert reading 
b Percentage of overestimated N-stages versus expert reading 
 
 
Management recommendations were correct in 80% of cases (86 errors out of 420 
recommendations, 42 in the experienced group and 44 in the inexperienced group). The 
accuracy versus expert reading was moderate (kappa 0.59) at either level of experience 
(Table 2). The level of agreement among inexperienced observers tended to be lower, 
but did not reach significance. Four scans accounted for a total of 38 errors (44%) while 
not a single mistake by any observer was made in eight. 
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Table 4 Accuracy of inexperienced and experienced observers to detect and 
localise the 26 mediastinal lymph node stations present according 
to the expert reading 
 
Inexperienced observers 
Identified  
[% (n)] a 
Correctly localised  
[% (n)] b 
INEXP 1 76.9 (20) 30.0 (6) 
INEXP 2 84.6 (22) 63.6 (14) 
INEXP 3 61.5 (16) 62.5 (10) 
INEXP 4 80.8 (21) 23.8 (5) 
INEXP 5 69.2 (18) 55.6 (10) 
INEXP 6 65.4 (17) 64.7 (11) 
INEXP 7 57.7 (15) 66.7 (10) 
Total 70.9% (129) 51.2% (66) 
Experienced observers 
 
EXP 1 76.9 (20) 65.0 (13) 
EXP 2 61.5 (16) 81.3 (13) 
EXP 3 69.2 (18) 83.3 (15) 
EXP 4 73.1 (19) 89.5 (17) 
EXP 5 84.6 (22) 77.3 (17) 
EXP 6 80.8 (21) 42.9 (9) 
EXP 7 69.2 (18) 38.9 (7) 
Total 73.6% (134) 67.9% (91) 
a Percentage of identified nodal stations versus expert reading 
b Percentage of correctly localised nodal stations versus expert reading (e.g. INEXP 1 identified 20 
out of the 26 stations, and 6 out of 20 were localised correctly). 
 
 
In the group of inexperienced readers, 29 (of 44; 66%) of the incorrect management 
recommendations were protocol violations (type ‘P’), versus 17 (of 42; 40%) in the  
experienced readers group (p = 0.12). On the contrary, errors that directly flow from 
reading errors (type ‘M’) were significantly more prevalent in the group of experienced 
readers (25 out of 42 = 59%), versus 15 out of 44 (34%) in the inexperienced readers 
group (p = 0.03). Common errors (type ‘P’, protocol violations) were e.g. to recommend 
‘expectative policy‘ or ‘directly to thoracotomy’ in a patient without enhanced PET uptake 
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in primary tumor and mediastinal lymph nodes. However, the provided clinical 
information stated that bronchoalveolar cell carcinoma had been proven histologically. 
Therefore, ‘mediastinal lymph node evaluation’ should have been recommended, because 
the mediastinum in a patient with adenocarcinoma without 18FDG uptake of the primary 
tumor cannot be reliably evaluated so that histological confirmation of the mediastinum is 
required. 
 
N-stage classifications were correct in 68% of cases (286 out of 420 assigned N-stages, 
138 in the inexperienced group and 148 in the experienced group). Experienced 
observers tended to have a better agreement with the expert reading than inexperienced 
ones (weighted kappa’s 0.72 and 0.58, respectively). N-stages were overestimated in 
17.4% (16.7% by the experienced and 18.1% by the inexperienced observers) and 
underestimated in 14.5% of cases (12.9% and 16.2%, respectively). The individual 
scores of the observers (Table 3) reveal that errors in either direction were made by 
most of them. 
Since we used three scans to practice on localising mediastinal lymph nodes, 27 scans 
remained with 26 separate lymph node localisations. The detection rate of individual 
mediastinal lymph node stations was similar for inexperienced and experienced observers 
(71% and 74%, respectively, Table 4), and the variation within the groups was also 
comparable. However, experienced readers were better at localising the stations than 
inexperienced readers were (correct in 68% versus 51%, respectively). The most 
common mislocalisations (Table 5 and the figure at page 16) were to classify right 
tracheobronchial stations (4R) as upper right paratracheal (2R), subcarinal (7) as right 
tracheobronchial (4R) and left para-esophageal (8/9L) as left tracheobronchial (4L). 
 
Discussion  
Observer variation is the Achilles’ heel of diagnostic imaging10, and especially of tests 
that apply visual interpretation. It is therefore surprising that the clinical PET literature 
contains few studies on observer variation beyond the level of occasional reports on  
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Table 5 Mediastinal lymph node stations * by experienced and 
inexperienced observers, according to Naruke 
 
 Experienced and Inexperienced Observers 
Expert (CA) 2 R 3 4 L 4 R 6 7 8 R 8 L SC
 T † Missed 
2 R (1 R) 4         1 9 
3 7   3      1 3 
4 L (5, 10 L)   24  1     14 31 
4 R (10 R) 18 1  85  1 1  1 14 19 
7  1 2 13  15    1 25 
8 R (9 R)    4   8   1 1 
8 L (9 L)   9  1   8  1 9 
SC 2   2     14 6 3 
* Using the simplified system mentioned in the methods section regarding the acceptance of 
different lymph node classifications, consistent with clinical practice, for expert and both groups of 
observers 
† T Tumor: observer identified pertaining mediastinal lymph node as primary or second primary 
tumor 
CA Correct Alternative, according to simplified system; SC Supra- or infraclavicular lymph nodes;  
 
 
variation between two observers participating in an accuracy study. The present study 
reports on the results of 14 observers stratified by their experience with PET, and it 
accounts for several aspects of the clinical context of NSCLC staging (management 
recommendation, N-stage, nodal stations). We found that the accuracy (versus expert 
reading) was moderate to substantial at moderate levels of interobserver agreement. Our 
results suggest that clinical experience with PET improves the ability of readers to 
localise mediastinal hot spots correctly, and this is relevant with respect to the next 
clinical step: i.e. to decide which invasive verification method should follow and to 
enhance the yield of such procedures. Moreover, within the more experienced group, the 
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agreement of assigning N-stages and management recommendations tended to be 
better. Finally, familiarity with clinical practice and staging protocols for NSCLC patients 
may have contributed to fewer inconsistencies in management recommendations. Our 
management advice constructs were designed to account for generally recognized 
limitations of PET in mediastinal staging. 
With slightly different endpoints the interobserver agreement of CT reading appears to be 
similar to what we have reported: in CT evaluation of mediastinal lymph node size, 
Guyatt et. al. reported a kappa of 0.61 regarding the presence of any nodes greater than 
1 cm on CT scan11. However, agreement in different nodal groups varied widely and it 
appeared to be far more difficult for the left superior mediastinal nodes. In our study we 
found that some mistakes were made relatively more often regarding localising separate 
lymph nodes (Table 5). With the increasing clinical methods to verify imaging findings 
(transesophageal, transbronchial ultrasound guided fine-needle aspiration, 
mediastinoscopy, video-assisted thoracoscopy), the relevance of interpreting images at 
the nodal level is growing. PET-CT may help to improve the yield of PET and CT reading, 
in patients newly presenting with lung cancer, but also in restaging after neo-adjuvant 
therapy. Limitations of our study were the lack of co-reading of PET with CT scans, the 
relative unfamiliarity of the observers with the display and registration software, and 
perhaps the lack of standardized computer screens.  
 
In the Netherlands, the availability of 18FDG-PET is rapidly expanding, even in smaller 
hospitals, and this has major implications for local nuclear medicine physicians as well as 
for residents. To our knowledge, the duration of time that is needed before results on 
PET are adequately reviewed and interpreted (´the learning curve´) by nuclear medicine 
physicians is unknown. We had anticipated striking differences between experienced and 
inexperienced readers, but this was not the case. However, there was obvious room for 
improvement in the experienced group and we suggest that optimal performance is not 
acquired by experience alone but requires higher levels of direct feedback12. We propose 
that such feedback could be achieved efficiently in experimental settings like applied in 
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our study. We believe that datasets like the present should play a key role in training of 
residents since they can learn and demonstrate improving skills at any time during their 
training. However, for example in the Dutch setting, this requires that residents should 
spend more time in such skills labs and less in daily clinical production.   
 
Conclusion 
Emerging alternatives to invasively stage the mediastinum in NSCLC puts high levels of 
skill to interpret PET and CT scans in NSCLC patients. Observer variation of PET and CT 
reading in mediastinal staging appear to be similar, with obvious room for improvement. 
Training of imaging specialists may require higher levels of feed-back which can more 
efficiently be obtained in skills labs using existing databases than currently achievable in 
local daily clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
Observer Variation of 18FDG-PET in Mediastinal Staging of NSCLC as a Function of Experience, and its potential Clinical Impact 
_______________________________________________________________________________________________________ 
 - 91 -
Reference List 
 (1)  Smulders SA, Smeenk FW, Janssen-Heijnen ML et al. Surgical mediastinal staging in daily practice. Lung 
Cancer 2005; 47(2):243-251. 
 (2)  Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell 
lung cancer. Eur J Radiol 2003; 45(1):49-59. 
 (3)  Kernstine KH. Positron emission tomography with 2-[18f]fluoro-2-deoxy-D-glucose: can it be used to 
accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy? 
Journal of Thoracic and Cardiovascular Surgery 2003; 126(6):1700-1703. 
 (4)  Gould MK, Maclean CC, Kuschner WG et al. Accuracy of positron emission tomography for diagnosis of 
pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285(7):914-924. 
 (5)  Joshi U, Hoekstra OS, Boellaard R et al. Initial experience with a prototype dual-crystal (LSO/NaI) dual-
head coincidence camera in oncology. Eur J Nucl Med Mol Imaging 2004; 31(4):596-598. 
 (6)  van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the 
preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre 
randomised trial. Lancet 2002; 359(9315):1388-1393. 
 (7)  Herder GJ, van Tinteren H, Comans EF et al. Prospective use of serial questionnaires to evaluate the 
therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected 
lung cancer. Thorax 2003; 58(1):47-51. 
 (8)  Hoekstra CJ, Stroobants SG, Hoekstra OS et al. The value of [18F]fluoro-2-deoxy-D-glucose positron 
emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for 
combined modality treatment. Lung Cancer 2003; 39(2):151-157. 
 (9)  Mountain C, Dresler C. Regional lymph node classification for lung cancer staging. Chest 1997; 
111:1718-1723. 
 (10)  Robinson PJ. Radiology's Achilles' heel: error and variation in the interpretation of the Rontgen image. Br 
J Radiol 1997; 70(839):1085-1098. 
 (11)  Guyatt GH, Lefcoe M, Walter S et al. Interobserver variation in the computed tomographic evaluation of 
mediastinal lymph node size in patients with potentially resectable lung cancer. Canadian Lung Oncology 
Group. Chest 1995; 107(1):116-119. 
 (12)  Brehmer B. In one word: not from experience. Acta Psychologica 1980; 45:223-241. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
_______________________________________________________________________________________________________ 
 - 92 -
 
  
Part II 
 
 
Postoperative Function 
 
 
 
 
 
 
 
 
 
 
 
  
 Chapter 5 
 
Actual and Predicted Postoperative Changes in 
Lung Function after Pneumonectomy  
A retrospective analysis 
 
 
Sietske A Smulders, Frank WJM Smeenk 
Maryska LG Janssen-Heijnen, Pieter E Postmus 
 
 
Chest 2004; 125: 1735-1741 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
_____________________________________________________________________________________________________ 
 - 96 -
 
Abstract  
Background: Little is known about long-term effects of pneumonectomy on lung function 
and exercise tolerance. We evaluated the long-term validity of two formulas frequently 
used to predict postoperative lung function as well as trends in postoperative lung 
function and late postoperative exercise capacity.  
 
Setting: Non-university teaching hospital of Eindhoven, The Netherlands. 
 
Patients: Patients who underwent pneumonectomy between 1993 and 1998 and survived 
for more than one year after the operation. 
 
Methods and Results: Lung function and exercise test data of 32 patients were analyzed. 
Postoperative forced vital capacity (FVC) and forced expiratory volume in one second 
(FEV1) according to Kristersson/Olsen (split function of resected lung) and Juhl and Frost 
(number of segments to be resected) were calculated and compared with observed 
values measured in the third postoperative year. Calculated values correlated well with 
observed values, whereas Kristersson/Olsen appeared to be more accurate than Juhl and 
Frost. When considering trends in FEV1, we found a mean decline of 44 ml/year; only 3 
patients (12%) showed a rapid decline of more than 100 ml/year. Of 14 patients (44%), 
postoperative maximal exercise capacity was impaired due to ventilatory limitation.  
 
Conclusions: The Kristersson/Olsen formula was more accurate in predicting 
postoperative lung function in the third postoperative year in pneumonectomy patients. 
Although the annual decline in FEV1 in these patients is almost the same as in healthy, 
non-COPD patients, pneumonectomy has serious implications on exercise capacity in 
many patients.  
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Introduction 
Lung cancer is currently the most common cause of cancer mortality throughout the 
world. It is the second most frequent type of cancer among men and women1;2. Non-
small cell lung cancer (NSCLC) accounts for 80% of all newly diagnosed lung cancers. At 
present, complete resection offers the best prospects and results in cure in a substantial 
number of patients with NSCLC. In order to determine whether lung resection is feasible 
in NSCLC patients and to what extent, resectable patients need to be carefully screened 
for their cardiopulmonary reserve. The best and most frequently used indicators for 
postoperative lung function are the forced expiratory volume during first second-predicted 
postoperative (FEV1-ppo)3-6, diffusion capacity of the lung for carbon monoxide-ppo (DLCO-ppo)6-9 
and maximal oxygen uptake during exercise-ppo (VO2max-ppo)4;10;11. There is consensus in 
the literature that lobectomy leads to very little permanent functional deficit after 6 
months4. Pneumonectomy causes a more permanent deficit which is higher for 
pulmonary function (i.e. forced vital capacity FVC and FEV1) than for exercise capacity 
(VO2max)4. FVC and FEV1 are lowered by approximately 33% whereas VO2max is 
decreased by approximately 20%. However, little is known about long-term (more than 
one year postoperative) effects of pneumonectomy on lung function and exercise 
tolerance. 
Several formulas are in use aiming to predict postoperative lung function after 
resection12-14. In general these formulas can be divided into two categories. The first 
category of formulas calculates postoperative FVC and FEV1 by the number of segments 
to be resected13. The second category of formulas includes the function of these 
segments by measuring their actual perfusion preoperatively12;14;15. These formulas 
proved reasonably valid when the predicted lung function was compared with the one 
measured relatively soon, within three months, after the operation. Since recruitment of 
underperfused or overventilated lung segments may occur after lung resection, especially 
after pneumonectomy16;17, it is still unclear what the validity of these formulas might be 
for predicting lung function at a much later stage. Furthermore, these formulas were 
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validated in a small number of patients after pneumonectomy. Nevertheless, they are 
worldwide accepted in guidelines3;4;18. Therefore, our main study objective was to 
investigate the validity of these formulas in pneumonectomy patients surviving for more 
than two years after the operation. Subsequently, we studied trends in postoperative 
lung function and examined the implications of pneumonectomy on exercise capacity in 
patients surviving for more than one year after the operation. 
 
Patients and Methods                                                             
In a retrospective study all data of patients who underwent pneumonectomy in a non-
university teaching hospital between 1993 and 1998 and survived for more than one year 
after the operation, were evaluated. Informed consent was obtained. 
From the patient records the following characteristics were gathered: demographic data, 
tumour histology and stage, date of surgery, site of operation and presence of chronic 
obstructive pulmonary disease, according to American Thoracic Society criteria19. We 
used these data to answer our three research questions. 
 
Predicting postoperative lung function 
The predicted postoperative lung function, FEV1 and FVC, were calculated by using the 
two most commonly used formulas: 
1) FEV1-ppo (or FVC-ppo) = FEV1-preop (or FVC-preop)* × (1- fractional contribution of                            
resected lung segments)12;14  
2) FEV1-ppo (or FVC-ppo) = FEV1-preop (or FVC-preop)* × (1- (S × 0.0526))13  
S being the number of resected lung segments, each segment accounts for 1/19 
of total lung function. 
*FEV1-preop = preoperative FEV1 (or FVC) 
 
The predicted and observed postoperative lung function data measured in the third year 
after the pneumonectomy were compared. We used the last available data in that third 
postoperative year for analysis. 
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Trends in postoperative lung function 
If more than two postoperative lung function tests were available, the changes in 
postoperative lung function over time were analyzed. These lung function tests had to be 
done at least more than 6 months postoperative and with a minimum time interval of 12 
months between the first and last available test. 
 
Exercise capacity 
The pre- and postoperative maximal incremental exercise test results, performed 
according to European Respiratory Society criteria20, were compared. The postoperative 
test had to be done more than one year after the operation. Ventilatory limitation of 
exercise capacity was defined as21: 
1) pCO2 at maximum exercise being > 45mmHg or 
2) Ventilation at maximum exercise (VEmax) ≥ 37.5 × FEV1  
 
Statistics  
SPSS 9.0 was used for statistical analysis. For the evaluation of the two formulas for 
predicting postoperative lung function, scatterplots were made and regression analysis 
performed with the predicted postoperative lung function as the independent variable 
and the observed postoperative lung function as the dependent variable. Long-term 
trends in lung function after pneumonectomy were studied by linear regression 
analysis22;23. 
 
Results  
Patients 
From 1993 until 1998, 76 patients underwent pneumonectomy in our hospital. Forty-
four patients were excluded from the study, 17 patients because of missing data, 26 
patients died within one year after the operation and 1 patient refused to participate. 
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Figure 1 
Schematic overview of included patients and drop-outs for each research question. 
 
 
Table 1 presents initial patient characteristics of the 32 included patients compared to 
the drop outs and the total patient group. There were no statistical significant 
differences between the groups. Figure 1 shows a schematic overview of evaluable 
postoperative data and drop outs for each separate research question. 
The diagnosis of lung malignancy was confirmed histologically in 31 patients; one 
patient underwent pneumonectomy because of an abscess with persisting empyema. Of 
 
Pneumonectomy patients from ’93-’98 
n = 76 
Drop outs 
- Missing data  n = 17 
- Death < 1 year   n = 26 
- Refused  n = 1 
Evaluable group 
n = 32 
Exercise testing Trends in 
lung function 
Predicting postoperative  
lung function, 3rd year 
Evaluable group 
Kristersson/Olsen 
Fractional contribution 
of resected lung 
segments 
n = 20 
Evaluable group 
Juhl and Frost 
Amount of lung 
segments to be 
resected 
n = 21 
Drop outs 
- Death < 3 years     n = 5 
- No test in 3rd year  n = 6 
- No perfusion scan n = 1 
Drop outs 
- < 3 tests  n = 4 
- Wrong interval n = 2 
Evaluable group 
n = 26 
Evaluable group 
n = 17 
Drop outs 
- Died < 1 year  n = 6 
- Not able to  n = 5 
- No preop. test  n = 4 
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Table 1 Initial patient characteristics of included patients (n=32) and total 
patient group 
 
 
Value 
Study group 
Value 
Drop outs 
Value 
Total group 
Patient Characteristics n=32 n=35 n=67 3 
Male / Female (n) 24 / 8 32 / 3 56 / 11 
Mean age (year) (range) 1 62.4 (42-75) 62.1 (37-76) 62.3 (37-76) 
Median survival  
(months postoperative) (range) 64.5 (19-110) 6.0 (1-21) 19.0 (1-110) 
COPD + (n) 1 9 11 20 
Pneumonectomy Right / Left (n) 13 / 19 18 / 17 31 / 36 
Preoperative Lung Function Data 2 n=32 n=35 n=67 3 
FVC (L)  
FVC % predicted 
3.41 ± 0.8 
89.8 ± 14.3 
3.39 ± 1.0 
84.9 ± 19.1 
3.40 ± 0.9 
87.2 ± 17.0 
FEV1 (L)  
FEV1 % predicted  
2.48 ± 0.7 
83.5 ± 18.9 
2.44 ± 0.7 
78.7 ± 18.8 
2.46 ± 0.7 
81.0 ± 18.9 
FEV1/FVC  69.0 ± 11.3 70.2 ± 9.6 69.5 ± 10.4 
Preoperative Exercise Test Data 2 n=28 n=29 n=57 
Wmax (W)  
Wmax % predicted  
121.2 ± 32.2 
99.3 ± 26.3 
111.5 ± 24.1 
89.5 ± 19.2 
116.3 ± 28.5 
94.3 ± 23.3 
VO2max (ml/min/kg)  
VO2max % predicted  
19.9 ± 5.7 
73.8 ± 23.0 
19.2 ± 3.3 
73.0 ± 11.9 
19.5 ± 4.6 
73.4 ± 18.1 
Ventilation at maximum exercise (L/min) 51.9 ± 13.2 57.8 ± 12.5 54.9 ± 13.1 
1 at time of surgery 
2 mean ± standard error of mean  
3 of which complete preoperative data could be obtained (n=67), 9 missing because of missing 
data 
 
 
all 31 malignant tumours, 20 were squamous cell carcinoma, 7 adenocarcinoma, 2 large 
cell undifferentiated carcinoma, 1 adenocystic carcinoma and 1 carcinoid tumour. 
Adjuvant radiotherapy was given to 10 patients, 9 because of residual disease and 1 
because of adenoid cystic carcinoma of the left main bronchus; 3 patients were treated 
with adjuvant chemotherapy. 
 
Chapter 5 
_____________________________________________________________________________________________________ 
 - 102 -
Predicting postoperative lung function 
Scatterplots of predicted lung function data according to both formulas versus observed 
postoperative lung function data obtained in the third year after pneumonectomy are 
depicted in Figures 2 and 3, as well as the results of the linear regression analysis. These 
figures show that in patients surviving for more than two years after pneumonectomy, 
calculation of predicted postoperative FVC and FEV1 by both formulas correlates well with 
the observed postoperative FVC and FEV1. Linear regression analysis showed that the 
coefficient of determination (R2) was higher for the Kristersson/Olsen formula than the 
Juhl and Frost formula. This indicates that the formula by Kristersson/Olsen12;14 was 
more accurate in predicting postoperative FVC and FEV1 than the formula by Juhl and 
Frost13 for the investigated postoperative year. Furthermore, the formula by Juhl and 
Frost predicted postoperative FEV1 roughly 300 ml lower than the Kristersson/Olsen 
formula. 
 
Trends in postoperative lung function 
Long-term postoperative changes in lung function of individual patients could be analyzed 
in 26 patients. The number of postoperative lung function tests varied between 3 and 12 
tests (mean: 7 tests) and the mean time interval between the operation and most recent 
lung function test over which trends were analyzed was 9.9 ± 63.0 months. The mean 
annual decline in FEV1 was 44 ml. Of 26 patients, 6 patients had improvement in FEV1  
postoperatively, 10 patients had a decline of 0-50 ml/year in FEV1, 7 patients had a 
decline of 50-100 ml/year in FEV1 and 3 patients had a decline over 100 ml/year in FEV1.  
 
Exercise capacity 
Table 2 shows the results of the pre- and postoperative exercise tests. These were 
available in 17 of 32 patients, with a mean time interval between the operation and the 
postoperative exercise test of 38 months (± 21.4; range 12–77 months). The decrease in 
workload at maximum exercise (Wmax) and VO2max was 27%, respectively 30%. 
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Table 2 Mean maximum incremental exercise test results preoperative and 
postoperative (n=17) 
 
 Preoperative 2 Postoperative 2 
Wmax (W) 123.6 ± 22 90 ± 24.2 
Wmax (% predicted) 102.1 ± 19.8 75.5 ± 17.3 
VO2max (ml/kg/min) 1 20.3 ± 4 14.2 ± 3.8 
VO2max (% predicted) 1 75.4 ± 16.9 53.6 ± 14.7 
Dyspnea Index 0.57 ± 0.15 0.67 ± 0.17 
Ventilatory Limited 4 5 
1 n=16, because of defective equipment  
2 ± standard error of the mean 
 
 
Preoperatively, maximal exercise tolerance was restricted due to a limited ventilatory 
capacity in 4 out of these 17 patients, whereas postoperatively this was the case in 5 out 
of these 17 patients. In all cases it was concluded that maximal exercise was restricted 
due to a limited ventilatory capacity because pCO2 exceeded the 45 mmHg limit at 
maximum exercise. 
 
Discussion 
This study shows that calculation of FVC-ppo and FEV1-ppo by both the Kristersson/Olsen 
and the Juhl and Frost formula correlated well with the observed postoperative FVC and 
FEV1 in the third year (mean 31.4 ± 3.7 months) after pneumonectomy. The formula by 
Kristersson/Olsen appeared to be more accurate in predicting postoperative FVC and 
FEV1 than the formula by Juhl and Frost. Roughly seen, the formula by Juhl and Frost, 
estimated FEV1-ppo in the third postoperative year about 300 ml lower than the formula by 
Kristersson/Olsen. When considering the long-term trend in lung function we found that 
the mean decrease in FEV1 was about 44 ml/year. Only three patients showed a rapid 
decline of more than 100 ml/year. No evidence for regeneration capacity in 
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Markos VC, 3rd yr postop.
4.0
3.0
2.0
1.0
4.03.02.01.0
n = 20
y = 0.978 x + 0.057
R2 = 0.75
 
Markos FEV1, 3rd postop.
4.0
3.0
2.0
1.0
4.03.02.01.0
n = 20
y = 1.081 x – 0.089
R2 = 0.79
 
 
Figures 2 A and 2 B 
Scatterplots of predicted FVC (Liters) versus observed postoperative FVC (Liters) (Figure 2 A) and 
of predicted FEV1 (Liters) versus observed postoperative FEV1 (Liters) (Figure 2 B), according to 
Kristersson/Olsen (using split function tests to determine the fractional contribution of resected 
lung segments to overall lung function) of 20 patients in the third year after pneumonectomy. 
Predicted postoperative FVC/FEV1 is on the x-axis and observed postoperative FVC/FEV1 is on the 
y-axis. Dots represent separate patients. The continuous line (regression line) represents results of 
the linear regression analysis. The dotted line represents the line of identity. R2 represents 
coefficient of determination. 
 
Figure 2 A; FVC 
Figure 2 B; FEV1  
Actual and Predicted Postoperative Changes in Lung Function after Pneumonectomy 
_______________________________________________________________________________________________________  
 - 105 -
Zeiher VC, 3rd yr postop.
4.0
3.0
2.0
1.0
4.03.02.01.0
n = 21
y = 0.882 x + 0.46
R2 = 0.62
 
Zeiher FEV1, 3rd yr postop.
4.0
3.0
2.0
1.0
4.03.02.01.0
n = 21
y = 0.969 x + 0.226
R2 = 0.69
 
 
Figures 3 A and 3 B 
Scatterplots of predicted FVC (Liters) versus observed postoperative FVC (Liters) (Figure 3 A) and 
of predicted FEV1 (Liters) versus observed postoperative FEV1 (Liters) (Figure 3 B), according to 
Juhl and Frost (using the amount of resected lung segments to determine postoperative lung 
function) of 21 patients in the third year after pneumonectomy. Predicted postoperative FVC/FEV1 
is on the x-axis and observed postoperative FVC/FEV1 is on the y-axis. Dots represent separate 
patients. The continuous line (regression line) represents results of the linear regression analysis. 
The dotted line represents the line of identity. R2 represents coefficient of determination. 
 
 
 
 
Figure 3 A; FVC 
Figure 3 A; FEV1 
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pneumonectomy patients could be detected. Finally, pneumonectomy appears to lower 
Wmax at least by 27% and VO2max by 30%. At least 40% of the patients experience 
impaired maximum exercise capacity due to ventilatory limitation. 
 
The lower postoperative FVC and FEV1 predicted by the Juhl and Frost formula compared 
to the observed FVC and FEV1, might be explained by the fact that this formula does not 
take into account the function of the segments that will be removed. Zeiher et al.24 found 
this underestimation of FEV1-ppo to be approximately 500 ml at 7.2 months (mean, 
ranging 24 days to 5 years) after pneumonectomy. In our study, we found an 
underestimation of FEV1-ppo of 225 ml, indicating further decrease in FEV1 in this period of 
time or a better prediction of FEV1-ppo by the Juhl and Frost formula a few years after 
pneumonectomy. Bolliger et al.25 recently found that both predictions of postoperative 
cardiopulmonary function by perfusion scan and quantitative CT scan (6 months 
postoperatively) were useful irrespective of the extent of resection. Unfortunately, we did 
not choose the use of quantitative CT scan for long-term prediction in our study, which 
would be very interesting to do. 
 
In healthy non-smokers, FEV1 physiologically decreases with approximately 30 ml/year. 
In current heavy male cigarette smokers (>25 cigarettes/day) this decline can increase 
to approximately 60 ml/year26;27. The mean annual decline in FEV1 was 44 ml in our 
study. No clear correlation between the amount of decline and presence of chronic 
obstructive pulmonary disease, adjuvant radiotherapy or adjuvant chemotherapy could 
be detected. When looking at the patients individually we found that 6 out of 26 patients 
showed an improvement in their FEV1 in time after their pneumonectomy whereas 3 
patients showed a rapid deterioration of more than 100 ml/year. One of the possible 
explanations for these findings might be the past and current smoking status of the 
patients. Unfortunately, we were not able to determine the exact past and current 
smoking status in our patients because of the retrospective nature of our study. A 
possible explanation for the improvement in FEV1 we observed in 6 of our patients might 
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be a better treatment of an underlying obstructive pulmonary disease or the occurrence 
of recruitment and distention of alveoli and capillaries after a pneumonectomy. Some 
investigators have suggested that this might be the main adaptive mechanism of the 
lung to the new situation after pneumonectomy16;17. Laros et al.28 found that because of 
recruitment and alveolar distention the vital capacity increased slightly during the first 
few years after pneumonectomy.   
 
In our study, Wmax and VO2max decreased with 27% and 30% at approximately 38 
months after the operation. Probably this decrease is an underestimation of the real 
decrease because 9 patients postoperatively could not be tested due to death or 
shortness of breath. Our data compare well with those of Nugent et al.29. They found that 
pneumonectomy was associated with impaired exercise performance and reduced 
VO2max by 28% 6 months after the operation. Others found reductions of 16%30 and 
20%4;31 at 6 months after the operation. These results suggest that long-term exercise 
performance might already be predicted at 6 months postoperatively. 
Only 17 out of the 32 patients were able to perform a postoperative exercise test, of 
which 5 tested to be ventilatory limited to exercise. When also taking into account the 15 
patients who were not available for postoperative exercise testing, we believe the actual 
number of ventilatory limited patients might be higher. Out of these 15 patients, 5 
patients were not able to perform this test because of poor lung function and shortness 
of breath, indicating that exercise limitation might be due to ventilatory problems. Six 
patients, of whom 4 had preoperative ventilatory limited exercise tests, died before 
having performed a postoperative exercise test. Death was attributed to respiratory 
failure in 4 out of these 6 patients also indicating ventilatory limitation postoperatively. 
Adding these 9 patients without a postoperative exercise test to the 5 with a test, results 
in 14 out of 32 (44%) patients probably being ventilatory limited to exercise after 
pneumonectomy. Two out of these 9 patients also experienced cardiac comorbidity, 
besides their pulmonary limitations, which probably contributed to their limited exercise 
capacity. The preoperative FVC and FEV1 of the 9 patients who were not able to perform 
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an exercise test postoperative, were compared to the preoperative FVC and FEV1 of the 
patients in whom it was proven that ventilatory problems were the reason for 
postoperative exercise limitation. The preoperative lung function results in these 9 
patients were worse, which makes it very likely that these 9 also have (had) ventilatory 
limitation as a reason for a restricted exercise capacity.  
 
When considering our results, it might be argued that our results are biased because of 
missing data. Because we found no indications for selective drop out when comparing the 
final study group and the drop out group on their initial patient characteristics we have 
no indication that this might be the case. This study was conducted solely to answer our 
three research questions in long-term survivors. Also, compared to previous studies6;24, 
we were able to include a relatively large number of patients which make our results 
more robust. Nevertheless, because of the retrospective character of this study, our 
results need to be confirmed by a prospective one. 
 
Conclusion 
In conclusion, this study showed that the Kristersson/Olsen formula was a better 
predictor of postoperative FVC and FEV1 than the Juhl and Frost formula in patients 
surviving for more than two years after pneumonectomy. Secondly, the annual decline in 
FEV1 in these patients is almost the same as in healthy, non-COPD patients. Finally, we 
found that Wmax more than one year after pneumonectomy (mean interval of 38 
months) decreased by 27% and VO2max by 30%, at least. Knowledge of these changes 
in lung function and exercise tolerance in these patients is extremely useful for the 
preoperative assessment and counseling of patients who are eligible for pneumonectomy.   
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Abstract 
Background: To study the adaptation of the right ventricle and pulmonary vascular bed 
shortly after pneumonectomy by cardiac MRI. 
 
Setting: Non-university teaching hospital of Eindhoven and VU University Medical Center in 
Amsterdam, the Netherlands. 
 
Methods: In 8 patients undergoing pneumonectomy (4 right-, 4 left), lung function and 
cardiac function were measured before surgery (t = 0), at two weeks (t = 1) and at three 
months (t = 2) postoperatively. 
 
Results: At t = 1, stroke volume and left ventricular end-diastolic volume were decreased (p 
= 0.036) and heart rate increased (p = 0.017), indicating depressed cardiac function. At t = 
2, these values were normalised indicating that adaptation had been successfully completed. 
No signs of right ventricular enlargement or – hypertrophy were found. 
 
Conclusions: This study shows that despite a sudden amputation of the pulmonary vascular 
bed, leading to an underfilling of the LV and a subsequent decrease in stroke volume shortly 
after pneumonectomy, RV and LV function remain stable in the postoperative phase. Within 
three months stroke volume, LV and RV structure and function are normalised compared to 
preoperative values. 
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Introduction 
In patients with non-small cell lung cancer (NSCLC), complete resection offers the best 
prospects and results in cure in a substantial number of patients. In case a pneumonectomy 
is required, this will lead to a sudden significant reduction of the pulmonary vascular bed 
demanding a quick adaptation of the heart. Successful adaptation of the heart to increased 
blood flow through the remaining lung and altered pressure relationships within the thorax 
after pneumonectomy depends upon the ability of the pulmonary vascular bed to expand1. 
Early and late effects of pneumonectomy on right ventricular (RV) function have been 
studied by echocardiography and thermodilution2-4. It was found that in patients with little or 
no lung disease in the remaining lung, in the long term, pulmonary artery pressure and 
pulmonary vascular resistance remain normal or are slightly increased at rest due to these 
adaptive mechanisms5-7.  
In contrast, the left side of the heart has been less studied in postpneumonectomy patients. 
We hypothesized that a reduction of the pulmonary vascular bed might lead to a decrease of 
pulmonary compliance and thereby directly altering left ventricular (LV) inflow8. According to 
Frank-Starling’s law, a decrease in preload will result in a decrease in stroke volume. For 
this reason, LV underfilling might also contribute to the depressed cardiac function 
postoperatively.  
In the present study we measured the consequences of a pneumonectomy on RV and LV 
filling and volumes, using MRI techniques in patients with normal lung parenchyma on the 
HRCT of the remaining lung. Furthermore, the ability of the LV to adapt in time will be 
investigated. 
 
Patients and Methods 
We prospectively studied 8 lung cancer patients eligible for pneumonectomy in an academic 
and in a non-university teaching hospital. Lung function and general health in all patients 
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was adequate enough to tolerate pneumonectomy9. Preoperatively, 2 patients had moderate 
(FEV1 (% of predicted) and FEV1/FVC of 78/51 and 64/46) chronic obstructive pulmonary 
disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria10. Although some patients had an obstructive flow pattern, the CT scans in 
these patients did not show any evidence for pulmonary emphysema. For this reason the 
mild obstruction must be interpreted as secondary due to airway obstruction in patients with 
centrally located carcinomas. A few months before pneumonectomy, 1 patient underwent 
cardiac surgery (aortic valve prosthetic bio-implant) and 2 other patients underwent 
induction chemotherapy. Informed consent was obtained from all subjects, and the local 
ethics committees approved the study. 
 
Lung function and cardiopulmonary exercise testing 
We performed lung function in all patients before (t = 0) pneumonectomy, directly 
postoperative (within 2 weeks) (t = 1) and at 3 months (t = 2) after pneumonectomy. Lung 
function measurements assessed were: vital capacity (VC), forced expiratory volume in 1 
second (FEV1) and diffusion capacity for carbon monoxide, corrected for alveolar volume 
(DLCO VA). 
Furthermore, exercise tests (maximum workload (Wmax); maximum oxygen uptake during 
exercise (VO2max); ventilation at maximum exercise (VEmax)) were done preoperatively (t 
= 0) and, if possible, also at 3 months postoperatively (t = 2). During maximum incremental 
exercise test, patients’ measurements were recorded after a 3-minute resting period on the 
bicycle, after which patients started exercising at a constant speed of 60 rpm at 0W during 2 
minutes. A ramp protocol based on patient’s age, gender and FEV1 followed till patients were 
exhausted. Recovery period lasted 6 minutes. The Vslope method was used to determine 
whether the anaerobic threshold was reached. 
Lung function and exercise tests were done in accordance with the American Association for 
Respiratory Care11 and European Respiratory Society criteria12 using standard equipment 
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Vmax 229 and 6200, SensorMedics, Yorba Linda, USA (for the academic centre) and 
standard equipment Oxycon Beta and Masterlab, Viasys, Bilthoven, the Netherlands (for the 
non-academic centre). 
 
Cardiac measurements 
All patients underwent CMR imaging preoperatively (t = 0), within 2 weeks postoperative (t 
= 1) (or, whenever this was not feasible, as soon as possible after surgery) and at 3 months 
(t = 2) after pneumonectomy (Figure 1), according to the following protocol. 
 
 
Figure 1 
Cardiac MR four chamber images of one patient during each measurement.  
From left to right: preoperative (t = 0), 2 weeks postoperative (t = 1) and 3 months postoperative (t 
= 2). 
R Right side of patient; RV, LV Right and left ventricle 
 
 
Magnetic Resonance Imaging Protocol13 
The patients were scanned using a 1.5 T Siemens Sonata whole body system (Siemens 
Medical Systems, Erlangen, Germany) in the academic centre or the 1.5 T Philips Intera, 
software release 10.3 ( Philips Medical Systems, Best, the Netherlands) in the non-academic 
teaching centre. On both systems a phased-array body coil was applied. All image 
acquisition was prospectively triggered by the R-wave of the electrocardiogram. The subject 
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was instructed to hold his breath in moderate inspiration during all image acquisitions (thus 
also during scout imaging for localization of the heart). 
Short-axis ventricular imaging 
The horizontal long-axis view was determined in a late diastolic frame using a black-blood 
prepared turbo gradient-echo sequence13. Then a breath hold cine-acquisition was 
performed of this long-axis view. By using the end-diastolic cine frame of this long-axis 
view, a series of parallel short-axis (SA) image planes was defined starting at the base of 
the LV and RV, and encompassing the entire LV and RV from base to apex. The most basal 
image plane was positioned close to the transition of the myocardium to the mitral and 
tricuspid valve leaflets (at a distance of half the slice thickness). This ensured that also the 
most basal part of the LV and RV was covered. At every SA plane, a breath hold cine 
acquisition was then performed (temporal resolution < 40 ms). Slice thickness was 6 mm 
and gap 4 mm. Thus the slice distance was 10 mm. Heart rate was monitored during the 
acquisition of the SA images. 
Image analysis 
The images were processed on a Sun Sparc station using the ‘MASS’ software package 
(Dept. of Radiology, Leiden University Medical Center, Leiden, the Netherlands) for the 
Siemens scanner and on a View Forum (release 3.2) workstation with a dedicated cardiac 
analysis software package for the Philips. End-diastole was defined as the first temporal 
frame directly after the R-wave of the ECG. End-systole was defined as the temporal frame 
at which the image showed the smallest right and left ventricular cavity area, usually 240-
320 ms after the R-wave. Epi- and endocardial contours were manually traced, and the 
papillary muscles were excluded from the RV and LV volume and included with the RV and 
LV mass as described before13. The LV end-diastolic mass was obtained from the volume of 
the LV muscle tissue including the interventricular septum, the RV end-diastolic mass in a 
similar way, but excluding the septum. In the mass calculation, the specific weight of muscle 
tissue was 1.05 g/cm3. 
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Statistical analysis 
We used SPSS 13.0 for statistical analysis. Wilcoxon signed rank up tests were used to 
determine whether differences in measurements regarding lung function, exercise capacity 
or cardiac function at t = 0, t = 1 and t = 2 were significantly different. Statistical 
significance was set at p < 0.05. 
 
Results 
In this study, 8 patients (5 males) (4 right-sided pneumonectomies) were included of which 
1 was measured in the academic centre and 7 in the non-academic teaching hospital. Mean 
age was 58 years (± 11.8, ranging from 34-69).  
In Table 1 results on preoperative data together with pTNM stages are presented for all 
patients. One patient underwent pneumonectomy because of a centrally located atypical 
carcinoid tumour, which was completely resected. The others underwent pneumonectomy 
for NSCLC. 
In one patient that underwent induction chemotherapy, surgical resection was not radical 
and in this patient a fistula of the right main bronchial stump developed within the first week 
after surgery, with complicating empyema for which eventually a ‘Clagett procedure’ (open 
thoracic cavity) was performed 2,5 months postoperatively. For this reason measurements 
at three months could not be performed in this patient, due to incapacitating dyspnoea and 
pain resulting from these complications. The postoperative course of another patient was 
complicated by paroxysmal atrial fibrillation, for which he received anticoagulation therapy. 
 
Lung function and cardiopulmonary exercise testing 
Table 2 presents the lung function test results for all measurements. At t = 1, FVC and FEV1 
decreased significantly (p = 0.018), by 49% and 34% of predicted, respectively, and 
remained decreased at t = 2 (p = 0.018) compared to t = 0. At t = 2, FVC increased again 
(not significantly), compared to t = 1. No significant changes were found regarding DLCO VA. 
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Table 1 Preoperative perfusion scan results of right and left lung, 
bronchoscopic view and pTNM stages from all 8 patients 
 
  
R / L * 
Perfusion %  
R / L 
 
Bronchoscopy 
 
pTNM-stage 
1 L 64 / 36 LUL obstructed T2N0M0 
2 R - Apex RLL obstructed T2N1M0 
3 R 34 / 66 No obstruction T2N0M0 
4 L 54 / 46 LLL obstructed T1N1M0 
5 R 38 / 62 RUL obstructed T2N1M0 
6 L - LUL growing into LLL Atypical carcinoid  
7 R 52 / 48 No obstruction T4N2M0 
8 L 62 / 38 Anterior segment LUL obstructed T2N1M0 
* Right- or left-sided pneumonectomy 
LLL Left lower lobe; LUL Left upper lobe; RLL Right lower lobe; RUL Right upper lobe 
 
 
Table 2  Preoperative and postoperative (within 2 weeks and at 3 months) 
lung function test results in all patients (n = 8) 
 
Mean ± SD 
Preoperative 
(t = 0) 
Postoperative 
(t = 1) * 
Postoperative 
(t = 2) * 
FVC (L) 
FVC % predicted 
4.0 ± 0.7 
105.1 ± 10.2 
2.1 ± 0.5    † 
56.0 ± 9.2  † 
2.4 ± 0.6    † 
61.9 ± 8.3  † 
FEV1 (L) 
FEV1 % predicted 
2.5 ± 0.4 
82.1 ± 11.7 
1.5 ± 0.2    † 
47.6 ± 6.7  † 
1.6 ± 0.3    † 
51.1 ± 6.0  † 
FEV1/FVC 63.0 ± 9.5 68.2 ± 12.1 ‡ 65.5 ± 9.1 
DLCO VA (mmol/min/kPa/L) 
DLCO VA % predicted 
1.21 ± 0.35 
85.6 ± 28.0 
1.17 ± 0.3 
79.7 ± 16.2 
1.26 ± 0.35 
86.3 ± 23.5 
* n = 7 due to postoperative complications in one patient 
† p = 0.018, compared to t = 0 
‡ p = 0.028, compared to t = 0 
DLCO VA Diffusion capacity for carbon monoxide, corrected for alveolar volume; FEV1 Forced expiratory 
volume in 1 second; FVC Forced vital capacity 
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Table 3 Preoperative and postoperative (at 3 months) exercise test results in 
all patients (n = 8) 
 
Mean ± SD 
Preoperative 
(t = 0) 
Postoperative 
(t = 2) * 
HR max (beats/min) 
HR max % predicted 
145 ± 18.6 
89.6 ± 10.8 
130.7 ± 24.2 † 
79.0 ± 11.2  † 
Wmax (W) 
Wmax % predicted 
135 ± 36.8 
83.9 ± 15.9 
89.8 ± 38.2 † 
54.3 ± 21.1 † 
VO2 max (ml/min/kg) 
VO2 max % predicted 
23.4 ± 2.2 
85.9 ± 16.9 
17.3 ± 3.3 † 
57.5 ± 16.2 † 
VE max (L/min) 
VE % predicted 
72.7 ± 14.0 
79.6 ± 16.1 
44.0 ± 12.1 † 
73.3 ± 8.8 
O2-pulse max (ml/beat) 
O2-pulse % predicted 
11.7 ± 1.4 
88.8 ± 15.8 
9.8 ± 2.6 † 
73.0 ± 15.7 † 
* n = 6 due to postoperative complications in one and fear of excessive exercise in another patient 
† Significantly different (p < 0.05) compared to t = 0 
HR Heart rate; VE max Ventilation at maximum exercise; VO2 max Maximum oxygen uptake during 
exercise; Wmax Maximum workload 
 
 
Results from the pre- and postoperative maximum exercise tests are presented in Table 3. 
Wmax and VO2max decreased by 30% and 28% of predicted, respectively. All patients 
reached their anaerobic threshold. Postoperative exercise tests were interrupted because of 
dyspnoea in 6 patients and because of exercised induced hypertension (230/128 mmHg) in 
1 patient. 
 
Cardiac measurements 
In Table 4, cardiac function results are presented. No differences were found regarding 
cardiac output, mass and ejection fraction for both ventricles at either point. At t = 1, heart 
rate was significantly increased (p = 0.017) and stroke volume significantly decreased (p = 
0.036) compared to t = 0. 
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Table 4 Preoperative and postoperative (within 2 weeks and at 3 months) left 
and right ventricular function in all pneumonectomy patients (n = 8) 
 
 
Mean ± SD 
Preoperative 
(t = 0) 
Postoperative 
(t = 1) 
Postoperative 
(t = 2) * 
HR (bpm) 69 ± 6.9 83 ± 14.8 † 75 ± 10.9 
SV (ml) 83.5 ± 16.6 73.8 ± 15.6 † 81.1 ± 11.3 
CO (l/min) 5.7 ± 1.1 5.9 ± 1.4 6.1 ± 0.9 
LVEF (%) 58.7 ± 5.5 59.3 ± 6.0 59.8 ± 4.2 
LVEDV (ml) 
LVEDVI 
148.3 ± 28.8 
79.1 ± 12.3 
128.0 ± 27.9 † 
68.9 ± 14.6 † 
140.1 ± 20.7 
75.9 ± 10.7 
RVEF (%) 59.5 ± 5.8 56.4 ± 6.2 56.9 ± 3.6 
RVEDV (ml) 
RVEDVI 
134.4 ± 28.2 
71.9 ± 13.6 
124.1 ± 26.4 
67.0 ± 15.0 
138.2 ± 20.9 
75.0 ± 13.0 
RVM (g) 32.1 ± 10.6 31.5 ± 7.1 33.3 ± 10.8 
LVM (g) 92.4 ± 27.9 89.7 ± 29.7 83.0 ± 22.0 
* n = 7 due to postoperative complications in one patient 
† Significantly different (p < 0.05) compared to t = 0 
CO Cardiac output; HR Heart rate; LVEDV, RVEDV Left and right ventricular end-diastolic volume; 
LVEDVI, RVEDVI = LVEDV, RVEDV index = EDV/BSA (body surface area); LVEF, RVEF Left and right 
ventricular ejection fraction; LVM, RVM Left and right ventricular mass; SV Stroke volume 
 
 
At t = 2, both returned to baseline (preoperative) values, although not significantly. 
Furthermore, at t = 1 LV end-diastolic volume (LVEDV) was significantly decreased (p = 
0.036) and this remained significant (p = 0.036) when corrected for body surface area 
(LVEDVI), compared to t = 0. Mean hematocrit value at t = 1 was normal (0.38 L/L). At t = 
2, LVEDV and LVEDVI increased again, almost reaching baseline values. RV volumes and 
function remained unaltered in the postoperative period.  
Figure 2 presents mean results for t = 0, t  = 1 and t = 2 for all patients regarding stroke 
volume and LVEDV. This figure clearly shows that overall LVEDV directly postoperative 
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Figure 2 
Mean stroke volume (ml) plotted against mean left ventricular end-diastolic volume (ml) for each 
separate measurement. Results for all patients. 
1;2 and 3 = Mean preoperative result; mean postoperative result and result at three months 
postoperatively, respectively. 
SV Stroke volume; LVEDV Left ventricular end-diastolic volume 
 
 
decreased, which was related to a similar decrease in stroke volume. After 3 months, LVEDV 
and stroke volume were normalised to preoperative values. 
 
Discussion 
The most important finding of our study was that LVEDV was decreased direct 
postoperatively, and that this was related to a decrease in stroke volume. Since we did not 
find signs of RV dysfunction, the underfilling of the LV must be interpreted as a direct 
consequence of the amputation of the pulmonary vascular bed. Furthermore, our findings 
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show that the human cardiorespiratory system is capable of adapting in a relatively short 
period of time. Although the overall cardiac function was depressed directly after the 
operation, reflected by a decreased stroke volume and LVEDV together with an increased 
heart rate, these values were normalised three months after surgery. 
The changes in pulmonary function and exercise capacity after pneumonectomy we found in 
our study at t = 2 are generally in agreement with those found in literature5;14;15. FVC, FEV1, 
Wmax and VO2max respectively decreased by 42%, 31%, 30% and 28% of predicted, which 
is less than would be expected after the removal of an entire lung. Preoperative obstruction 
of large airways, due to a centrally situated obstructive tumour, can explain this finding 
(Table 1)16. 
In healthy persons, the RV is capable of handling an increased cardiac output by 3 to 4 fold 
during exercise, while pulmonary artery pressures increase only mildly17. Several studies 
have previously shown that after pneumonectomy, development of pulmonary hypertension 
only occurs in patients with emphysematous lung, due to the limited recruitment capacity of 
the remaining pulmonary vascular bed in the diseased lung6;18;19. Since none of our patients 
showed signs of emphysema on the CT, it is thus not surprising that pneumonectomy in our 
patients did not lead to signs of RV pressure overload, such as an increased RV end-diastolic 
volume, decreased RV ejection fraction and signs of septal flattening on the dynamic MR 
short-axis cines. Thus, RV dysfunction is unlikely the cause of the decrease in stroke volume 
at t = 1 and underfilling of the LV. Although a decreased vascular filling state, due to a 
restricted postoperative fluid administration in order to prevent pulmonary edema, could 
explain lowered stroke volume and decreased LV end-diastolic volume, this is unlikely, since 
the mean hematocrit values at t = 1 remained normal (0.38 L/L). Therefore, the most likely 
explanation for the underfilling of the LV is the pulmonary vascular bed itself. 
Pneumonectomy leads to a significant reduction of the compliance of the pulmonary vascular 
bed, directly impairing the filling of the left side of the heart as has been described before8. 
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Since we found no significant differences in cardiac structure and function at t = 2, 
compared to t = 0, and since none of our patients died within the first 90 days after surgery, 
these results show that the adaptation of the pulmonary vascular bed of the lung and heart 
have been successfully completed. 
Obviously, the findings from our study are from a limited number of patients. However, the 
findings were consistent in all patients and MRI has proven to be an extremely useful tool for 
consecutive measurements of cardiac function because its results are accurate as well as 
reproducible in both normal and abnormal ventricles20-22. For this reason we believe our 
results are an accurate reflection of the hemodynamic adaptation in time after 
pneumonectomy. 
 
Conclusion 
The postoperative state of the patient 2 weeks after pneumonectomy is characterized by a 
decrease of stroke volume together with a decrease of left ventricular end-diastolic volume, 
without signs of right ventricular dysfunction. Therefore, the reduction in left ventricular 
end-diastolic volume might be interpreted as a direct consequence of a decreased 
compliance of the pulmonary vascular bed. Within 3 months, stroke volume is normalised 
while overall cardiac function remains unaltered in comparison to preoperative values. 
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Abstract 
Background: Pneumonectomy not only reduces the pulmonary vascular bed but also 
changes the position of the heart and large vessels, which may affect the function of 
the heart. We investigated long-term effects of pneumonectomy on right and left 
ventricular (RV and LV) function and whether this function is influenced by the side 
of pneumonectomy or the migration of the heart to its new position. 
 
Methods: In 15 patients who underwent pneumonectomy and survived for more than 
5 years we evaluated by dynamic MRI the function of the RV and LV and the position 
of the heart within the thorax. 
 
Results: Long-term effect of pneumonectomy on the position of the heart is 
characterised by a lateral shift after right-sided pneumonectomy and rotation of the 
heart after left-sided pneumonectomy. Postoperatively, heart rate was high (p = 
0.006) and stroke volume was low (p = 0.001), compared to the reference values 
indicating impaired cardiac function. Patients after right-sided pneumonectomy had 
an abnormal low RV end-diastolic volume of 99 ± 29ml1 together with a normal LV 
function. No signs of RV hypertrophy were found. In left-sided pneumonectomy 
patients RV volumes were normal whereas LV ejection fraction was abnormally low1. 
 
Conclusions: The long-term effects of pneumonectomy on the position of the heart 
are characterized by a lateral shift in patients after right-sided pneumonectomy and 
rotation of the heart in patients after left-sided pneumonectomy. Overall, cardiac 
function in long term survivors after pneumonectomy is compromised which might be 
explained by the altered position of the heart. 
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Introduction 
Major lung resection, especially pneumonectomy, decreases ventilatory function and 
has significant effects on right ventricular (RV) function2-4. Immediately after 
pneumonectomy, the RV dilates and RV ejection fraction decreases5;6. Increasing RV 
afterload, due to rising pulmonary artery pressure and pulmonary vascular resistance 
occurring after major lung resection, is supposed to be the main cause of this RV 
dysfunction5. However, it is unclear to what extent the early post-pneumonectomy 
RV dysfunction recovers in the long-term and whether this may still play a role in the 
exercise limitation of post-pneumonectomy patients.  
Pneumonectomy not only changes the pulmonary hemodynamics but also leads to a 
migration of the heart and large vessels through the thoracic cavity, a process that 
takes years after the resection. Due to the production of fibrotic tissue in the empty 
pleural space, intrathoracic pressure changes, with elevation of the diaphragm and 
overdistension of the remaining lung, the heart and mediastinum shift to the side 
that was operated on. These changes might induce alterations in cardiac structure 
and function, which might be different after left-sided pneumonectomy in comparison 
to right-sided pneumonectomy, and pending on the position of the heart in the 
thoracic cavity. However, this has not been studied until now, since the altered 
cardiac position hampers the use of echocardiography in these pneumonectomy 
patients. For this reason, we used cardiovascular magnetic resonance (CMR) imaging 
in this study because this technique has the advantage of being independent on the 
geometric assumptions and acoustic windows that limit echocardiography7. The aim 
of the present study was to measure the effects of right- and left-sided 
pneumonectomy on the structure and function of the heart, more than 5 years after 
the operation.  
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Methods 
We studied 15 consecutive patients presenting for a routine follow up exam in an 
academic and in a non-university, teaching hospital. At that time, approximately 10 
pneumonectomies were done in both hospitals each year. All patients studied 
underwent pneumonectomy more than five years ago and had a FEV1 above 71% of 
predicted on the preoperative lung function test. In addition, no signs of emphysema 
or interstitial lung disease were visible on the preoperative CT scan. No other 
significant pulmonary or cardiac diseases were present before pneumonectomy, 
except lung cancer. None of the patients received chemotherapy or radiotherapy 
prior to surgery. Informed consent was obtained from all subjects, and the local 
ethics committees approved the study.  
 
Lung function and cardiopulmonary exercise testing  
We performed lung function (vital capacity (VC) and forced expiratory volume in 1 
second (FEV1)) and maximal incremental exercise tests (maximum workload 
(Wmax), maximum oxygen uptake during exercise (VO2max) and ventilation at 
maximum exercise (VEmax)) in accordance with the American Association for 
Respiratory Care8 and European Respiratory Society criteria9 in all patients. Standard 
equipment Vmax 229 and 6200, SensorMedics, Yorba Linda, USA (for the academic 
centre) and standard equipment Oxycon Beta and Masterlab, Viasys, Bilthoven, the 
Netherlands (for the non-academic centre) were used for all pulmonary function 
tests. During maximal incremental exercise test, patients’ measurements were 
recorded after a 3-minute resting period on the bicycle, after which patients started 
exercising at a constant speed of 60 rpm at 0W during 2 minutes. A ramp protocol 
based on patient’s age, gender and FEV1 followed till patients were exhausted. 
Recovery period lasted 6 minutes. The Vslope method was used to determine 
whether the anaerobic threshold was reached10. 
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Figure 1 
Assessment of the degree of rotation of the heart, by measuring the angle (*) between a 
normally positioned interventricular septum (set at 0 degrees) and the position of the 
interventricular septum in the postpneumonectomy heart. Clockwise rotation results in a 
negative angle and counterclockwise rotation in a positive angle. 
A Apex of left ventricle; LV, RV Left and Right Ventricle 
 
 
Geometric position of the heart 
Using the four chamber view images according to the method depicted in Figure 1, 
we established the degree of rotation of the heart in our patients. In normal patients, 
the angle of the interventricular septum with the anteroposterior line (through the 
middle of the sternum and the middle of the spinal cord) is approximately 70 
degrees. This angle was used as the reference angle, and set at 0 degrees. Clockwise 
rotation resulted in a negative angle and counterclockwise rotation in a positive angle 
(Figure 1). By doing this, we tried to establish the differences in degree of rotation of 
the hearts in our patients, rather than using these angles for mathematical purposes. 
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Magnetic Resonance Imaging Protocol11 
The patients were scanned using a 1.5 T Siemens Sonata whole body system 
(Siemens Medical Systems, Erlangen, Germany) in the academic centre or the 1.5 T 
Philips Intera, software release 10.3 ( Philips Medical Systems, Best, the 
Netherlands) in the non-academic teaching centre. On both systems a phased-array 
body coil was applied. All image acquisition was prospectively triggered by the R-
wave of the electrocardiogram. The subject was instructed to hold his breath in 
moderate inspiration during all image acquisitions (thus also during scout imaging for 
localization of the heart). 
Short-axis ventricular imaging 
The horizontal long-axis view was determined in a late diastolic frame using a black-
blood prepared turbo gradient-echo sequence11. Then a breath hold cine-acquisition 
was performed of this long-axis view. By using the end-diastolic cine frame of this 
long-axis view, a series of parallel short-axis image planes was defined starting at 
the base of the left ventricle (LV) and RV, and encompassing the entire LV and RV 
from base to apex. The most basal image plane was positioned close to the transition 
of the myocardium to the mitral and tricuspid valve leaflets (at a distance of half the 
slice thickness). This ensured that also the most basal part of the LV and RV was 
covered. At every short-axis plane, a breath hold cine acquisition was then 
performed (temporal resolution < 40 ms). Slice thickness was 6 mm and gap 4 mm. 
Thus the slice distance was 10 mm. Heart rate was monitored during the acquisition 
of the short-axis images. 
Image analysis 
The images were processed on a Sun Sparc station using the ‘MASS’ software 
package (Dept. of Radiology, Leiden University Medical Center, Leiden, the 
Netherlands) for the Siemens scanner and on a View Forum (release 3.2) 
workstation with a dedicated cardiac analysis software package for the Philips. End-
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diastole was defined as the first temporal frame directly after the R-wave of the ECG. 
End-systole was defined as the temporal frame at which the image showed the 
smallest right and left ventricular cavity area, usually 240-320 ms after the R-wave. 
Epi- and endocardial contours were manually traced, and the papillary muscles were 
excluded from the RV and LV volume and included with the RV and LV mass as 
described before11. The LV end-diastolic mass was obtained from the volume of the 
LV muscle tissue including the interventricular septum, the RV end-diastolic mass in 
a similar way, but excluding the septum. In the mass calculation, the specific weight 
of muscle tissue was 1.05 g/cm3. 
 
Data analysis 
Results on lung function, exercise tests and cardiac function were compared between 
patients after left- and right-sided pneumonectomy. Results on RV and LV function in 
pneumonectomy patients were compared with normal ventricular dimensions for MRI 
from healthy controls (n = 25). Recently, data from these healthy controls were in 
part also presented by Vonk-Noordegraaf et al1. To our knowledge, this is one of the 
few recent studies on establishment of these values, addressing both LV and RV 
structure and function in adults. Other studies that obtained reference values for 
LV11-13 and RV12;13 function by MRI provided only information on the LV (Marcus11) or 
included children (Lorenz12) in their study group. 
 
Statistical analysis 
We used SPSS 13.0 for statistical analysis. Mann Whitney U tests for independent 
samples were used to determine differences comparing healthy controls with patients 
and comparing patients after left- or right-sided pneumonectomy regarding cardiac 
function, lung function and exercise tolerance. Statistical significance was set at p < 
0.05. 
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Table 1  Initial patient characteristics and smoking status 
 
 Initial characteristics  
Patient 1 M/F 2 Age 3 Survival (months) PY * 
2_I F 53 62 25 
2_II M 69 107 40 
2_III M 71 91 47 
2_IV F 65 69 45 
2_V M 74 96 40 
2_VI M 64 125 44 
2_VII M 71 141 40 
2_VIII F 64 118 0 
2_IX M 53 77 30 
3_I M 67 85 18 
3_II F 77 117 60 
3_III F 47 191 0 
3_IV F 51 89 30 
3_V F 59 92 35 
3_VI M 80 137 50 
1 Patient: Number corresponds to the images and legends from Figures 2 and 3; Figure 2 
(left-sided pneumonectomy): Top: from left to right numbers I, II and III; Middle: from left to 
right numbers IV, V and VI; Bottom: from left to right numbers VII, VIII and IX.  
Figure 3 (right-sided pneumonectomy): Top: from left to right numbers I, II and III; Bottom: 
from left to right numbers IV, V and VI 
2 M / F: Male or Female 
3 Age (years) at the time of the study 
* Number of pack years smoked before surgery 
 
 
Results 
Table 1 presents initial patient characteristics; 2 never-smoking females underwent 
pneumonectomy because of a carcinoid tumor and an adenocystic carcinoma, others 
because of non-small cell lung cancer. Mean age of all patients was 64.3 years 
(range 47-80), and mean time after pneumonectomy 106.5 months (range 62-191). 
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Mean age of the healthy controls was significantly lower compared to our patients 
(Table 2). Preoperatively, mean FEV1 % of predicted, mean Wmax % of predicted 
and mean VO2max % of predicted were 84.6 (± 14.1), 101.4 (± 42.3) and 86.5 (± 
30.4), respectively. In 1 patient, the phrenic nerve was crushed during left-sided 
pneumonectomy with the surgeons’ intention to enhance filling of the 
postpneumonectomy space. Postoperatively, chest tubes were placed in all patients 
and connected to a balanced drainage system during the first short postoperative 
period. The postoperative course in 1 patient that underwent pneumonectomy with 
partial resection of the pericardium was complicated by the development of 
insufficiency of the tricuspid valve and in another patient by the development of 
residual cancer on the bronchial stump for which he underwent a curative re-
resection, complicated by hypertension and viral pericarditis which were treated. One 
patient received medication (nifedipine) for the treatment of systemic hypertension. 
 
Lung function and cardiopulmonary exercise testing 
Lung function and exercise tests were done more than 5 years after pneumonectomy 
in all patients except 1, who underwent the exercise test at 28 months after surgery. 
We found no statistically significant differences regarding lung function or exercise 
capacity comparing patients after right- or left-sided pneumonectomy. Mean % of 
predicted FVC and FEV1 were 58.2 (± 14.3) and 49.1 (± 10.6), respectively. All 
patients reached their anaerobic threshold during the exercise test. Mean VO2max, 
Wmax and VEmax were 15.1 ml/min/kg (± 3.3), 84.1 watt (± 33.3) and 41.6 l/min 
(± 12.7) respectively, which were 62%, 56% and 77% of predicted. Mean oxygen 
pulse at maximum exercise was 9.7 ± 3.1 ml/beat, with markedly impaired 
progression from rest to maximum exercise of 219 ± 76%. Patients after left-sided 
pneumonectomy tended to have lower VO2max % of predicted (56.5 ± 11.9) 
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compared to right-sided pneumonectomy patients (70.6 ± 16.5) although this was 
not significant. 
 
MRI measurements 
MRI scans were performed in all patients with a mean time interval between the 
pneumonectomy and the MRI of 101 months (range 60-179) postoperative. 
Reviewing MRI scan results revealed a myocardial infarction in 1 patient, which had 
not been diagnosed previously (Figure 2-II). 
 
Geometric measurements 
Figure 2 (for left-sided pneumonectomy patients) and Figure 3 (for right-sided 
pneumonectomy patients) present an overview of four chamber views by MRI of all 
patients who were studied. All patients demonstrated some degree of mediastinal 
shift, which seemed to be more extensively in case the post-pneumonectomy space 
was completely obliterated (Figures 2-IV, 2-V, 2-VIII and 3-III). Using the method 
depicted in Figure 1, we established the degree of rotation of the hearts in our 
patients. We found that after left- and right-sided pneumonectomy respectively, the 
mean degree of rotation was 28 (± 62, ranging -96 to 102) and 33 (± 9, ranging 23 
to 44) degrees. Resulting from this and from Figures 2 and 3, it is clear that after 
left-sided pneumonectomy, the heart and vascular structures not only shift into the 
left hemithorax but also rotate, while the extent of rotation extremely varied 
between patients. In contrast, rotation of the heart was nearly absent after right-
sided pneumonectomy and mostly signs of lateral shifting of the heart and vessels 
were found in these patients. No correlation was found between the degree of 
rotation and the LV and RV end-diastolic volumes or LV ejection fraction. 
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Figure 2 
Four chamber views of all patients after left-sided pneumonectomy. Star = LV cavity; Rhomb 
= RV cavity. Anatomical orientation of the separate figures: top = ventral, bottom = dorsal, 
right = left side of patient, left = right side of patient. 
(Top: from left to right figure numbers I, II and III; Middle: from left to right figure numbers 
IV, V and VI; Bottom: from left to right figure numbers VII, VIII and IX) 
 
 
Cardiac function 
In Table 2 results on RV and LV function are presented, comparing patients with 
healthy controls and comparing patients after left- and right-sided pneumonectomy. 
Although cardiac output was normal in all patients, stroke volume was significantly  
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Figure 3 
Four chamber views of all patients after right-sided pneumonectomy. Star = LV cavity; Rhomb 
= RV cavity. Anatomical orientation of the separate figures: top = ventral, bottom = dorsal, 
right = left side of patient, left = right side of patient. 
(Top: from left to right figure numbers I, II and III; Bottom: from left to right figure numbers 
IV, V and VI) 
 
 
lower (p = 0.001), compensated by an increased resting heart rate (p = 0.006) 
compared to healthy controls. No significant difference in stroke volume was 
observed between the right and left sided pneumonectomy patients. 
Patients after left-sided pneumonectomy had an increased LV end-diastolic volume 
together with a decrease in LV ejection fraction, whereas RV volumes were normal. 
In contrast, patients after right-sided pneumonectomy had signs of RV hypotrophy 
together with a decreased RV end-diastolic volume (99 ± 29ml), while LV volume 
and function were normal. 
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Table 2 Postoperative LV and RV function 1, comparing patients with 
healthy controls and comparing patients after right- and left-
sided pneumonectomy 
 
 
 
All 
n = 15 
Healthy  
controls 
n = 25 p 
 
Right 
n = 6 
 
Left 
n = 9 p 
Age (yr) 64 ± 10 43 ± 14 .0001    
HR (bpm) 80 ± 17 65 ± 12 .006 89 ± 19 74 ± 13 .099 
SV (ml) 64 ± 12 83 ± 17 .001 59 ± 14 67 ± 10 .195 
CO (l/min) 5.0 ± 0.9 5.4 ± 1.5 .567 5.2 ± 1.2 4.9 ± 0.8 .480 
LVEF (%) 58 ± 14 72 ± 8 .001 64 ± 11 54 ± 15 .239 
LVEDV (ml) 
LVEDVI 
126 ± 67 
64 ± 26 
120 ± 18 
61 ± 10 
.270 
.645 
94 ± 23 
52 ± 9 
148 ± 80 
73 ± 31 
.025 
.059 
RVEDV (ml) 
RVEDVI 
123 ± 39 
64 ± 17 
148 ± 32 
75 ± 12 
.043 
.061 
99 ± 29 
55 ± 14 
139 ± 38 
70 ± 16 
.059 
.099 
RVM (g) 48 ± 24 51 ± 20 .434 33 ± 17 57 ± 24 .018 
LVM (g) 120 ± 41 148 ± 36 .017 108 ± 45 127 ± 39 .289 
1 Mean ± standard deviation 
CO Cardiac output; HR Heart rate; LVEDV, RVEDV Left and right ventricular end-diastolic 
volume; LVEDVI, RVEDVI Left and right ventricular end-diastolic volume index = EDV/BSA 
(Body surface area); LVEF Left ventricular ejection fraction; LVM, RVM Left and right 
ventricular mass; SV Stroke volume 
 
 
Discussion  
Our study shows that in a group of long-term survivors after pneumonectomy (> 5 
years), considerable intrathoracic anatomical changes occur together with a 
reduction of stroke volume compensated by an increased heart rate at rest, 
indicative for a compromised cardiac function. Although we did not measure stroke 
volume during exercise, the abnormal stroke volume response during exercise in the 
presence of a normal ventilatory reserve at maximal exercise provide further 
evidence that cardiovascular limitation contributes to the limited exercise capacity in 
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these patients. Since we did not find any signs of RV hypertrophy, the decreased 
stroke volume is unlikely due to increased pulmonary artery pressures (increased 
afterload). Furthermore, we conclude that based on the differences found between 
right- and left-sided pneumonectomy patients, the RV underfilling is the primary 
factor that compromised RV function, whereas LV failure is the primary factor in left-
sided pneumonectomy patients. 
 
Previous studies by Biondetti and Suarez have mentioned the finding of more 
extreme mediastinal shifting in case the post-pneumonectomy space is completely 
obliterated14;15. Although we did not relate the amount of pleural filling with the lung 
function it is clear from the MRI images that there is variation in the amount and 
location of pleural filling and both hemidiaphragms influencing the expansion of the 
remaining lung. Our findings show that mostly rotation of the heart occurs after left-
sided pneumonectomy and that there is a huge variability between patients. Factors 
that determine the extent of rotation are unclear, however it is conceivable that 
variation in the shape of the thoracic cavity, extent of elevation of the ipsilateral 
hemidiaphragm and degree of obliteration of the pleural cavity all might influence the 
final position of the heart. In contrast to this, the alteration of the heart in right-
sided pneumonectomy patients is characterized by a lateral shift with only minor 
rotation of the heart. The extent of the lateral shift seemed to be determined by the 
degree of obliteration of the pleural space.  
 
Although the group of patients was to small to draw firm conclusions on the effects 
of right-sided pneumonectomy in comparison to left-sided pneumonectomy on 
cardiac function, remarkable differences were observed between both groups. First, 
RV end-diastolic volume and LV mass were extremely low in patients after right-
sided pneumonectomy. An explanation for this could be the lateral shift observed in 
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these patients which possibly impairs RV filling due to external compression of the 
thoracic wall. Low LV mass could be due to the effect of a chronically reduced stroke 
volume on the LV wall. Secondly, despite large standard deviations, patients after 
left-sided pneumonectomy seemed to have a relatively low LV ejection fraction and a 
significantly increased LV end-diastolic volume, compared to patients after right-
sided pneumonectomy. Although we could not find a relation between LV ejection 
fraction and the degree of rotation of the heart, this does not preclude a causal 
relationship between cardiac rotation and loss of systolic function. However, the 
numbers were too small to perform further analysis. 
 
We did not find any signs of RV hypertrophy or RV dilatation in our cohort, making 
the presence of pulmonary hypertension in our study population very unlikely. In the 
past few decades, several studies have reported on the effect of pneumonectomy on 
cardiopulmonary function (measurements ranging from 2-168 months 
postoperative). In general, these studies agree to the fact that in pneumonectomy 
patients, pulmonary artery pressure, RV systolic pressure and pulmonary vascular 
resistance are normal or slightly increased at rest16-22, and increase during exercise 
due to the limited recruitment capacity of the pulmonary vascular bed, confirming 
our findings2;5;17;18. Furthermore, Burrows et al. found that RV hypertrophy only 
occurred in patients with an abnormal remaining lung. Since our patients had no 
signs of emphysema radiologically, we conclude that the pulmonary vascular bed in 
the remaining lung was sufficient to prevent the development of increased RV 
afterload. 
 
Conclusions 
This study shows that the long-term effects of pneumonectomy on the position of the 
heart are characterized by a lateral shift after right-sided pneumonectomy, whereas 
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left-sided pneumonectomy leads to a rotation of the heart. Overall, cardiac function 
in long term survivors after pneumonectomy is compromised which might be 
explained by the altered position of the heart.   
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Case Report 
A 64-year old female with a history of pneumonectomy for non-small cell lung cancer 102 
months ago, presented without severe complaints of dyspnoea or cough, for a routine 
follow-up exam at our hospital. Chest X-ray revealed (however somewhat stable for the 
last few years) extreme shifting of mediastinal structures to the side that was operated 
on (Figure 1). Exact localisation of the heart was not possible by chest X-ray alone, which 
is often the case after pneumonectomy. For research purpose (written informed consent 
obtained), we performed a CT scan (Figure 2). This revealed a very unusual localisation 
of the heart, where the left ventricular free wall was placed against the left dorsal chest 
wall. Despite these extreme anatomical changes, she was functioning adequately without 
severe dyspnoea on exertion. Lung function test showed a FVC and FEV1 of 91% and 
79% of predicted, respectively, and she was not ventilatory limited. No overt signs of 
cardiac dysfunction were observed.  
Changes in anatomy of the postpneumonectomy space places these patients at risk of 
injury to the liver, spleen or heart in case of blind percutaneous needle and/or chest tube 
insertion1. Direct visual guidance with ultrasonography or CT is recommended when 
placing chest tubes in such patients, in order to prevent serious complications2. 
 
Presenting case reports like this, we believe, once more shows the need for knowledge 
on these extreme anatomical changes and the importance of careful localising thoracic 
structures in postpneumonectomy patients before invasively entering the 
postpneumonectomy space for any given reason. 
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Figure 1a (left) and 1b (right) 
The patients’ posteroanterior (a) and lateral (b) chest radiographs 102 months following left-sided 
pneumonectomy demonstrating extreme left-sided mediastinal shifting. 
L Left side of patient 
 
 
 
Figure 2 
The patients’ axial computed tomography image. Notice that the left ventricle is repositioned and 
placed against the left dorsal chest wall. 
L Left side of patient; LV, RV Left and right ventricle 
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Abstract  
We present a case of a left-sided pneumonectomy patient who collapsed while digging. 
This was caused by the limited space for expansion of the left ventricle hampering its 
filling, as can be documented by dynamic cardiac MRI imaging. 
 
 
 
 
 
 
Figure 1A 
Ventricular short-axis images. Numbers 1 to 4 are consecutive images during patients’ Valsalva 
manoeuvre. Notice that the left ventricular wall flattening is most clearly seen in ‘3’. 
‘1’ Start of systole at the R wave 
‘2’ Midsystole 
‘3’ Early diastolic phase 
‘4’ Late diastolic phase 
D Left hemidiaphragm; LV, RV Left and right ventricle 
Left Ventricular Encasement after Pneumonectomy 
_________________________________________________________________________________________ 
 - 151 -
 
Case Report 
A 53 year old male with a history of hypertension and left-sided pneumonectomy 7 years 
previously was referred to our hospital. He complained about dizziness and had collapsed 
twice while digging. No other complaints were present, especially no dyspnoea. There 
were no signs of airway obstruction (FVC 51% and FEV1 47% of predicted) and CO 
diffusion capacity was normal (DLCO corrected for alveolar volume 106% of predicted). 
Maximum exercise test results were normal for a pneumonectomy patient, with Wmax of 
62% and VO2max of 77% of predicted. Arterial blood gas analysis showed 
normoventilation. Echocardiography showed normal right and left ventricular function 
and slight left ventricular free wall flattening. Finally, dynamic cardiac MRI imaging was 
performed to study the influence of increasing abdominal pressure on the right and left 
ventricular (RV and LV) function on a beat per beat basis. During MRI imaging we asked 
the patient to perform a Valsalva manoeuvre, while short-axis cine images were made 
(Figure 1A). As is clear from Figure 1A and B (coronal image), the position of the heart in 
this patient has shifted in the years after his pneumonectomy and the LV free wall was 
repositioned all the way on top of the paralysed left hemidiaphragm. During Valsalva, 
intra-abdominal pressure increases and probably hampers LV filling in this patient by a 
direct transmission of the intra-abdominal pressure to the LV free wall. Note that in the 
normal thorax the LV free wall is adjacent to the left lung, staying free of contact with 
the diaphragm. Additionally, we asked the patient to lift both his legs mimicking a 
digging position and hold his breath for approximately 10 seconds while laying supine in 
the MRI scanner. The real-time short-axis cine images (Figure 2) showed a progressive 
LV free wall flattening leading to a decrease of the LV cross-sectional area, as is shown in 
Figure 2. These changes of the LV cross-sectional area at midventricular level are 
probably representing the LV volume changes. Thus, the LV end-diastolic volume and 
stroke volume decreased due to the shifted position of the LV on top of the paralysed 
hemidiaphragm which seemed to worsen its compliance. LV filling was further 
deteriorated during breath holding and legs’ tilting manoeuvres. In retrospect, it 
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Figure 1B 
Coronal image focusing on the inferior vena cava, pulmonary artery and the left ventricle. The left 
ventricular free wall is positioned against the paralytic elevated left hemidiaphragm. 
LV Left ventricle; PA Pulmonary artery; R Right lung; VCI Inferior caval vene 
 
 
appeared that during pneumonectomy, the phrenic nerve was severed with the surgeons’ 
intention to fill the postpneumonectomy space faster postoperatively, a method that is 
currently considered controversial1. 
Although we initially proposed surgical plication of the diaphragm as a possible solution, 
the low frequency of collapse (twice), uncertainty of the outcome of surgery and the 
assurance of the patient after being informed about the reason of his collapse ultimately 
were factors not to pursue any surgical solution. 
 
This case report presents an unusual long-term complication of pneumonectomy, which 
was seen during real-time dynamic cardiac MRI imaging. Therefore, dynamic MRI  
 
Left Ventricular Encasement after Pneumonectomy 
_________________________________________________________________________________________ 
 - 153 -
 
Figure 2 
The left ventricular short-axis cross-sectional area (in cm2) at midventricular level, plotted against 
time (s). After about 8 seconds, the influence of the breath holding manoeuvre with lifting both 
legs in the supine position is clearly depicted. The LV cross-sectional area comes back to the initial 
values while breathing normally with both legs stretched and relaxed again. 
LV Left ventricle 
 
 
provides an excellent tool to analyse the complications caused by the relocation of the 
heart and large vessels in the postpneumonectomy patient. 
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Abstract  
Pneumonectomy can give rise to extreme mediastinal shifting, especially a few years after 
the operation. We present a case of such a patient with incapacitating dyspnoea due to 
compression of the left upper pulmonary vein between the left atrium and descending aorta, 
which was treated by repositioning of the mediastinum. 
 
 
 
 
 
 
 
 
Figure 1 
MRI images before (left) and after (right) operation. The obstruction of the pulmonary vein (arrow) is 
removed by repositioning of the heart. The presented images show the first temporal phase after the 
ECG-R wave. 
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Case Report 
Six years after right pneumonectomy a 67 year old man developed progressive dyspnoea 
during exercise. Finally, he was admitted to the hospital due to severe dyspnoea after some 
exercise. The chest X-ray showed signs of pulmonary edema, improving rapidly after 
furosemide and oxygen therapy. There were no signs of tumour recurrence or airway 
obstruction on CT. Pulmonary function tests were not changed compared to the years before 
(FEV1 2.1 liter/sec, DLCO 70% of predicted). Cardiopulmonary exercise testing showed a 
decreased peak work load (44% of predicted), together with a low peak O2 pulse (48% of 
predicted) and a normal breathing reserve of 30%. Echocardiography showed a normal left 
ventricular function. For further analysis of the heart and pulmonary vasculature, MRI 
analysis was performed. 
This showed compression of the left upper pulmonary vein between the left atrium and 
descending aorta (Figure 1, left). Stroke volume was measured by flow velocity 
quantification and was 40 ml with a cardiac index of 1.8 liter/m2. For this reason, a re-
thoracotomy was performed for the repositioning of the heart and placement of 2 silicone 
prostheses inside the pleural cavity (Figure 1, right). Flow measurement results performed 
by MRI orthogonal to the left upper pulmonary vein before and after the thoracotomy are 
presented in Figure 2. Six months after the re-thoracotomy, he had no complaints of 
shortness of breath and his exercise capacity was 88 % of predicted. Stroke volume and 
cardiac index at that time were 86 ml and 4 liter/m2, respectively. 
 
This case demonstrates that compression of pulmonary veins, due to shifting of heart and 
mediastinum to the operated side after pneumonectomy, might result in severe complaints 
and pulmonary congestion. It improves after re-establishing the normal diameter of these 
vessels. 
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Figure 2 
Flow measurement results during one cardiac cycle performed by MRI in the left upper pulmonary vein 
before (dashed line) and after (black line) thoracotomy. Time (in ms) after the ECG R-wave is on the 
x-axis and flow through the pulmonary vein (in ml/sec) is on the y-axis. Pre-op: preoperative flow 
measurement results (dashed line). Post-op: postoperative flow measurement results (black line). 
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Summary 
Lung cancer is a disease that is frequently asymptomatic in its early stage, and as a 
consequence many patients present themselves at a rather late stage of the disease. 
Despite extensive research efforts in lung cancer patients, mortality rates remain high. In 
fact, the prognostic most favourable group is the same as several decades ago and 
consists of patients in whom surgical resection of the tumor is possible. However, the 
majority of patients present with an unresectable or disseminated tumor. For a small 
group of these patients, combined modality loco-regional treatment might offer a better 
prospect. For instance induction chemo-radiotherapy, sometimes followed by surgery, 
may result in long-term disease free survival. In order to be able to distinguish patients 
that can be cured by primary surgical resection or combined modality treatment from 
those who cannot, a number of aspects are important. Several of these (for instance 
comorbidity, the TNM stage and (predicted) postoperative cardiac and pulmonary 
function) are described in this thesis. Lung cancer is a disease of the middle aged and 
older part of the population; these people have to deal with all the consequences of aging 
and the effects of an unhealthy life-style like smoking. Additional disease may affect the 
choice of treatment. Another extremely important aspect is adequate staging of the 
tumor. For this, several imaging modalities (computed tomography (CT) scanning, 
magnetic resonance imaging (MRI) and F-18-deoxyglucose positron emission 
tomography (18FDG-PET) scanning) and invasive tools (bronchoscopy, transbronchial 
needle aspiration (TBNA), mediastinoscopy, transoesophageal ultrasound-guided fine 
needle aspiration (EUS-FNA) and endobronchial ultrasound (EBUS)) are being used. 
 
In Part I of this thesis, several aspects influencing treatment choice in NSCLC patients, 
like age, comorbidity and the TNM-stage, were investigated.  
With the relatively high age many patients will be diagnosed with one or more other 
serious diseases at the time of lung cancer diagnosis (comorbidity). Since elderly (>70 
years) patients are often excluded from clinical trials, little is known about either the best 
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way to treat elderly patients with comorbidity or the outcome of treatment. In Chapter 1 
the independent prognostic effects of age and comorbidity for patients with NSCLC were 
evaluated. We found that elderly patients were treated less aggressively. The proportion 
of patients with localized (stage I and II) NSCLC who underwent surgery decreased from 
92% of patients younger than 60 to 9% of those aged 80 or older. Among patients aged 
60-79 this proportion also decreased with comorbidity. Among patients with non-
localized (stage III and IV) NSCLC the proportion receiving chemotherapy was 
considerably higher for patients younger than 60 (24%) than those aged 80 or older 
(2%). The number of comorbid conditions had no significant influence on treatment 
chosen for patients with non-localized disease. Multivariate survival analyses showed that 
age, tumour size and treatment were independent prognostic factors for patients with 
localized disease, and stage of disease and treatment for those with non-localized 
disease. Comorbidity had no independent prognostic effect. 
 
In Chapter 2, we investigated the accuracy of preoperative surgical mediastinal staging 
procedures in 4 hospitals. Guidelines to perform or to skip mediastinoscopy in patients 
suspected for malignant lung lesions were adequately followed in all-day clinical practice 
in approximately two-third of cases in 4 general hospitals. Physicians were especially 
reluctant to perform mediastinoscopy in patients with peripheral lesions without a 
preoperative histological diagnosis. Within the 4 hospitals that were investigated, the one 
with the smallest number of evaluated patients scored the worst percentage of correctly 
indicated mediastinoscopies, which was significantly different from the other hospitals. 
We also found that of all mediastinoscopies performed, only 40% were done according to 
‘gold standards’ with regard to sampling of lymph nodes. There was a close relation 
between the number of mediastinoscopies yearly performed and the percentage of 
mediastinoscopies performed according to gold standards. Finally, sampling of 
mediastinal lymph nodes during thoracotomy was done more often and more thorough in 
the hospitals were most patients were evaluated and operated on. We found that 
mediastinal lymph node sampling during thoracotomy was done in approximately 50% of 
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cases, which led to upstaging in 17% of patients. In almost 1 out of every 5 cases, 
upstaging and surgical intervention could theoretically have been prevented when 
mediastinoscopy would have been indicated and performed according to gold standards. 
 
In Chapter 3, we studied whether the introduction of 18FDG-PET in our hospital resulted 
in an improved adherence to surgical mediastinal staging protocols and performance of 
mediastinoscopy. We found that adherence to guidelines, compared to the results 
presented in Chapter 2, increased significantly (p = 0.002). Although we hypothesized 
that performance of mediastinoscopy would increase because of the awareness of the 
results from our previous study and the introduction of PET, the opposite appeared to be 
true. In fact, the number of mediastinoscopies performed according to gold standards 
decreased (not significantly), from 39% to 27%. Nevertheless, a higher percentage of 
mediastinoscopies was positive (17.6%) for metastases, compared to our previous study 
(15.5%). Apparently, the combination of PET and CT can guide the surgeon to possible 
metastasized mediastinal lymph nodes and therefore increases the number of positive 
mediastinoscopies. 
 
In Chapter 4 we studied accuracy and interobserver variation in determining presence of 
mediastinal lymph node metastases by 18FDG-PET in NSCLC patients. Two groups of 
nuclear medicine physicians with different levels of PET experience (‘experienced’ (n=7) 
and ‘inexperienced’ (n=7)) reviewed 30 PET scans of patients with suspected operable 
NSCLC. They were requested to identify and localise suspicious mediastinal lymph nodes 
on each scan and to formulate a clinical management advice using standardized 
algorithms. Results were compared between the 2 groups, between individuals and with 
expert reading (which was considered the ‘gold standard’). We found that 80% of the 
management recommendations and 68% of N-stage classifications were correct, with 
moderate and good interobserver agreement (kappa 0.59 and 0.65, respectively). 
Detection rate (72% versus expert reading) and most common mislocalisations of 
separate mediastinal lymph node stations were equally distributed between the 2 groups. 
Summary 
_________________________________________________________________________________________ 
 - 163 -
Experience with PET translated into a better ability to localise mediastinal lymph node 
stations (68% versus 51%, respectively), and experienced readers appeared to be more 
familiar with translating PET readings into clinically useful statements. However in 
general, even among experienced readers there was obvious room for improvement. 
 
In Part II of this thesis, we presented studies regarding postoperative cardiac and 
pulmonary function, with emphasis on effects in patients after pneumonectomy.  
Lung capacity obviously decreases after resection for lung cancer. Several formulas are in 
use aiming to predict postoperative lung function. In general, these formulas can be 
divided into two categories. The first category of formulas calculates postoperative FVC 
and FEV1 by the number of pulmonary segments to be resected. The second category of 
formulas includes the function of these segments by measuring their actual perfusion 
preoperatively. In Chapter 5 we evaluated the long-term validity of 2 formulas 
frequently used to predict postoperative lung function as well as trends in postoperative 
lung function and late postoperative exercise capacity in pneumonectomy patients. 
Postoperative forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) 
according to the ‘Kristersson/Olsen formula’ (split function of resected lung) and the ‘Juhl 
and Frost formula’ (number of segments to be resected) were calculated and compared 
with observed values measured in the third postoperative year. Calculated values 
correlated well with observed values, whereas the Kristersson/Olsen formula appeared to 
be more accurate than the one by Juhl and Frost. When considering trends in FEV1, we 
found a mean decline of 44 ml/year; only 3 patients (12%) showed a rapid decline of 
more than 100 ml/year. In 14 patients (44%), postoperative maximal exercise capacity 
was impaired due to ventilatory limitation. 
 
Besides postoperative lung function we also studied the effects of pneumonectomy on 
cardiac function. Nowadays, cardiovascular magnetic resonance (CMR) imaging offers a 
unique possibility to study the cardiac function in an altered geometric position of the 
heart. CMR not only is accurate and reproducible in normal as well as abnormal 
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ventricles, but also free of ionising radiation and independent of the geometric 
assumptions and acoustic windows that limit echocardiography. Therefore, we studied 
short- and long-term effects of pneumonectomy on cardiac function by MRI. 
In Chapter 6, the short-term effects of pneumonectomy on cardiac function were 
studied. We found that shortly after the operation, heart rate increased and stroke 
volume decreased, both significantly, indicating depressed cardiac function. Furthermore, 
left ventricular end-diastolic volume was significantly decreased and this was related to 
the decrease in stroke volume. Since we did not find any signs of right ventricular 
dysfunction, the underfilling of the left ventricle must be interpreted as a direct 
consequence of a decreased compliance of the pulmonary vascular bed. Eventually 
however, at 3 months postoperatively, these values normalised indicating that initial 
adaptation of the heart had been successfully completed.  
In Chapter 7, the long-term effects of pneumonectomy on cardiac function, exercise 
limitation and geometric position of the heart were studied in 15 patients more than 5 
years postoperatively. Large deviations of the normal position of the heart within the 
thorax were observed in patients after right-sided pneumonectomy whereas torsion of 
the heart was predominantly seen after left-sided pneumonectomy. There were findings 
indicative for compromised cardiac function, such as an increased heart rate and 
decreased stroke volume at rest, and these findings together with an abnormal stroke 
volume response during exercise provided further evidence that cardiovascular limitation 
contributed to the limited exercise capacity in our patients. As an explanation, we found 
in the right-sided pneumonectomy patients an underfilling of the right ventricle most 
probable due to thoracic wall compression, whereas in the left-sided pneumonectomy 
patients left ventricle dysfunction was frequently present. We did not find any signs of 
right ventricular enlargement or hypertrophy, making the presence of pulmonary 
hypertension unlikely. Based on these findings, we concluded that the impaired cardiac 
function can be explained by the altered position of the heart. 
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In Chapter 8 three unusual features in patients after pneumonectomy were presented. 
The first described patient was asymptomatic despite a replacement of the heart to the 
dorsal side of the thorax after pneumonectomy. The left ventricular free wall was 
positioned against the left dorsal chest wall (Chapter 8.1), placing this patient at risk of 
injury (or worse) in case of blind percutaneous needle and/or chest tube insertion.  
Secondly (Chapter 8.2), a case of a pneumonectomy patient who had the tendency to 
collapse while bending due to compression of the left ventricular free wall against the 
paralytic left hemidiaphragm, causing a sever diastolic filling disorder in case the 
intraabdominal and intrathoracic pressure increased. 
Finally (Chapter 8.3), a pneumonectomy patient experiencing dyspnoea due to 
compression of the pulmonary vein between the left atrium and descending aorta, which 
was treated by repositioning of the mediastinum. 
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Samenvatting 
Door het ontbreken van vroege symptomen presenteren patiënten met niet-kleincellig 
longkanker (NKL) zich vaak pas in een laat stadium van de ziekte. Ondanks uitgebreid 
wetenschappelijk onderzoek de afgelopen decennia blijft het aantal patiënten wat 
jaarlijks overlijdt hoog en bestaat de groep patiënten met de meest gunstige prognose 
nog altijd uit patiënten waarbij chirurgische resectie de aangewezen methode van 
behandeling is. Helaas presenteert de meerderheid van de patiënten zich met een 
irresectabel of gedissemineerd stadium. Slechts een klein deel van deze groep kan na 
inductie chemo-radiotherapie alsnog curatief geopereerd worden. Om de groep patiënten 
die genezen kunnen worden door primair chirurgische resectie, al dan niet voorafgegaan 
door chemo- en/of radiotherapie, te kunnen onderscheiden van de groep waarin geen 
curatieve therapie meer mogelijk is, zijn een aantal aspecten van belang. Ten eerste is 
longkanker in het algemeen een ziekte die voorkomt op middelbare en oudere leeftijd, 
waar factoren als leefstijl (rookstatus) en co-morbiditeit een rol gaan spelen. Daarnaast 
is adequate stadiering van de tumor van groot belang. Hiertoe worden verschillende 
beeldvormende (computer tomografie (CT) scan, magnetische resonantie (MR) scan en 
F-18-deoxyglucose positron emissie tomografie (18FDG-PET) scan) en invasieve 
technieken (bronchoscopie, transbronchiale naaldaspiratie (TBNA), mediastinoscopie, 
transoesofageale echogeleide fijne naaldaspiratie (EUS-FNA) en endobronchiale 
echografie (EBUS)) gebruikt. 
 
In Deel I van dit proefschrift komen aspecten aan bod die invloed hebben op de 
therapiekeuze bij patiënten met NKL, zoals onder andere leeftijd, co-morbiditeit en het 
TNM stadium waarin de ziekte zich bevindt bij eerste presentatie. 
Een hogere leeftijd ten tijde van de diagnose longkanker zal bij veel patiënten gepaard 
gaan met het hebben van meerdere (ernstige) aandoeningen (co-morbiditeit). Omdat 
oudere (> 70 jaar) patiënten vaak worden buitengesloten van wetenschappelijk 
onderzoek, is er enerzijds weinig bekend over de beste manier om longkanker bij 
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ouderen met co-morbiditeit te behandelen en anderzijds over de resultaten van de 
behandeling. In Hoofdstuk 1 worden de onafhankelijke prognostische effecten van 
leeftijd en co-morbiditeit bij patiënten met NKL onderzocht. Het blijkt dat ouderen met 
longkanker minder agressief worden behandeld dan jongere patiënten. Het percentage 
patiënten met gelokaliseerde stadia NKL (stadium I of II) die worden geopereerd neemt 
af van 92% bij patiënten jonger dan 60 naar 9% bij patiënten ouder dan 80 jaar. Binnen 
de leeftijdsgroep 60-79 jaar neemt dit percentage ook af naarmate co-morbiditeit 
toeneemt. Jongere patiënten (< 60 jaar) met gevorderde stadia (III en IV) worden vaker 
(24%) behandeld met chemotherapie dan patiënten van 80 en ouder (2%). Het aantal 
ziektes dat een patiënt heeft buiten longkanker heeft geen significante invloed op de 
therapiekeuze bij patiënten met gevorderde ziekte. Multivariate analyse laat zien dat 
leeftijd, grootte van de tumor en therapiekeuze onafhankelijke prognostische factoren 
zijn voor patiënten met gelokaliseerde ziekte, terwijl het stadium en de therapiekeuze 
dat zijn voor patiënten met gevorderde ziekte. Co-morbiditeit alleen heeft geen 
onafhankelijk effect op prognose. 
 
In Hoofdstuk 2 hebben we onderzocht in hoeverre preoperatieve mediastinale 
stadieringsmethoden accuraat worden toegepast in 4 perifere ziekenhuizen. Het blijkt dat 
richtlijnen met betrekking tot het al dan niet uitvoeren van een mediastinoscopie bij 
patiënten die verdacht worden van longkanker in 2/3 van de gevallen correct worden 
gevolgd. Vooral in geval van een verdachte perifere nodus waarvan geen histologische 
diagnose verkregen kan worden, zijn longartsen terughoudend in het laten uitvoeren van 
een mediastinoscopie. Binnen de 4 onderzochte klinieken blijkt het ziekenhuis waar het 
minst aantal patiënten wordt geëvalueerd het significant slechter te doen dan de rest. 
Van alle uitgevoerde mediastinoscopieën, wordt 40% volgens ‘gouden standaard’ 
uitgevoerd (adequate sampling van lymfklierstations Naruke 4 rechts, 4 links en 7). Er is 
een relatie tussen het aantal uitgevoerde mediastinoscopieën in een ziekenhuis en het 
percentage dat volgens de gouden standaard wordt verricht. Ook wordt sampling van 
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mediastinale lymfklieren gedurende thoracotomie vaker en nauwkeuriger gedaan 
naarmate er in een ziekenhuis meer patiënten worden behandeld. 
In het algemeen wordt mediastinale lymfkliersampling tijdens thoracotomie in 50% van 
de gevallen verricht, wat uiteindelijk resulteert in 17% van de patiënten waarbij 
postoperatief mediastinale lymfkliermetastasen worden geconstateerd. Theoretisch had 1 
op de 5 patiënten een thoracotomie bespaard kunnen blijven indien richtlijnen met 
betrekking tot het indiceren en uitvoeren van een mediastinoscopie volgens gouden 
standaard uitgevoerd waren. 
 
In Hoofdstuk 3 analyseren we of de introductie van de FDG-PET scan in ons ziekenhuis 
geresulteerd heeft in een verbetering van het volgen van bestaande richtlijnen met 
betrekking tot mediastinale stadiering en de uitvoering van mediastinoscopie bij 
patiënten met NKL, ten opzichte van Hoofdstuk 2 (voor de introductie van PET). 
Richtlijnen worden significant beter gevolgd (p = 0.002) dan voorheen. Terwijl we 
verwachten dat het aantal mediastinoscopieën dat volgens gouden standaard uitgevoerd 
wordt zou zijn toegenomen, gezien de resultaten van Hoofdstuk 2 en de introductie van 
de PET scan, is het tegenovergestelde waar. Het percentage mediastinoscopieën dat 
wordt uitgevoerd volgens gouden standaard neemt af (niet significant) van 39% 
(Hoofdstuk 2) naar 27%, echter het percentage mediastinoscopieën met een positief 
resultaat neemt daarentegen toe (niet significant) naar 17.6% ten opzichte van 15.5% in 
het vorige onderzoek. Blijkbaar kan de combinatie van PET en CT de chirurg exacter 
vertellen waar hij moet biopteren tijdens mediastinoscopie, zodat het percentage 
positieve klieren toeneemt.  
 
In Hoofdstuk 4 beoordelen we de accuratesse en interobserver variatie van nucleair 
geneeskundigen ten aanzien van de detectie en het correct lokaliseren van mediastinale 
lymfkliermetastasen op een 18FDG-PET scan bij patiënten met NKL. Twee groepen 
nucleair geneeskundigen met verschillend niveau van ervaring met betrekking tot 
beoordelen van PET (‘ervaren’ (n = 7) en ‘beginner’ (n = 7)) beoordelen ieder 
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afzonderlijk 30 PET scans van patiënten met mogelijk operabel NKL. Er wordt hen 
gevraagd om iedere verdachte hot spot op PET te identificeren en te lokaliseren, en om 
een advies te formuleren met betrekking tot het verdere beleid (bv mediastinoscopie, 
thoracotomie), gebruik makende van standaard algoritmen. Resultaten worden 
vergeleken tussen de beide groepen, tussen individuen en met experts (wordt 
beschouwd als zijnde de ‘gouden standaard’). In totaal is 80% van de beleidsadviezen en 
68% van de ‘N-stadium’ classificaties correct, met een gemiddeld tot goede interobserver 
overeenkomst (kappa 0.59 en 0.65, respectievelijk). Detectiepercentage (72% 
vergeleken met beoordeling door experts) en meest voorkomende fouten in lokalisatie 
van aparte mediastinale lymfklierstations zijn eerlijk verdeeld tussen de beide groepen. 
Ervaring met PET resulteert in het beter kunnen lokaliseren van verdachte mediastinale 
lymfklierstations (68% versus 51%, respectievelijk) en het adequater kunnen 
interpreteren van de resultaten van PET naar klinisch bruikbare informatie. In het 
algemeen echter blijft er ruimte voor verbetering bestaan, zelfs in de groep van ervaren 
PET beoordelaars. 
 
In Deel II van dit proefschrift presenteren we studies over cardiale en pulmonale functie 
bij patiënten die geopereerd werden voor NKL, in het speciaal bij patiënten na 
pneumonectomie. 
Na resectie van een (deel van) de long neemt de longfunctie af. Er zijn verschillende 
formules die de postoperatieve longfunctie van patiënten na een resectie proberen te 
voorspellen. Deze formules worden verdeeld in 2 categorieën. De eerste categorie 
formules berekent de postoperatieve functie van het resterende longweefsel door het 
aantal longsegmenten wat verwijderd gaat worden te tellen en zo het percentage te 
berekenen van het aantal segmenten dat overblijft. Een andere categorie formules neemt 
in deze berekening de daadwerkelijke functie van deze segmenten mee, die bepaald 
wordt met behulp van de ventilatie-perfusiescan. In Hoofdstuk 5 bepalen we de 
validiteit van 2 van dit soort formules voor de voorspelling van postoperatieve longfunctie 
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op lange termijn, alsmede de trend in postoperatieve longfunctie en de mate van 
inspanningstolerantie bij patiënten na pneumonectomie. 
Postoperatieve ‘geforceerde vitale capaciteit’ (FVC) en 1 seconde capaciteit (FEV1) 
worden berekend volgens de formule van ‘Kristersson/Olsen’ (perfusie van verwijderde 
segmenten) en de formule van ‘Juhl en Frost’ (aantal segmenten wat verwijderd wordt) 
en vergeleken met daadwerkelijk gemeten postoperatieve waarden 3 jaar na 
pneumonectomie. Berekende waarden komen goed overeen met de gemeten waarden, 
maar de formule van ‘Kristersson/Olsen’ is beter in het voorspellen van postoperatieve 
functie dan de formule van ‘Juhl en Frost’. Met betrekking tot de jaarlijkse trend in 
longfunctie bij patiënten na pneumonectomie, vinden we dat er een gemiddelde jaarlijkse 
afname is van FEV1 van 44 ml/jaar; slechts 3 patiënten (12%) hebben een versnelde 
achteruitgang van 100 ml/jaar. Postoperatieve inspanningstolerantie is afgenomen bij 14 
patiënten (44%) ten gevolge van ventilatoire beperking. 
 
Naast postoperatieve longfunctie bestuderen we ook de effecten van pneumonectomie op 
cardiale functie. Cardiovasculaire MRI geeft een unieke mogelijkheid om de functie van 
het hart te bestuderen in geval van veranderde anatomische verhoudingen. Het geeft 
nauwkeurige en reproduceerbare resultaten voor zowel normale als pathologische 
ventrikels, maakt daarbij geen gebruik van radioactieve straling en doet geen 
anatomische aannames zoals echocardiografie. Daarom onderzoeken we korte- en lange 
termijn effecten van pneumonectomie op de functie van het hart middels MRI. 
In Hoofdstuk 6 worden de korte termijn effecten van pneumonectomie op de functie 
van het hart onderzocht. Direct na de operatie (2 weken) neemt het slagvolume af terwijl 
de hartfrequentie toeneemt, beiden significant, wat duidt op afgenomen hartfunctie. 
Verder is het linker ventrikel eind-diastolisch volume direct postoperatief significant 
afgenomen. Deze afname is direct gerelateerd aan het afgenomen slagvolume. Omdat 
we geen tekenen van rechter ventrikel dysfunctioneren vinden, moet de verminderde 
vulling van de linker ventrikel dan ook geïnterpreteerd worden als zijnde direct 
veroorzaakt door verminderde compliantie van het pulmonale vaatbed. Drie maanden na 
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de operatie zijn deze waarden weer genormaliseerd dus het lijkt erop dat de initiële 
aanpassing van het hart aan de nieuwe situatie postpneumonectomie dan voltooid is.  
In Hoofdstuk 7 bestuderen we de lange termijn effecten van pneumonectomie op de 
functie van hart en longen en anatomische positie van het hart binnen de thorax bij 15 
patiënten meer dan 5 jaar na de operatie. Er wordt in het algemeen een forse horizontale 
verschuiving naar de aangedane zijde gezien van het hart binnen de thorax terwijl torsie 
van het hart om zijn eigen as alleen gezien wordt bij patiënten na linkszijdige 
pneumonectomie. We vinden aanwijzingen voor verminderde hartfunctie, zoals 
verminderd slagvolume en toegenomen hartfrequentie. Deze bevindingen tezamen met 
het feit dat we een abnormale toename vinden van het slagvolume tijdens inspanning 
duiden erop dat het verminderd cardiovasculair functioneren bijdraagt aan gedaalde 
inspanningscapaciteit in onze patiënten. Bij rechtszijdige pneumonectomie patiënten 
wordt een ondervulling gevonden van de rechter ventrikel, waarschijnlijk ten gevolge van 
druk door de thoraxwand op de ventrikel, en bij linkszijdige pneumonectomie patiënten 
constateerden we met name een verminderde linker ventrikelfunctie. Er is postoperatief 
geen rechter ventrikel dilatatie of hypertrofie dus het bestaan van pulmonale hypertensie 
is onwaarschijnlijk. Gebaseerd op deze bevindingen concluderen we dat de verminderde 
hartfunctie bij patiënten 5 jaar na pneumonectomie het gevolg kan zijn van de 
veranderde postoperatieve positie van het hart in de thorax. 
  
In Hoofdstuk 8 worden drie zeldzame situaties beschreven bij patiënten na 
pneumonectomie. 
Ten eerste (Hoofdstuk 8.1) een patiënt met ernstige anatomische veranderingen een 
paar jaar na de operatie, waarbij de linker ventrikel helemaal tegen de dorsale zijde van 
de linker thoraxhelft gepositioneerd is. Hierdoor loopt deze patiënt ernstig gevaar in 
geval invasieve diagnostiek van de post-pneumonectomieholte noodzakelijk zou zijn en 
dit gebeurt zonder begeleiding van beeldvormende technieken. 
Ten tweede (Hoofdstuk 8.2) een casus van een pneumonectomie patiënt die de neiging 
had te collaberen tijdens bukken ten gevolge van een diastolische dysfunctie van de 
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linker ventrikel. Dit trad op doordat de vrije wand van de ventrikel tegen het linker 
hemidiafragma aan lag zodat bij bukken (verhogen intrathoracale- en intra-abdominale 
druk) dit aanleiding gaf tot afplatting van de vrije wand en vermindering van de linker 
ventrikel preload. 
Als laatste (Hoofdstuk 8.3) een patient die een aantal jaar na pneumonectomie last 
kreeg van dyspnoe ten gevolge van compressie van een grote vena pulmonalis tussen 
het linker atrium en de aorta descendens. Dit werd succesvol behandeld door 
chirurgische repositie van het mediastinum. 
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General Discussion and Future Considerations 
Overall, the presence of serious comorbidity in NSCLC patients is high, especially in the 
elderly. Because elderly patients (> 70 years) are often excluded from clinical trials, little 
is known about the best ways to treat them and about the outcome of such treatment. 
With the rising mean age, more people will be older with more comorbid conditions at the 
time of lung cancer diagnosis. Therefore, more studies on this subject are needed. 
Especially because we found in Chapter 1 that elderly patients are treated less 
aggressively than younger patients, while the choice of treatment was not influenced by 
the presence of comorbidity, but mainly by age. Furthermore, comorbidity had negligible 
influence on survival of NSCLC patients, despite the less aggressive treatment in case of 
comorbidity. So, we question whether this less aggressive treatment in the elderly is 
always justified. In recently published Dutch guidelines it is recommended that patients 
of 70-80 (and even > 80) years old eligible for resection, should be evaluated like 
younger patients, with special attention to comorbidity and overall condition, and that 
surgical resection should not be denied on age only1. We agree on this, however, it is 
known that pneumonectomy (especially right-sided) in patients more than 80 years old is 
associated with significantly more complications and worse survival2-4, compared to 
younger patients. Therefore we believe this procedure should probably be refrained from 
in these particular patients and one should consider (radical) radiotherapy as an 
alternative, if eligible. Besides this, being also responsible for elderly patients with lung 
cancer, we believe one should keep in mind that in everyday practice resectability is not 
primarily determined by the number of comorbid conditions but by the impact of 
comorbidity, such as pulmonary and cardiac function. 
 
In every new NSCLC patient, one of the first problems a pulmonary physician has to 
solve is assigning the disease to the correct TNM stage, because this has major impact 
on the choice of treatment. Recently, EUS-FNA and EBUS were introduced for invasive 
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lung cancer staging and without doubt, these modalities will become more available and 
probably change current NSCLC staging guidelines in the near future. 
Nowadays however, mediastinoscopy still is the overall gold standard and remains the 
most available and frequently used tool for invasive staging. So, how come that in daily 
practice only 40% of ‘gold standard’ mediastinoscopies is actually done according to gold 
standards and sampling of mediastinal lymph nodes during thoracotomy is done in only 
50% of all patients (Chapter 2)? After confronting surgeons with these results they 
mentioned that often ‘no mediastinal lymph nodes were found’, ‘it was not possible to 
biopsy that particular lymph node’ or ‘fear of complications existed’. Apparently “normal” 
daily practice differs from published data obtained in large academic centers. A reason 
for this could be the retrospective data gathering. Perhaps, in case data would have been 
collected prospectively and surgeons had to work according to a fixed protocol, like in 
other prospective studies, overall results would have been better. Secondly, because 
quality of care relates to the number of procedures performed in a hospital5-7. Therefore, 
it might be recommended to perform these procedures according to a fixed protocol and 
only in those centres where one has sufficient experience. Unfortunately however, 
perhaps due to the limited number of patients in our study, we have not been able to 
show that this non-adherence to guidelines in fact also had a negative effect on clinical 
outcome or survival in these patients (data therefore not presented in this thesis). 
Nevertheless, we believe that one should always make the maximum effort to adhere to 
existing guidelines, because only then it will be possible to adequately monitor these 
aspects of care and to find out whether problems in these areas are present and if so, 
how they need to be approached. 
 
In the past few years, a lot of studies have been published on the utility of FDG-PET 
scanning in the conventional work-up of patients with possible curable NSCLC. In a 
review from 2003, Silvestri et al. recommended PET to evaluate the mediastinum in all 
patients who are candidates for surgery8. In a more recent review by Detterbeck et al.9 
there appears to be only a minor role for PET imaging in patients with peripheral cT1 
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tumours because evidence indicates that the incidence of finding either unsuspected 
distant or mediastinal metastases on PET in this particular group of patients is quite low. 
In patients with evidence of mediastinal lymph node enlargement on CT, 
mediastinoscopy (or other invasive biopsy) is likely to be indicated regardless of the PET 
findings in the mediastinum10. Furthermore, especially in certain subgroups of patients 
(those with tumours adjacent to the mediastinum, adenocarcinomas, or N1 nodal 
involvement), physicians seem to argue whether or not mediastinoscopy is needed in 
case of a negative PET result, according to Detterbeck.  
Obviously, the first few months (even years) after a new and promising diagnostic tool 
becomes available, recommendations considering its use and applicability can still 
change, like we have seen with PET. Therefore, when implementing such a tool, we 
believe we can say that physicians are almost obliged to do this according to current 
literature and guidelines. Because, only in that case, results of this implementation can 
be adequately monitored, problems will become more clear and with that, probably also 
the possible solutions.  
In Chapter 3, we tried to monitor the implementation of FDG-PET in our hospital. We 
hypothesized that its’ introduction would result in an improved staging process and 
better selection of patients for surgical resection. This appeared to be true, however, 
there was obvious room for further improvement. Certainly, PET-CT will help to improve 
the yield of PET and CT reading in the future. We found that the proportion of tumour 
positive invasive staging procedures increases with PET, which has recently been 
suggested in literature11;12. The yield of whole-body PET pertains to typing the primary 
pulmonary lesion (benign / malignant) and to identify and localise distant and 
mediastinal lymph node metastases. Since the mediastinal areas covered by 
mediastinoscopy, EUS-FNA, TBNA and EBUS are largely complementary, proper 
localisation of possible malignant nodes is important to assign patients to the appropriate 
procedure.  
While studying accuracy in PET readings by experienced and inexperienced nuclear 
medicine physicians, we had anticipated differences between these two groups, however 
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this was not the case. While realizing that it takes practice to reach an expert level, 
apparently even inexperienced observers can achieve credible levels of performance. 
Previously, it has been questioned whether people always improve their judgements with 
experience13. Because without adequate feedback, how do you really know that what you 
think is true, is actually true? In Chapter 4 we discussed the importance of education 
with structured databases in a skills’ lab setting because the guarantee of validity might 
not be the experience itself! Therefore we suggested the need for higher levels of 
feedback from expert observers in such educational settings. 
 
 
Algorithm for preoperative evaluation of surgical risk, adapted from v Meerbeeck et al.14 
 
- FEV1 > 80% predicted 
- TLCO > 80% predicted 
- No unexpected dyspnea 
Yes  
Yes  
Yes  
Yes  
Yes  
Yes  
Calculate postoperative function 
using split function of lung 
segments to be resected 
- FEV1 postoperative > 40% 
- TLCO postoperative > 40% 
- No unexpected dyspnea 
- FEV1 postoperative < 40% 
- TLCO postoperative < 40% 
VO2max postoperative > 10 ml/min/kg 
VO2max postoperative ≤ 10 ml/min/kg 
Normal risk 
Normal risk 
Increased risk 
Normal risk 
Highly increased risk 
Moderately increased risk 
Exercise test ? VO2max: 
- Lobectomy > 15 ml/min/kg 
- Pneumonectomy > 20 ml/min/kg 
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In NSCLC patients eligible for resection, postoperative pulmonary and cardiac function 
should preoperatively be calculated in order to predict postoperative lung function. 
Operating on a patient while leaving him a respiratory cripple after the resection with 
obviously very poor quality of life is unacceptable. In recently published Dutch guidelines, 
the algorithm on the previous page is recommended for evaluation of operative risk and 
prediction of possible outcome for patients with NSCLC, eligible for surgical resection15. 
Prediction of postoperative lung function in pneumonectomy patients is done more 
accurately by formulas using the split function of lung segments that are going to be 
resected, compared to formulas just counting the number of segments (Chapter 5).  
Trends in postoperative lung function have been extensively studied. Pneumonectomy in 
adults produces overdistention of the remaining lung rather than compensatory lung 
growth16-18. In the majority of studies done in children however, compensatory growth 
appears to be present. 
 
Figure presenting the adaptive mechanism related to the age at operation, adapted from 
Laros et al.17 
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Laros et al. showed (see figure) that the adaptive mechanism related to the age at 
operation17. Compensatory growth, hyperplasia (shaded area) with a gradual shift to 
simple hypertrophy (open area), occurs in the age groups 0-20 years, after which 
dilatation becomes the most important mechanism. As such, post-operative measured 
lung volumes might be somewhat better than the preoperative calculations predicted. 
However, one should keep in mind that the amount of functioning tissue is not increasing 
and the only “reserve-capacity” is therefore improvement by recruitment, enhanced by 
dilatation of less used areas. Despite these adaptive mechanisms, pneumonectomy has 
serious implications on exercise capacity in long term survivors, possibly also due to the 
presence of COPD preoperatively. 
 
Cardiac MRI can be considered the gold standard for the assessment of cardiac structure 
and function. Pneumonectomy influences cardiac structure and function, especially of the 
right ventricle. The first few days after pneumonectomy, the right ventricle increases its 
preload (right ventricular end-diastolic volume) supposedly due to increased 
afterload19;20. In Chapter 6 we found that 2 weeks after surgery, no signs of right 
ventricular enlargement were found but increased heart rate and decreased stroke 
volume in stead. Furthermore, left ventricular filling was impaired, and this was related 
to the decreased stroke volume. Since there were no signs of right ventricular 
dysfunction, the underfilling of the left ventricle must be interpreted as a direct 
consequence of a decreased compliance of the remaining pulmonary vascular bed. We 
hypothesize that adaptation by decreasing stroke volume is a mechanism by which the 
heart aims to prevent further increase in afterload and possibly right ventricular failure 
(like in case of massive pulmonary embolism). This might also explain why we did not 
find right ventricular hypertrophy in long term survivors after pneumonectomy (Chapter 
7). However, in the long term, this chronically state of underfilling might again result in 
worsening of left ventricular function (ejection fraction) with dilatation and decreased 
wall mass, like we found in our patients 5 years after pneumonectomy. 
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The fact that we did not find any signs of RV hypertrophy in our studies in 
pneumonectomy patients could indicate that even in patients with some pulmonary 
hypertension a not too large reduction of the vascular bed (segmentectomy or even 
lobectomie) might be safe, because recently it was shown that RV hypertrophy is an 
early sign of adaptation of the RV to intermittent pressure overload in COPD patients21. 
Whether pneumonectomy will be possible in combination with already existing mild 
pulmonary hypertension is questionable. 
Due to the fact that long term survivors after pneumonectomy are relatively hard to find, 
the number of patients in both studies was relatively small. Therefore, larger prospective 
studies are needed to validate our results and to determine the effects of left-sided 
pneumonectomy in comparison to right-sided pneumonectomy. While studying left- and 
right-sided pneumonectomy patients by dynamic MRI, we found remarkable differences 
between both groups. After left-sided pneumonectomy, in contrast to right sided-
pneumonectomy, the heart not only shifts but also rotates with large individual 
differences. It is not inconceivable that the postoperatively impaired cardiac function is in 
part due to these differences. However, if this is really the case remains unclear because 
our patient groups were too small to draw firm conclusions. These extreme anatomical 
changes after pneumonectomy may result in unusual features, described in Chapter 8. 
MRI provides an excellent tool to analyse the complications caused by the repositioning 
of the heart and great vessels in the postpneumonectomy patient. These patients 
illustrate in an impressive way how important cardiac MRI is as a diagnostic tool in 
patients with unexplained shortness of breath after pneumonectomy. Circulatory 
problems are potentially a cause of this complaint and therefore cardiac evaluation needs 
to be incorporated into the diagnostic approach of these patients. 
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Conclusions 
This thesis evaluated several aspects influencing treatment choice in NSCLC patients and 
studied postoperative cardiac and pulmonary function in pneumonectomy patients. 
Several conclusions originated from this thesis.  
 
Chapter 1 Effect of Comorbidity on the Treatment and Prognosis of Elderly patients 
with NSCLC 
* Elderly patients were treated less aggressively than younger patients. 
* Age had more influence on the choice of treatment than comorbidity did. 
* Age, stage of disease and treatment were independent prognostic factors for 
patients with localised disease, and stage of disease and treatment for those with 
non-localized disease. Comorbidity had no independent prognostic effect. 
 
Chapter 2 Surgical Mediastinal Staging in Daily Practice 
* In clinical practice, accuracy of preoperative mediastinal staging procedures and 
sampling of mediastinal lymph nodes is not as adequate as one should hope for. 
* Mediastinoscopy was done according to gold standards in 40% of cases. 
* There is probably a direct relationship between the number of mediastinoscopies 
performed and quality. 
* Adequate mediastinal staging can result in less futile thoracotomies. 
 
Chapter 3 Influence of Introduction of PET on Adherence to Mediastinal Staging 
Protocols and Performance of Mediastinoscopy 
*  After introduction of PET, adherence to mediastinal staging procedures increased 
significantly (p = 0.002). 
*  The combination of PET and CT can guide the surgeon to possible metastasized 
mediastinal lymph nodes and therefore increases the number of positive 
mediastinoscopies. 
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* Monitoring of these aspects of care, especially after the introduction of new 
diagnostic tools like for instance, FDG-PET scanning, is important firstly, to see 
whether problems regarding its’ implementation are present and secondly to find 
out how improvement can be achieved, if necessary. 
 
Chapter 4 Accuracy and Interobserver Variation in Determining Presence of 
Mediastinal Lymph node Metastases by 18FDG-PET in patients with NSCLC 
* Clinical experience with PET increases observers’ ability to read and interpret 
results from PET adequately compared to expert observers. However, there is 
obvious room for improvement because overall performance of experienced 
observers was only slightly better than that of inexperienced observers. 
* Optimal performance is not acquired by experience alone but requires higher 
levels of feed-back from expert observers. 
 
Chapter 5 Actual and Predicted Postoperative Changes in Lung Function after 
Pneumonectomy 
* In patients surviving for more than 2 years after pneumonectomy, the formula 
that calculates the split function of lung segments that will be removed is a better 
predictor of postoperative lung function than the formula that only counts the 
number of lung segments. 
* The annual decline in FEV1 in long-term survivors after pneumonectomy, if quitted 
from smoking, is almost the same as in healthy non-COPD patients, while Wmax 
and VO2max in these patients are both decreased by approximately 30%. 
  
Chapter 6 Underfilling of the Left Ventricle is the primary cause of a Low Stroke 
Volume after Pneumonectomy 
* Shortly after pneumonectomy the right ventricle adapts to the new situation of 
increased pulmonary blood flow through one lung by increasing heart rate and 
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decreasing its stroke volume together with, and related to, a decrease of left 
ventricular end-diastolic volume. 
* Since no signs of right ventricular enlargement or hypertrophy at 2 weeks or 3 
months after surgery were found, underfilling of the left ventricle must be due to 
decreased compliance of the pulmonary vascular bed. 
* Three months after pneumonectomy no signs of hemodynamical impairment are 
found and cardiac adaptation to the new situation seems complete. 
 
Chapter 7 Cardiac Function and Position more than 5 years after Pneumonectomy 
* Cardiac function 5 years after pneumonectomy is impaired (increased heart rate 
and decreased stroke volume) which might be explained by the altered position of 
the heart. 
* Long term effect of pneumonectomy on the position of the heart is characterised 
by a lateral shift after right-sided pneumonectomy and rotation of the heart to a 
variable degree after left-sided pneumonectomy. 
* No signs of right ventricular hypertrophy were found. 
 
Chapter 8 Unusual Features after Pneumonectomy 
* Extreme shifting and torsion of the heart and great vessels can occur after 
pneumonectomy.  
* Careful localisation of intrathoracic structures before invasively entering the 
postpneumonectomy space is extremely important in order to prevent serious 
complications. 
* MRI provides an excellent tool to analyse the complications caused by the 
replacement of the heart and large vessels in the postpneumonectomy patient. 
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Dankwoord  
Met veel plezier en toewijding heb ik aan dit proefschrift gewerkt. Natuurlijk had ik 
destijds geen flauw benul wat promoveren daadwerkelijk inhield, dacht ik ‘dat wel even 
te doen binnen 2 jaar’, en zijn er slapeloze nachten geweest: ‘waar ben ik in hemelsnaam 
aan begonnen’?? Desondanks is dit een ervaring geweest die ik achteraf nooit had willen 
missen en waarvan ik ongelooflijk veel geleerd heb. Eindelijk aangekomen bij wat 
ongetwijfeld ook nu weer het ‘meest gelezen deel’ van een proefschrift zal gaan worden, 
wil ik een aantal mensen hiervoor speciaal bedanken. 
 
Om te beginnen was er Dr. BEEM van den Borne, die mij tijdens mijn co-schap 
interne in het ‘Catharien’ de mogelijkheid bood mijn wetenschapsstage bij de afdeling 
longziekten te volgen. “We doen een leuk onderzoekje en daar kun je dan wel een 
artikeltje over publiceren!” Beste Ben, bedankt voor je enthousiasme en initiële ideeën. 
Een onderzoek-je, daar had ik wel oren naar. Maar dat dit uiteindelijk de ingang bleek te 
zijn voor dit proefschrift, had ik nooit gedacht. Promoveren stond niet echt boven aan 
mijn verlanglijstje en het werken als AGNIO longziekten in het ‘Catharien’ beviel me 
prima. Tijdens een functioneringsgesprek met mijn opleider, Dr. FWJM Smeenk, werd 
me een opleidingsplaats aangeboden. Echter, ik mocht kiezen. Meteen opleiding, of eerst 
promoveren. Beste Frank, bedankt voor je vertrouwen. Jouw voor mij legendarische en 
inspirerende woorden: “dat kun jij”, hebben mij geholpen in mijn beslissing. Je moet me 
toch eens uitleggen hoe je ondanks je gigantisch drukke bestaan het voor elkaar krijgt 
een concept van een artikel steeds weer binnen een aantal dagen te corrigeren! Jouw 
verhelderende en kritische blik zette mij steeds weer op het goede spoor en je maakte 
altijd tijd voor me. Jij hamerde erop ‘de lezer bij de hand te nemen’ en schrapte 
standaard al mijn bijzinnen en onnodige proza (zoals vrouwen praten en denken, 
schrijven ze blijkbaar ook). Bedankt Frank, voor je plaatsvervangende zenuwen tijdens 
mijn eerste ‘oral presentation’ op de ERS in Florence, en voor deze verrijkende kans. 
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Promoveren in een perifere opleidingskliniek was natuurlijk nooit mogelijk 
geweest zonder de andere ‘maten’ in Eindhoven. Speciale dank ten eerste voor RM 
Schipper. Beste Rob, jij was het brein achter het idee om de uitvoering van de 
mediastinoscopie onder de loep te nemen (hoofdstuk 2) en zorgde voor mijn eerste 
introductie bij de promotor. Jouw humor en enthousiasme maakten samenwerken met 
jou tot iets wat ik niet snel zal vergeten. Bedankt ook Dr. RHH van Balkom, JPHM 
Creemers en PLML Wielders. Beste Roland, Jacques en Pascal, bedankt voor deze 
kans, jullie tips, momenten van overleg en vertrouwen. 
 
De 1e auteur van hoofdstuk 1, Dr. MLG Janssen-Heijnen, beste Maryska, 
bedankt voor al je werk en onmisbare aanvulling van mijn data vanuit het ‘Integraal 
Kankercentrum Zuid’ (IKZ). Bedankt ook voor je kritische en nauwkeurige commentaar 
op hoofdstukken 2 en 5 en je verhelderende visie op het gebied van de statistiek. 
 
Pas na enige tijd onderzoek doen, maakte ik kennis met mijn promotor, Prof.dr. 
PE Postmus aan het VU te Amsterdam. Tot grote hilariteit van Frank stond er boven een 
email van mij aan hem altijd ‘beste professor’ in plaats van Piet. Beste Piet……… (mag ik 
Piet zeggen?), wellicht hadden wij minder intensief contact dan gebruikelijk is voor een 
promovendus en promotor, doordat ik mijn eigenlijke werk in Eindhoven deed. Jij gaf 
desondanks steeds de goede richting aan een onderzoek, een artikel en het proefschrift 
in zijn geheel. En ook al eindigde ons overleg soms met 4 onderzoeksvragen en 
potentiële artikelen meer dan ik überhaupt gekomen was, jij had er vertrouwen in dat 
het goed kwam. Bedankt daarvoor. 
Tijdens de samenwerking met Dr. OS Hoekstra aan hoofdstuk 4 werd het me 
eens te meer duidelijk hoe moeilijk het kan zijn om gedegen onderzoek te doen. Beste 
Otto, zonder je diplomatie, enthousiasme en gedrevenheid om goed onderzoek te doen, 
was het denk ik heel anders gelopen met onze studie. Bedankt voor je hulp, ook middels 
je bewonderenswaardige Engelse schrift en de heldere momenten van overleg. 
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Voor de laatste hoofdstukken kwam ik terecht bij Dr. A Vonk Noordegraaf. 
Beste Anton, jij bent echt ‘made for science’. Volgens mij draaien die radertjes in je 
hoofd altijd op volle toeren en ben je dag en nacht bezig nieuwe studies te verzinnen. 
Jammer voor jou, maar je kunt even geen ideetjes meer bij me kwijt, ik ben voorlopig op 
‘research-sabbatical’. Bedankt voor je praktische visie op onze onderzoeksresultaten. Dat 
had ik wel eens nodig, daar ik overal een verklaring voor wilde vinden, die er soms 
simpelweg gewoon niet was. Bedankt ook voor je toegankelijkheid en de gezellige 
momenten van overleg. Bij jou ging ik altijd vandaan met een gevoel van: “het komt wel 
goed”.  
Het werkpaard achter mijn data vanuit het VU, S Holverda, beste Bas, bedankt 
voor al je werk en je positieve reacties op mijn email als ik weer eens wat van je gedaan 
moest hebben. Jij kon je natuurlijk goed verplaatsen in mijn situatie. Speciale dank ook 
voor CT Gan, Tji, voor je werk in de laatste fase van mijn promotie. Ik wens jullie veel 
succes met je eigen promotie. 
 
De researchafdeling longziekten van het Catharien, waar ik de meeste tijd van 
mijn promotie doorbracht, bedankt voor alle koffie en gezellige momenten. Ik heb met 
plezier bij jullie mijn werk gedaan. Speciale dank voor Robert Quanjel voor al je 
ondersteuning op computer gebied. Ook alle dames op de poli longziekten natuurlijk 
bedankt voor de administratieve ondersteuning (en goede roddels!). 
De longartsen uit de regio Eindhoven, bedankt voor het doorsturen van patiënten. 
Tevens de artsen uit ’t Catharien die mijn data hebben gecreëerd danwel gecontroleerd, 
Harrie CM van den Bosch, Dr. Johannes C Post, Dr. Alette W Daniels-Gooszen, 
Dr. Astrid B Donkers-van Rossum, Dr. Michela A Edelbroek en Dyde A Huysmans, 
bedankt voor jullie inzet en enthousiasme. Speciale dank ook voor de dames laboranten 
van de MRI. 
Arts-assistenten longziekten in ’t Catharien, bedankt dat ik mijn nukken bij jullie 
mocht uiten, mijn praatjes op jullie mocht oefenen en voor de ‘vrolijke noot’ die er was 
op momenten dat ik dat nodig had. 
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Een aantal studies waren uiteraard niet mogelijk geweest zonder de inzet van de 
patiënten zelf. Graag wil ik ze dan ook bedanken voor hun inzet en moeite die zij voor 
me namen in tijden dat ze eigenlijk wel wat anders aan hun hoofd hadden. Fantastisch! 
 
Marielle Erich, bedankt voor het ontwerpen van de kaft en je hulp met het 
drukken van mijn proefschrift. Veel succes met je bedrijf ‘Mixed Media’ gewenst voor de 
toekomst. 
 
Mijn paranimfen, Tim Smulders en Kristien Dill- van de Broek. Bedankt dat 
jullie de functie als mijn paranimfen hebben willen aanvaarden. Lieve Tim, je zus gaat nu 
weer gewoon patiënten ‘pamperen’. Kristien, ook al proberen we allebei werk en privé 
stevig gescheiden te houden, naast collega ben je wat mij betreft toch ook een maatje 
geworden. 
Mijn schoonouders, lieve Gerard en Annelies, bedankt voor de hartelijke manier 
waarop jullie mij een plaatsje geven in jullie gezin. 
Bedankt ook al mijn lieve vriendinnen voor jullie interesse ondanks het feit dat 
jullie je misschien moeilijk konden voorstellen waar ik me nou precies de hele dag (en 
dat al die jaren lang!) mee bezig hield. Bedankt voor alle momenten met motto: “Geniet 
nooit met mate”, waarop jullie me de promotiestress even deden vergeten. Dokter Siets 
is Doktor geworden….. 
 
Lieve pap en mam, bedankt dat jullie er altijd voor me zijn, voor jullie trots, 
liefde, steun en vertrouwen.  
Allerliefste Joost, jij bent ‘alles’ en daar kan ik je onmogelijk voor bedanken. Als 
geen ander weet jij hoe ik alles ervaren heb de afgelopen jaren. Dit boek is af maar die 
van ons nog lang niet. Inmiddels kom ik weer thuis met leuke verhalen ……. 
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Curriculum Vitae 
Sietske Anke Smulders werd op 29 mei 1975 geboren te Tilburg. Na haar eindexamen 
Atheneum B in 1993 aan het Titus Brandsma Lyceum te Oss ging zij geneeskunde 
studeren aan de Universiteit van Maastricht. Onder leiding van Dr. FWJM Smeenk en RM 
Schipper deed zij tijdens haar co-schappen een wetenschappelijke stage op de afdeling 
longziekten van het Catharina ziekenhuis te Eindhoven. In augustus 2000 haalde zij haar 
artsexamen en per september begon zij haar loopbaan als AGNIO longziekten in het 
inmiddels vertrouwde Eindhovense. 
Haar promotieonderzoek begon in januari 2002 op de researchafdeling longziekten van 
het Catharina ziekenhuis te Eindhoven, onder leiding van Dr. FWJM Smeenk (Catharina 
ziekenhuis te Eindhoven), Dr. A Vonk Noordegraaf en Prof.dr. PE Postmus (Vrije 
Universiteit te Amsterdam). De resultaten daarvan staan beschreven in dit proefschrift.  
Met 5 jaar klinische en wetenschappelijk ervaring begon zij per september 2005 haar 
vooropleiding interne geneeskunde in het Bosch Medisch Centrum, lokatie GZG, te        
’s-Hertogenbosch (opleider Dr. P Netten). Hierna zal zij haar opleiding tot longarts 
afronden in het Catharina ziekenhuis te Eindhoven. 
Kort geleden is zij samen met Joost Eijsink in het huwelijksbootje gestapt. 
 
 
 
 
 
 
 
 
 
 
 
